SETID,SPL_VERSION,ingredients_names,ingredients_rxcuis,condition_name,pt_meddra_id,pt_meddra_term,file,title
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,GIB,10013839,duodenal ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
00fd1905-27e4-420e-8dc5-a69e4ddc1526,11,nitisinone,61805,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240124_00fd1905-27e4-420e-8dc5-a69e4ddc1526.json,"These highlights do not include all the information needed to use NITYR safely and effectively. See full prescribing information for NITYR.
NITYR® (nitisinone) tablets, for oral useInitial U.S. Approval: 2002"
03880372-2c68-45c6-a53a-f420c49541d6,21,rilpivirine,1102270,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20221103_03880372-2c68-45c6-a53a-f420c49541d6.json,"These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. 
EDURANT® (rilpivirine) tablets for oral useInitial U.S. Approval: 2011"
09beda19-56d6-4a56-afdc-9a77b70b2ef3,33,linaclotide,1307404,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/gold_xml/20230921_09beda19-56d6-4a56-afdc-9a77b70b2ef3.json,"These highlights do not include all the information needed to use 
LINZESS
 
safely and effectively. 
See full prescribing information for 
LINZESS
.

  

LINZESS

®

 (
linaclotide
) 
capsules, for oral use

Initial U.S. Approval: 
 
2012"
0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7,7,buspirone,1827,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7.json,"Buspirone Hydrochloride Tablets, USP"
0b1332a1-0581-4707-9bf6-1eccfa39bef4,2,futibatinib,2628190,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230203_0b1332a1-0581-4707-9bf6-1eccfa39bef4.json,"These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI.
LYTGOBI® (futibatinib) tablets, for oral use
Initial U.S. Approval: 2022"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,terbinafine,37801,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992"
0daf09f8-d884-439d-aa5e-00d445edc38f,8,lithium carbonate,42351,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_0daf09f8-d884-439d-aa5e-00d445edc38f.json,"These highlights do not include all the information needed to use LITHIUM CARBONATE CAPSULES safely and effectively. See full prescribing information for LITHIUM CARBONATE CAPSULES.
 



LITHIUM CARBONATE capsules, for oral use
 



Initial U.S. Approval: 1970"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
1502544d-1b3a-46bd-84f5-af92cab72ce8,9,rifapentine,35617,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240110_1502544d-1b3a-46bd-84f5-af92cab72ce8.json,"These highlights do not include all the information needed to use PRIFTIN® safely and effectively. See full prescribing information for PRIFTIN.
 PRIFTIN (rifapentine) tablets, for oral use Initial U.S. Approval: 1998"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,ALI,10047216,venoocclusive liver disease,../data/2024_latest_labels/gold_xml/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
1793e218-7b49-497d-879f-1020de6e6d68,8,prednisolone,8638,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_1793e218-7b49-497d-879f-1020de6e6d68.json,Prednisolone Sodium Phosphate Oral Solution
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,dipyridamole,3521,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,GIB,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23527b8b-9b28-4e6d-9751-33b143975ac7,24,dalteparin,67109,GIB,10069829,intestinal haematoma,../data/2024_latest_labels/latest_labels_ingredients/20230922_23527b8b-9b28-4e6d-9751-33b143975ac7.json,"These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. 
FRAGMIN® (dalteparin sodium) injection, USP, for subcutaneous use Initial U.S. Approval: 1994"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
2421dc8f-a60d-4249-b093-c9e8e1d4bb82,10,glyburide,4815,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_2421dc8f-a60d-4249-b093-c9e8e1d4bb82.json,"Glyburide Tablets, USP
 

1.25, 2.5, and 5 mg"
24815546-658b-4b01-ac11-de7fbd0ebd16,2,salsalate,36108,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240209_24815546-658b-4b01-ac11-de7fbd0ebd16.json,"Salsalate Tablets, USP 500 mg and 750 mg"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
25c2b417-eeea-4ba6-8eb9-a7d8a08c6093,2,potassium chloride,8591,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_25c2b417-eeea-4ba6-8eb9-a7d8a08c6093.json,"These highlights do not include all the information needed to use POTASSIUM CHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for POTASSIUM CHLORIDE ORAL SOLUTION.
 

POTASSIUM CHLORIDE oral solution
 
Initial U.S. Approval: 1948"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,desvenlafaxine,734064,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008"
32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,desvenlafaxine,734064,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008"
33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,ertapenem,325642,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001"
3495a71a-cc04-4776-851f-f185956f32af,22,azacitidine,1251,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004"
34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9,11,praziquantel,8628,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240110_34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9.json,"These highlights do not include all the information needed to use BILTRICIDE safely and effectively.  See full prescribing information for BILTRICIDE.BILTRICIDE (praziquantel) tablets, for oral use
Initial U.S. Approval: 1982"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,ALI,10023025,ischaemic hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,brentuximab vedotin,1147320,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,levetiracetam,114477,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999"
3e4842ec-773b-4aeb-b37d-1c4e3cf53424,102,dicloxacillin,3356,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240119_3e4842ec-773b-4aeb-b37d-1c4e3cf53424.json,"Dicloxacillin Sodium Capsules USP


Rx only"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
455892c3-d144-4ba8-9ab4-79cabff9876d,11,capmatinib,2362165,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020"
49596de6-ab18-49d1-9e5b-30968fc21c36,26,vincristine,11202,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230202_49596de6-ab18-49d1-9e5b-30968fc21c36.json,"VinCRIStine Sulfate 

Injection, USP"
499ab990-2b21-474f-aaba-d86388965f40,9,amikacin,641,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231005_499ab990-2b21-474f-aaba-d86388965f40.json,"These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. 
ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4be9cc3f-0016-4426-a700-574b45ce245b,10,rifabutin,55672,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231108_4be9cc3f-0016-4426-a700-574b45ce245b.json,"Rifabutin Capsules USP, 150 mg
Rx only"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6,1,isotretinoin,6064,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6.json,"These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES.
 ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
4ffd02a3-86b8-4af7-b539-aa32e38c6b12,14,colesevelam,141626,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_4ffd02a3-86b8-4af7-b539-aa32e38c6b12.json,"These highlights do not include all the information needed to use COLESEVELAM HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for COLESEVELAM HYDROCHLORIDE TABLETS.
 COLESEVELAM HYDROCHLORIDE tablets, for oral use
 Initial U.S. Approval: 2000"
50d0dd0c-7682-43d0-aa1b-ca26e9181aee,3,lapatinib,480167,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231207_50d0dd0c-7682-43d0-aa1b-ca26e9181aee.json,"These highlights do not include all the information needed to use lapatinib tablets safely and effectively. See full prescribing information for lapatinib tablets. LAPATINIB tablets, for oral use Initial U.S. Approval: 2007"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,ALI,10071198,allergic hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
55ad6325-16f6-4f0c-a1dc-734847052d0b,2,danazol,3102,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,"Danazol Capsules, USP
 

Rx only"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,liraglutide,475968,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,pralatrexate,662019,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
61492681-4be8-448b-b4c6-ef2261503d1a,12,metformin,6809,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_61492681-4be8-448b-b4c6-ef2261503d1a.json,"These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
 

METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1995"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
65d254c0-67ad-42c4-b972-ad463b755b2d,8,ivosidenib,2049873,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231108_65d254c0-67ad-42c4-b972-ad463b755b2d.json,"These highlights do not include all the information needed to use TIBSOVO safely and effectively. See full prescribing information for TIBSOVO.
 TIBSOVO® (ivosidenib tablets), for oral use Initial U.S. Approval: 2018"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,GIB,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
71448ab0-e23e-4cf7-940e-7d67e7362fb4,1,cetirizine,20610,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240212_71448ab0-e23e-4cf7-940e-7d67e7362fb4.json,"CETIRIZINE HYDROCHLORIDE ORAL SOLUTION USP

1 mg/mL

Rx Only"
71448ab0-e23e-4cf7-940e-7d67e7362fb4,1,cetirizine,20610,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240212_71448ab0-e23e-4cf7-940e-7d67e7362fb4.json,"CETIRIZINE HYDROCHLORIDE ORAL SOLUTION USP

1 mg/mL

Rx Only"
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
72e6b33c-0351-4070-9172-eeaa186c01d2,14,tenofovir alafenamide,1721603,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240215_72e6b33c-0351-4070-9172-eeaa186c01d2.json,"These highlights do not include all the information needed to use VEMLIDY safely and effectively. See full prescribing information for VEMLIDY. 
 VEMLIDY® (tenofovir alafenamide) tablets, for oral use  Initial U.S. Approval: 2015"
74a611bc-9977-46bb-b626-0370b3031628,8,fexinidazole,2564146,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021"
768aa02b-8231-5799-e053-2a91aa0a618d,7,ondansetron,26225,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_768aa02b-8231-5799-e053-2a91aa0a618d.json,"ONDANSETRON INJECTION, USP 4mg/2mL (2mg/mL) VIAL"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16,4,pexidartinib,2183102,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231130_7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16.json,"These highlights do not include all the information needed to use TURALIO safely and effectively. See full prescribing information for TURALIO.
 TURALIO® (pexidartinib) capsules, for oral use Initial U.S. Approval: 2019"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,AKI,10083346,anticoagulant-related nephropathy,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7f10bf63-06c8-477d-a13e-fb88e287617a,103,repaglinide,73044,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997"
7f10bf63-06c8-477d-a13e-fb88e287617a,103,repaglinide,73044,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997"
7fbea274-d6b5-4faa-bbf0-05fefab42114,6,atazanavir,343047,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240218_7fbea274-d6b5-4faa-bbf0-05fefab42114.json,"These highlights do not include all the information needed to use ATAZANAVIR CAPSULES safely and effectively. See full prescribing information for ATAZANAVIR CAPSULES.
 ATAZANAVIR capsules, for oral use Initial U.S. Approval: 2003"
81d9e47e-ae81-4755-a5ee-546a038fadb4,7,mirtazapine,15996,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_81d9e47e-ae81-4755-a5ee-546a038fadb4.json,"These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS.
 

MIRTAZAPINE tablets, for oral use
 
Initial U.S. Approval: 1996"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,oseltamivir,260101,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
8f7f73b8-586a-4df0-935f-fecd4696c16c,17,isavuconazonium,1608322,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23,21,pamidronate,11473,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231220_9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23.json,Pamidronate Disodium Injection
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,alogliptin,1368001,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013"
ad965f38-dd22-4607-a673-2fb92f3b527a,8,rilonacept,763450,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20230510_ad965f38-dd22-4607-a673-2fb92f3b527a.json,"These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. 
ARCALYST® (rilonacept) for injection, for subcutaneous use Initial U.S. Approval: 2008"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
b9bc3907-bfa7-4d9f-90d9-c2097230f7e4,5,ethacrynate,62349,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231231_b9bc3907-bfa7-4d9f-90d9-c2097230f7e4.json,"Ethacrynic Acid Tablets, USP 

(25 mg)


Rx Only"
bcb387ac-2e90-4f5e-94b2-d3635190678e,9,miltefosine,1494066,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231018_bcb387ac-2e90-4f5e-94b2-d3635190678e.json,"These highlights do not include all the information needed to use IMPAVIDO safely and effectively.  See full prescribing information for IMPAVIDO.
IMPAVIDO (miltefosine) capsules, for oral useInitial U.S. Approval: 2014"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,ALI,10019713,hepatic vein thrombosis,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c6c48eee-240b-4425-8691-35462523652e,1,propoxyphene,8785,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,"DARVON-N  - propoxyphene napsylate tablet, film coated"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c9fe3f32-4219-466e-acb9-3f609b4f4df1,5,tisotumab,2571095,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230805_c9fe3f32-4219-466e-acb9-3f609b4f4df1.json,"These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.
TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 2021"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cc0cb812-48f9-a138-e053-2a95a90a7666,7,chloroquine,2393,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_cc0cb812-48f9-a138-e053-2a95a90a7666.json,"Chloroquine Phosphate Tablets, USP"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cd86ee78-2781-468b-930c-3c4677bcc092,25,vorinostat,194337,AKI,10046406,ureteric obstruction,../data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006"
cf74ba2f-afc5-4baa-8594-979c889a5831,44,tofacitinib,1357536,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20231128_cf74ba2f-afc5-4baa-8594-979c889a5831.json,"These highlights do not include all the information needed to use XELJANZ/XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution. 
XELJANZ® (tofacitinib) tablets, for oral use XELJANZ® XR (tofacitinib) extended-release tablets, for oral use XELJANZ® (tofacitinib) Oral Solution Initial U.S. Approval: 2012"
d138ab10-1ed9-44be-8d81-49dda1e434ac,2,anidulafungin,341018,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240221_d138ab10-1ed9-44be-8d81-49dda1e434ac.json,"These highlights do not include all the information needed to use ERAXIS safely and effectively. See full prescribing information for ERAXIS. 
ERAXIS® (anidulafungin) for injection, for intravenous use Initial U.S. Approval: 2006"
d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,apalutamide,1999574,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
de5bad69-a014-4e25-b1b9-214373ca57a5,1,triamcinolone,10759,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_de5bad69-a014-4e25-b1b9-214373ca57a5.json,"Triamcinolone Acetonide

 Cream USP, 0.1%"
de61685e-2b8c-4e22-84bb-869e13600440,38,peginterferon alfa-2a,120608,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221214_de61685e-2b8c-4e22-84bb-869e13600440.json,"These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. 
 PEGASYS® (peginterferon alfa-2a) injection, for subcutaneous use  Initial U.S. Approval: 2002"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
ec1bb0d1-f38a-4080-831a-68791d1d1fdb,7,roflumilast,1091836,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240209_ec1bb0d1-f38a-4080-831a-68791d1d1fdb.json,"These highlights do not include all the information needed to use ZORYVE cream safely and effectively. See full prescribing information for ZORYVE cream.
 ZORYVE® (roflumilast) cream, for topical use Initial U.S. Approval: 2011"
f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846,3,deferiprone,11645,ALI,10019719,hepatitis a,../data/2024_latest_labels/train_xml/20211210_f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846.json,"These highlights do not include all the information needed to use FERRIPROX Oral Solution safely and effectively. See full prescribing information for FERRIPROX Oral Solution.FERRIPROX® (deferiprone) oral solution, for oral useInitial U.S. Approval: 2011"
f0cd76e9-460c-450e-b094-172e636f340a,7,mitotane,7004,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_f0cd76e9-460c-450e-b094-172e636f340a.json,"These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.
 LYSODREN® (mitotane) tablets, for oral use Initial U.S. Approval: 1970"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f7e9a4b3-a2ee-4f0a-becd-6ef90867332b,37,morphine,7052,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_f7e9a4b3-a2ee-4f0a-becd-6ef90867332b.json,"These highlights do not include all the information needed to use MORPHINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MORPHINE SULFATE EXTENDED-RELEASE CAPSULES.


MORPHINE SULFATE extended-release capsules, for oral use, CIIInitial U.S. Approval: 1941"
f86cb4a7-c358-4136-ae57-b32bda9bba00,34,golimumab,819300,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/train_xml/20231122_f86cb4a7-c358-4136-ae57-b32bda9bba00.json,"These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI.
 



SIMPONI (golimumab) injection, for subcutaneous use
 

Initial U.S. Approval: 2009"
f89f2933-0743-45e7-9a91-086f9b2e56da,10,pentoxifylline,8013,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240202_f89f2933-0743-45e7-9a91-086f9b2e56da.json,"PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, USP 400 mg


Rx Only"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10013839,duodenal ulcer haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0422fe47-c372-494f-bac2-612f550b44a4,12,cefazolin,2180,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_0422fe47-c372-494f-bac2-612f550b44a4.json,"Cefazolin for Injection, USP"
04fb6cd5-3c21-433e-a053-623b73218bd6,2,niacin,7393,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240126_04fb6cd5-3c21-433e-a053-623b73218bd6.json,"Niacin Tablets, USP 500 mg"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
083a3282-254f-4042-b0eb-70f76a279f10,100,vardenafil,306674,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_083a3282-254f-4042-b0eb-70f76a279f10.json,"These highlights do not include all the information needed to use VARDENAFIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for VARDENAFIL HYDROCHLORIDE TABLETS.
 



VARDENAFIL HYDROCHLORIDE tablets, for oral use
 

Initial U.S. Approval: 2003"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0c717ae4-ec27-47db-ac1b-e504dbb379be,11,dexmethylphenidate,352372,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_0c717ae4-ec27-47db-ac1b-e504dbb379be.json,"These highlights do not include all the information needed to use DEXMETHYLPHENIDATE hydrochloride tablets safely and effectively. See full prescribing information for DEXMETHYLPHENIDATE hydrochloride tablets.
  



DEXMETHYLPHENIDATE HYDROCHLORIDE TABLETS, for oral use, CII
  

Initial U.S. Approval: 2001"
0d6111be-aabe-88e2-e063-6394a90a3963,2,mycophenolic acid,7145,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004"
0d6111be-aabe-88e2-e063-6394a90a3963,2,mycophenolic acid,7145,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004"
101b2d4d-4740-4225-94bc-aecc05d82c6b,10,risperidone,35636,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240224_101b2d4d-4740-4225-94bc-aecc05d82c6b.json,"These highlights do not include all the information needed to use RISPERIDONE TABLETS safely and effectively. See full prescribing information for RISPERIDONE TABLETS.
 

RISPERIDONE tablets, for oral use
 



Initial U.S. Approval: 1993"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
1738a682-5903-b675-3a7a-61d299a6f248,19,zoledronic acid,77655,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001"
17e597bc-d663-4d8e-a5d3-39816b628996,8,stavudine,59763,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1ecb2311-eee3-4230-a019-a3496308cff1,9,dihydroergotamine,3418,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_1ecb2311-eee3-4230-a019-a3496308cff1.json,"Dihydroertotamine Mesylate Nasal Spray, 4 mg/mL"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AKI,10038380,renal artery thrombosis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
29ba0172-7ca3-4122-af1b-f0da522318cb,6,hydroxychloroquine,5521,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_29ba0172-7ca3-4122-af1b-f0da522318cb.json,"These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.
HYDROXYCHLOROQUINE SULFATE Tablets, for oral use
Initial U.S. Approval: 1955"
2c631ce7-ea15-4b51-b5bc-4962e3c315cd,3,fluorouracil,4492,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231202_2c631ce7-ea15-4b51-b5bc-4962e3c315cd.json,"FLUOROURACIL TOPICAL SOLUTION Rx only  FOR TOPICAL USE ONLY  NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE"
2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,andexanet alfa,2045114,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9,11,praziquantel,8628,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9.json,"These highlights do not include all the information needed to use BILTRICIDE safely and effectively.  See full prescribing information for BILTRICIDE.BILTRICIDE (praziquantel) tablets, for oral use
Initial U.S. Approval: 1982"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
369e89a4-9898-4a9f-a316-17d0fce8a08b,100,methazolamide,6826,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240206_369e89a4-9898-4a9f-a316-17d0fce8a08b.json,Methazolamide Tablets USP Rx only
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38955939-8d1e-4db2-9aed-3bab72ca5f8f,8,bleomycin,1622,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231224_38955939-8d1e-4db2-9aed-3bab72ca5f8f.json,"​ 
BLEO 15K

Bleomycin sulfate.  

Bleomycin sulfate powder for injection contains bleomycin sulfate 15,000 IU per vial"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
38f5341f-5ae3-46bf-8bfc-30dff2068477,102,alosetron,85248,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_38f5341f-5ae3-46bf-8bfc-30dff2068477.json,"These highlights do not include all the information needed to use ALOSETRON TABLETS safely and effectively. See full prescribing information for ALOSETRON TABLETS. 
ALOSETRON tablets, for oral use   Initial U.S. Approval: 2000"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
47547f93-489c-4298-aeea-d6a37ca6cb1d,5,duvelisib,2058509,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018"
47547f93-489c-4298-aeea-d6a37ca6cb1d,5,duvelisib,2058509,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,olutasidenib,2623641,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022"
4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,olutasidenib,2623641,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4b4725eb-95f1-45cc-852f-152beb5f1e2c,4,thiotepa,10473,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231229_4b4725eb-95f1-45cc-852f-152beb5f1e2c.json,"These highlights do not include all the information needed to use THIOTEPA FOR INJECTION safely and effectively. See full prescribing information for THIOTEPA FOR INJECTION.THIOTEPA for injection, for intravenous, intracavitary, or intravesical useInitial U.S. Approval: 1959"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
52fea941-0b47-41c1-b00d-f88150e8ab93,13,thioridazine,10502,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20211217_52fea941-0b47-41c1-b00d-f88150e8ab93.json,WARNING
55ae23ff-60f5-4de6-bd1b-472243b8636b,8,pioglitazone,33738,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5ccf0e9a-8935-4c8c-b883-b4967281eb4a,7,nilutamide,31805,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20220712_5ccf0e9a-8935-4c8c-b883-b4967281eb4a.json,"NILANDRON®
 (nilutamide) Tablets"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
632bb50c-3bcb-4c85-9056-fc33410550ae,5,lurbinectedin,2374729,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230811_632bb50c-3bcb-4c85-9056-fc33410550ae.json,"These highlights do not include all the information needed to use ZEPZELCA safely and effectively.  See full prescribing information for ZEPZELCA.

ZEPZELCA® (lurbinectedin) for injection, for intravenous use
Initial U.S. Approval: 2020"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
7276803b-5b97-d886-e053-2a91aa0a184e,5,dofetilide,49247,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240124_7276803b-5b97-d886-e053-2a91aa0a184e.json,"Dofetilide Capsules
 

Rx Only
 















Rx only"
75c0c785-38e0-4049-a6fb-b77581f5b35c,6,cefiderocol,2265702,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7974d4ad-c419-4c7f-bbd6-f631d53e30de,3,tranylcypromine,10734,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230527_7974d4ad-c419-4c7f-bbd6-f631d53e30de.json,"These highlights do not include all the information needed to use TRANYLCYPROMINE SULFATE TABLETS safely and effectively. See full prescribing information for TRANYLCYPROMINE SULFATE TABLETS.TRANYLCYPROMINE SULFATE USP tablets, for oral useInitial U.S. Approval: 1961"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,AKI,10038470,renal infarct,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
80eb1080-fe20-4af0-b2a5-a67999923fa8,10,tagraxofusp,2109055,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230804_80eb1080-fe20-4af0-b2a5-a67999923fa8.json,"These highlights do not include all the information needed to use ELZONRIS®safely and effectively.  See full prescribing information for ELZONRIS.
			
ELZONRIS (tagraxofusp-erzs) injection, for intravenous use
			Initial U.S. Approval: 2018"
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,AMI,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,arsenic trioxide,18330,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000"
88698921-cd8f-4d41-96e6-ff671913c5c3,7,nateglinide,274332,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231110_88698921-cd8f-4d41-96e6-ff671913c5c3.json,"These highlights do not include all the information needed to use NATEGLINIDE TABELTS safely and effectively. See full prescribing information for NATEGLINIDE TABELTS.
NATEGLINIDE tablets, for oral useInitial U.S. Approval: 2000"
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,nisoldipine,7435,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,Nisoldipine
8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,nisoldipine,7435,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,Nisoldipine
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8b4c8696-e23e-4c51-a4d2-babab5bd945a,3,remifentanil,73032,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231223_8b4c8696-e23e-4c51-a4d2-babab5bd945a.json,"These highlights do not include all the information needed to use ULTIVA safely and effectively.  See full prescribing information for ULTIVA. 
ULTIVA® (remifentanil hydrochloride), for injection, for intravenous use, CII
Initial U.S. Approval: 1996"
8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,cetuximab,318341,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8ea61d0d-4403-4d9f-a946-85a459cc0aa0,5,fondaparinux,321208,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_8ea61d0d-4403-4d9f-a946-85a459cc0aa0.json,"These highlights do not include all the information needed to use FONDAPARINUX SODIUM INJECTION safely and effectively. See full prescribing information for FONDAPARINUX SODIUM INJECTION.
 FONDAPARINUX SODIUM injection, for subcutaneous use Initial U.S. Approval: 2001"
8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc,3,amphetamine,725,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc.json,"Amphetamine Sulfate Tablets, USP, CII"
93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda,3,naratriptan,141366,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231219_93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda.json,"These highlights do not include all the information needed to use NARATRIPTAN TABLETS safely and effectively. See full prescribing information for NARATRIPTAN TABLETS.


NARATRIPTAN tablets, for oral use


Initial U.S. Approval: 1998"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,AKI,10046406,ureteric obstruction,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
9f489295-1156-52c7-5fd0-5c4c52f9b813,8,voclosporin,2475166,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021"
a07195bc-7442-32b4-e053-2995a90a0151,2,heparin,5224,AKI,10038460,renal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_a07195bc-7442-32b4-e053-2995a90a0151.json,"HEPARIN SODIUM INJECTION, USP 10,000 USP UNITS/mL 1mL VIAL"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a26cfa07-14a7-4468-8eed-3529f3d613f4,6,efavirenz,195085,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998"
a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,alogliptin,1368001,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a586be28-96af-4fed-a13f-9b94fd4c7405,24,medroxyprogesterone,6691,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240227_a586be28-96af-4fed-a13f-9b94fd4c7405.json,"PROVERA®

 (medroxyprogesterone acetate tablets, USP)"
a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,10,enasidenib,1940332,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.json,"These highlights do not include all the information needed to use IDHIFA safely and effectively. See full prescribing information for IDHIFA. 
IDHIFA® (enasidenib) tablets, for oral use Initial U.S. Approval: 2017"
aaeaef94-f3f5-4367-8ea2-b181d7be2da8,19,ribociclib,1873916,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20230907_aaeaef94-f3f5-4367-8ea2-b181d7be2da8.json,"These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI.
		
KISQALI® (ribociclib) tablets, for oral use
		Initial U.S. Approval: 2017"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b31ff20a-c363-4be0-9bc0-3081c163b63c,7,atovaquone,60212,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b72ca065-6396-41b9-a195-a8819688f471,9,spironolactone,9997,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_b72ca065-6396-41b9-a195-a8819688f471.json,"These highlights do not include all the information needed to use SPIRONOLACTONE TABLETS safely and effectively. See full prescribing information for SPIRONOLACTONE TABLETS.
 



SPIRONOLACTONE tablets for oral use
 



Initial U.S. Approval: 1960"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bf93022c-a965-49c5-a852-c59e580d7d91,14,indomethacin,5781,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/gold_xml/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10027141,melaena,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
da3c2935-817d-4331-83c3-ed68ba5d35fd,2,chlorpromazine,2403,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20240214_da3c2935-817d-4331-83c3-ed68ba5d35fd.json,"ChlorproMAZINE Hydrochloride Tablets, USP 
Rx only"
dc495e54-8917-42de-a9fa-1f961bd99d61,1,dapsone,3108,AKI,10038491,renal papillary necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240214_dc495e54-8917-42de-a9fa-1f961bd99d61.json,"These highlights do not include all the information needed to use DAPSONE GEL safely and effectively.
 See full prescribing information for DAPSONE GEL.
 DAPSONE gel, for topical use
 Initial U.S. Approval: 1955"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e0fa4bca-f245-4d92-ae29-b0c630a315c2,157,panitumumab,263034,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230629_e0fa4bca-f245-4d92-ae29-b0c630a315c2.json,"These highlights do not include all the information needed to use 
VECTIBIX
 safely and effectively.  See full prescribing information for 
VECTIBIX
.

   

VECTIBIX

®

 
(panitumumab)
 
I
njection 
for 
intravenous 
use

Initial U.S. Approval: 
200
6"
e2dbbdf9-ddfd-4d6d-ad42-6e658969f11e,1,pyrazinamide,8987,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240220_e2dbbdf9-ddfd-4d6d-ad42-6e658969f11e.json,"Pyrazinamide Tablets, USP
  
Rx Only
  
8478901/0923F"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
e55f3dc2-c754-4550-a2c0-c304471a8791,2,nitrofurantoin,7454,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only"
e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,carbidopa,2019,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,CARBIDOPA tablets
eeb0fcfd-e4e8-4fb1-9635-901dc9446235,8,iloperidone,73178,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221224_eeb0fcfd-e4e8-4fb1-9635-901dc9446235.json,"These highlights do not include all the information needed to use ILOPERIDONE TABLETS safely and effectively. See full prescribing information for ILOPERIDONE TABLETS.
ILOPERIDONE tablets, for oral use
Initial U.S. Approval: 2009"
f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846,3,deferiprone,11645,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20211210_f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846.json,"These highlights do not include all the information needed to use FERRIPROX Oral Solution safely and effectively. See full prescribing information for FERRIPROX Oral Solution.FERRIPROX® (deferiprone) oral solution, for oral useInitial U.S. Approval: 2011"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,ALI,10047216,venoocclusive liver disease,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f7e9a4b3-a2ee-4f0a-becd-6ef90867332b,37,morphine,7052,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240215_f7e9a4b3-a2ee-4f0a-becd-6ef90867332b.json,"These highlights do not include all the information needed to use MORPHINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MORPHINE SULFATE EXTENDED-RELEASE CAPSULES.


MORPHINE SULFATE extended-release capsules, for oral use, CIIInitial U.S. Approval: 1941"
f86cb4a7-c358-4136-ae57-b32bda9bba00,34,golimumab,819300,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231122_f86cb4a7-c358-4136-ae57-b32bda9bba00.json,"These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI.
 



SIMPONI (golimumab) injection, for subcutaneous use
 

Initial U.S. Approval: 2009"
f941fc61-f7a3-4e4a-ab7c-87c1667fa05b,5,rituximab,121191,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240104_f941fc61-f7a3-4e4a-ab7c-87c1667fa05b.json,"These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. 
RUXIENCE® (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 
RUXIENCE (rituximab-pvvr) is biosimilar
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RUXIENCE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.
 to RITUXAN (rituximab)"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,ALI,10019676,hepatic haematoma,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
00fd1905-27e4-420e-8dc5-a69e4ddc1526,11,nitisinone,61805,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240124_00fd1905-27e4-420e-8dc5-a69e4ddc1526.json,"These highlights do not include all the information needed to use NITYR safely and effectively. See full prescribing information for NITYR.
NITYR® (nitisinone) tablets, for oral useInitial U.S. Approval: 2002"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
09716a24-d7da-42b2-af29-c03a1b6670bd,12,mefloquine,6694,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230217_09716a24-d7da-42b2-af29-c03a1b6670bd.json,Mefloquine Hydrochloride Tablets USP
0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7,7,buspirone,1827,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7.json,"Buspirone Hydrochloride Tablets, USP"
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
11d5a86e-7861-43f1-ae04-84daa0de7888,13,exemestane,258494,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999"
16a4a314-f97e-4e91-95e9-576a3773d284,35,milnacipran,588250,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_16a4a314-f97e-4e91-95e9-576a3773d284.json,"These highlights do not include all the information needed to use 
SAVELLA
 
safely and effectively. See full prescribing information for 
SAVELLA
.  

   

SAVELLA
®
 (
milnacipran HCl
) 
t
ablets

Initial U.S. Approval: 2009"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
18fb1c2b-0c1e-436c-a5b6-d4840b5da228,12,nicardipine,7396,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_18fb1c2b-0c1e-436c-a5b6-d4840b5da228.json,"These highlights do not include all the information needed to use NICARDIPINE HYDROCHLORIDE safely and effectively. See full prescribing information for NICARDIPINE HYDROCHLORIDE.
 NICARDIPINE 
HYDROCHLORIDE injection, for intravenous use

Initial U.S. Approval: 1988"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1dbac120-d4e6-45a9-b950-3d82aa7a1271,10,labetalol,6185,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_1dbac120-d4e6-45a9-b950-3d82aa7a1271.json,"Labetalol Hydrochloride Tablets, USP
 

Rx only"
1de49a4d-dc7e-48ff-b18c-e1414282fe71,102,imiquimod,59943,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_1de49a4d-dc7e-48ff-b18c-e1414282fe71.json,"These highlights do not include all the information needed to use IMIQUIMOD Cream safely and effectively. See full prescribing information for IMIQUIMOD Cream.
IMIQUIMOD cream, for topical useInitial U.S. Approval: 1997"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
32167dd7-5d37-457b-9b00-cd735de6b060,5,tinidazole,10612,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3e4842ec-773b-4aeb-b37d-1c4e3cf53424,102,dicloxacillin,3356,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240119_3e4842ec-773b-4aeb-b37d-1c4e3cf53424.json,"Dicloxacillin Sodium Capsules USP


Rx only"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
49873158-5c0a-41da-86a2-369ef6b0cbc8,2,ranolazine,35829,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_49873158-5c0a-41da-86a2-369ef6b0cbc8.json,"These highlights do not include all the information needed to use RANOLAZINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for RANOLAZINE EXTENDED-RELEASE TABLETS.
 RANOLAZINE extended-release tablets, for oral use Initial U.S. Approval: 2006"
4c2a1403-3862-1efd-0a91-444989222b37,6,aspirin,1191,ALI,10039012,reye's syndrome,../data/2024_latest_labels/latest_labels_ingredients/20151015_4c2a1403-3862-1efd-0a91-444989222b37.json,"These highlights do not include all the information needed to use DURLAZA™ safely and effectively.  See full prescribing information for DURLAZA.
DURLAZA (aspirin) Extended Release Capsules, for oral useInitial U.S. Approval:2015"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
5359b759-db7c-4672-9e8a-59c93869bd91,5,telavancin,473837,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,cladribine,44157,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,CLADRIBINE INJECTION
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5ccf0e9a-8935-4c8c-b883-b4967281eb4a,7,nilutamide,31805,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220712_5ccf0e9a-8935-4c8c-b883-b4967281eb4a.json,"NILANDRON®
 (nilutamide) Tablets"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
6240792b-9224-2d10-e053-2a91aa0a2c3e,8,orlistat,37925,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999"
6240792b-9224-2d10-e053-2a91aa0a2c3e,8,orlistat,37925,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999"
645af8f4-0843-4afb-9ddc-f587f38adb68,8,demeclocycline,3154,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only"
67e3ba3c-77e1-43b5-a93c-5bf5e3855780,2,griseofulvin,5021,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_67e3ba3c-77e1-43b5-a93c-5bf5e3855780.json,"GRISEOFULVIN ORAL SUSPENSION, USP


Microsize


125 mg/5 mL




Rx only"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,AKI,10061481,renal injury,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,GIB,10052535,small intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
749e42fb-2fe0-45dd-9268-b43bb3f4081c,32,bosentan,75207,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_749e42fb-2fe0-45dd-9268-b43bb3f4081c.json,"These highlights do not include all the information needed to use TRACLEER safely and effectively. See full prescribing information for TRACLEER.
 



TRACLEER 
 ®(bosentan) tablets, for oral use
 

TRACLEER 
 ®(bosentan) tablets for oral suspension
 

Initial U.S. Approval: 2001"
74d94dbf-0567-6c15-e053-2991aa0ac6e4,5,verapamil,11170,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74d94dbf-0567-6c15-e053-2991aa0ac6e4.json,"VERAPAMIL HYDROCHLORIDE INJECTION, USP 10mg (2.5 mg/mL) 4mL ANSYR SYR"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
860c799c-5199-4f0c-b21b-9910273474d9,6,pentamidine,7994,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,Pentamidine isethionate for injection
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8993651b-fff6-4e3f-9b60-78587bc9bcee,2,sulfadiazine,10171,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20231221_8993651b-fff6-4e3f-9b60-78587bc9bcee.json,"sulfADIAZINE Tablets, USP"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,cetuximab,318341,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004"
8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,decitabine,15657,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006"
8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,oseltamivir,260101,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999"
8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4,2,oxacillin,7773,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240104_8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4.json,"Oxacillin for Injection, USP
 

For Intramuscular or Intravenous Injection"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
962b20df-88ff-4ab7-a900-135adb6c1d74,5,indapamide,5764,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_962b20df-88ff-4ab7-a900-135adb6c1d74.json,Indapamide Tablets USP Rx only
9914e793-a49c-eb00-1ab7-f606c786fe25,7,dactinomycin,3100,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964"
9914e793-a49c-eb00-1ab7-f606c786fe25,7,dactinomycin,3100,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964"
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9f416ce0-012f-4194-9382-74ac71e4b2a9,6,ranitidine,9143,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3b50576-cd40-4f7e-9506-bd0a61988424,3,famotidine,4278,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_a3b50576-cd40-4f7e-9506-bd0a61988424.json,"These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS.
 
FAMOTIDINE tablets, for oral use
 
Initial U.S. Approval: 1986"
aa80b9f4-8a5d-3e14-e053-2a95a90a8aab,4,theophylline,10438,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240201_aa80b9f4-8a5d-3e14-e053-2a95a90a8aab.json,"Theophylline (Anhydrous) Extended-Release Tablets
 

400 mg and 600 mg"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,moexipril,30131,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg"
bca1e4c6-4b2b-4876-8ab3-654629c4ff1b,10,prucalopride,2107310,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221108_bca1e4c6-4b2b-4876-8ab3-654629c4ff1b.json,"These highlights do not include all the information needed to use MOTEGRITY safely and effectively. See full prescribing information for MOTEGRITY. 
 MOTEGRITY (prucalopride) tablets, for oral use Initial U.S. Approval: 2018"
bcb387ac-2e90-4f5e-94b2-d3635190678e,9,miltefosine,1494066,GIB,10027141,melaena,../data/2024_latest_labels/gold_xml/20231018_bcb387ac-2e90-4f5e-94b2-d3635190678e.json,"These highlights do not include all the information needed to use IMPAVIDO safely and effectively.  See full prescribing information for IMPAVIDO.
IMPAVIDO (miltefosine) capsules, for oral useInitial U.S. Approval: 2014"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,GIB,10061577,ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c6c48eee-240b-4425-8691-35462523652e,1,propoxyphene,8785,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,"DARVON-N  - propoxyphene napsylate tablet, film coated"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c9fe3f32-4219-466e-acb9-3f609b4f4df1,5,tisotumab,2571095,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230805_c9fe3f32-4219-466e-acb9-3f609b4f4df1.json,"These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.
TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 2021"
ca1d3449-ea29-49a4-8863-365ec95f1553,6,potassium iodide,8597,GIB,10061298,mucosal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_ca1d3449-ea29-49a4-8863-365ec95f1553.json,"SSKI® 
Potassium Iodide Oral Solution, USP (Saturated) 1 g/mL"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cdfbe0cd-eb15-45a1-ac17-531bcda21aec,11,obeticholic acid,1798288,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20221021_cdfbe0cd-eb15-45a1-ac17-531bcda21aec.json,"These highlights do not include all the information needed to use OCALIVA® safely and effectively.  See full prescribing information for OCALIVA. 
OCALIVA® (obeticholic acid) tablets, for oral use Initial U.S. Approval: 2016"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,apalutamide,1999574,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018"
d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,neratinib,1940643,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017"
d267f492-43f6-45ba-8421-82ae2771788b,6,montelukast,88249,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_d267f492-43f6-45ba-8421-82ae2771788b.json,"These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS safely and effectively. See full prescribing information for MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS .


MONTELUKAST SODIUM tablets, for oral use
  
MONTELUKAST SODIUM chewable tablets, for oral use 
 

Initial U.S. Approval: 1998"
d2af616e-673a-4fdd-ace8-db2d0f154604,15,alfuzosin,17300,ALI,10067969,cholestatic liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240120_d2af616e-673a-4fdd-ace8-db2d0f154604.json,"These highlights do not include all the information needed to use ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. ALFUZOSIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2003"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d3832a1a-a140-49c1-a7df-134fa81341e3,8,disulfiram,3554,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231227_d3832a1a-a140-49c1-a7df-134fa81341e3.json,"Disulfiram Tablets, USP
 
IN ALCOHOLISM
 

Rx only"
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d9db3882-a7b5-435b-9d5a-a5e4ef7c2537,2,fluphenazine,4496,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_d9db3882-a7b5-435b-9d5a-a5e4ef7c2537.json,"Fluphenazine Hydrochloride Tablets, USPRx only"
df4cd207-c3b8-4008-5290-02f296c2b4a6,21,fenoldopam,24853,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,cefotaxime,2186,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,"CEFOTAXIME FOR INJECTION, USP"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2,5,osilodrostat,2286252,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231115_f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2.json,"These highlights do not include all the information needed to use
ISTURISA ® safely and effectively. See full prescribing information for
ISTURISA.


ISTURISA (osilodrostat) tablets, for oral use
Initial U.S. Approval: 2020"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,8,hydromorphone,3423,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240130_f9ca2ef5-46d8-475a-a26e-f7c8becd6db7.json,"These highlights do not include all the information needed to use HYDROMORPHONE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for HYDROMORPHONE HYDROCHLORIDE INJECTION.
HYDROMORPHONE HYDROCHLORIDE injection, for intravenous, intramuscular, or subcutaneous use, CII
Initial U.S. Approval: 1984"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10027141,melaena,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
ff3b5265-f533-4332-a861-d8c9c1664ffd,15,lamivudine,68244,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
03b39d40-90fe-11df-9de6-0002a5d5c51b,21,romidepsin,877510,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230603_03b39d40-90fe-11df-9de6-0002a5d5c51b.json,"These highlights do not include all the information needed to use ISTODAX safely and effectively.  See full prescribing information for ISTODAX.
ISTODAX® (romidepsin) for injection, for intravenous useInitial U.S. Approval:  2009"
06a0322b-eb28-44e2-9925-88bebd8fa91b,9,carmustine,2105,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231206_06a0322b-eb28-44e2-9925-88bebd8fa91b.json,"These highlights do not include all the information needed to use carmustine for injection, USP safely and effectively. See full prescribing information for carmustine for injection, USP.
Carmustine for injection, USP, for intravenous use Initial U.S. Approval: 1977"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0919b927-c57c-40ae-88a8-39e9efe4f677,5,17-alpha-hydroxyprogesterone,5542,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230803_0919b927-c57c-40ae-88a8-39e9efe4f677.json,""
0ab861c2-d5ca-4f92-854c-6477971a1b38,1,pirfenidone,1592254,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20141028_0ab861c2-d5ca-4f92-854c-6477971a1b38.json,"These highlights do not include all the information needed to use ESBRIET safely and effectively.  See full prescribing information for ESBRIET.
ESBRIET® (pirfenidone) capsules, for oral useInitial U.S. Approval: 2014"
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
11d5c110-c48c-438f-9c7d-5adf99938534,6,tedizolid,1540825,ALI,10054889,transaminases increased,../data/2024_latest_labels/gold_xml/20221019_11d5c110-c48c-438f-9c7d-5adf99938534.json,"These highlights do not include all the information needed to use SIVEXTRO® safely and effectively. See full prescribing information for SIVEXTRO. 
SIVEXTRO® (tedizolid phosphate) for injection, for intravenous use  SIVEXTRO® (tedizolid phosphate) tablet, for oral use Initial U.S. Approval:  2014"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
16a4a314-f97e-4e91-95e9-576a3773d284,35,milnacipran,588250,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_16a4a314-f97e-4e91-95e9-576a3773d284.json,"These highlights do not include all the information needed to use 
SAVELLA
 
safely and effectively. See full prescribing information for 
SAVELLA
.  

   

SAVELLA
®
 (
milnacipran HCl
) 
t
ablets

Initial U.S. Approval: 2009"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
1aa75a3a-18c9-49e1-91a6-293d0b7da756,8,procarbazine,8702,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231121_1aa75a3a-18c9-49e1-91a6-293d0b7da756.json,"MATULANE 
  ®(procarbazine hydrochloride) Capsules"
1c90aa68-cc12-41ef-aebc-2616ae45683a,11,candesartan,214354,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998"
1dbac120-d4e6-45a9-b950-3d82aa7a1271,10,labetalol,6185,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240215_1dbac120-d4e6-45a9-b950-3d82aa7a1271.json,"Labetalol Hydrochloride Tablets, USP
 

Rx only"
1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,sulindac,10237,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,SULINDAC TABLETS USP
202d5142-6180-4d48-9a9f-1bd6992fc49b,2,nebivolol,31555,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,GIB,10056091,varices oesophageal,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
24815546-658b-4b01-ac11-de7fbd0ebd16,2,salsalate,36108,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_24815546-658b-4b01-ac11-de7fbd0ebd16.json,"Salsalate Tablets, USP 500 mg and 750 mg"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,GIB,10018836,haematochezia,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,AKI,10061481,renal injury,../data/2024_latest_labels/train_xml/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10019663,hepatic failure,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
2ecc0f15-1d46-4b87-a6ae-aebb7b38bc73,2,lumateperone,2275602,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240113_2ecc0f15-1d46-4b87-a6ae-aebb7b38bc73.json,"These highlights do not include all the information needed to use CAPLYTA safely and effectively. See full prescribing information for CAPLYTA.


CAPLYTA 
  ® (lumateperone) capsules, for oral use 
 

Initial U.S. Approval: 2019"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
32fd2bb2-1cfa-4250-feb8-d7956c794e05,16,gemtuzumab ozogamicin,1294580,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20210905_32fd2bb2-1cfa-4250-feb8-d7956c794e05.json,"These highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG.
 MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000"
33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,ertapenem,325642,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
388aad52-fc01-4784-9791-1dbc80c69306,14,ascorbic acid,1151,AKI,10071503,crystal nephropathy,../data/2024_latest_labels/latest_labels_ingredients/20240202_388aad52-fc01-4784-9791-1dbc80c69306.json,"ASCOR HIGHLIGHTS OF PRESCRIBING INFORMATION
 
These highlights do not include all the information needed to use ASCOR® safely and effectively. See full prescribing information for ASCOR.
 
ASCOR (ascorbic acid injection), for intravenous use Initial U.S. Approval: 1947
 




Initial U.S. Approval: 1947"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/gold_xml/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
3a1424d8-844c-4e24-9ebd-b2c2b61b61a3,6,fosamprenavir,358262,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231030_3a1424d8-844c-4e24-9ebd-b2c2b61b61a3.json,"These highlights do not include all the information needed to use FOSAMPRENAVIR CALCIUM TABLETS safely and effectively.  See full prescribing information for FOSAMPRENAVIR CALCIUM TABLETS. FOSAMPRENAVIR CALCIUM tablets, for oral useInitial U.S. Approval: 2003"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
3f22c14f-3148-4037-9df0-5d910bc241f5,7,clonidine,2599,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_3f22c14f-3148-4037-9df0-5d910bc241f5.json,"CLONIDINE HYDROCHLORIDE TABLETS, USP"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
455892c3-d144-4ba8-9ab4-79cabff9876d,11,capmatinib,2362165,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
48aa32cb-047a-414a-822e-82a5f26d8817,17,diazepam,3322,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240222_48aa32cb-047a-414a-822e-82a5f26d8817.json,"Diazepam Tablets, USP, CIV


Rx only"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10027141,melaena,../data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4b4725eb-95f1-45cc-852f-152beb5f1e2c,4,thiotepa,10473,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231229_4b4725eb-95f1-45cc-852f-152beb5f1e2c.json,"These highlights do not include all the information needed to use THIOTEPA FOR INJECTION safely and effectively. See full prescribing information for THIOTEPA FOR INJECTION.THIOTEPA for injection, for intravenous, intracavitary, or intravesical useInitial U.S. Approval: 1959"
4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,20,cariprazine,1667655,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240217_4b5f7c65-aa2d-452a-b3db-bc85c06ff12f.json,"These highlights do not include all the information needed to use 
VRAYLAR
 safely and effectively.  
See full prescribing information for 
VRAYLAR
.  

   

VRAYLAR

®

 (
cariprazine
)
 
c
apsules
,
 
for 
o
ral 
u
se

Initial U.S. Approval: 
2015"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5526617c-c7b9-4556-886d-729bbabbc566,21,tolvaptan,358257,ALI,10019663,hepatic failure,../data/2024_latest_labels/gold_xml/20221119_5526617c-c7b9-4556-886d-729bbabbc566.json,"These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.
 SAMSCA® (tolvaptan) tablets, for oral use Initial U.S. Approval: 2009"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,pralatrexate,662019,ALI,10054889,transaminases increased,../data/2024_latest_labels/gold_xml/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,ALI,10066758,mixed liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
6240792b-9224-2d10-e053-2a91aa0a2c3e,8,orlistat,37925,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999"
6296e2ed-334c-b9af-e053-2991aa0aae0c,5,erythromycin,4053,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_6296e2ed-334c-b9af-e053-2991aa0aae0c.json,"Erythromycin Ophthalmic Ointment, USP 0.5% (Sterile)"
6370e342-16a5-4339-a13f-ba275fd5de09,103,clomiphene,2596,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_6370e342-16a5-4339-a13f-ba275fd5de09.json,Clomiphene Citrate Tablets
6a44eefe-fbe8-431c-a418-2571b26aa42e,4,tegaserod,139778,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200605_6a44eefe-fbe8-431c-a418-2571b26aa42e.json,"These highlights do not include all the information needed to use ZELNORM

™

 safely and effectively. See full prescribing information for ZELNORM

™

.  

ZELNORM

™

 (tegaserod) tablets, for oral use

Initial U.S. Approval: 2002"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
75d68f19-4208-109e-e053-2991aa0ac857,19,riluzole,35623,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20240210_75d68f19-4208-109e-e053-2991aa0ac857.json,"These highlights do not include all the information needed to use TIGLUTIK® safely and effectively. See full prescribing information for TIGLUTIK.
 



TIGLUTIK (riluzole) oral suspension
 

Initial U.S. Approval: 1995"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
866e9f35-9035-4581-a4b1-75a621ab55cf,22,baricitinib,2047232,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230322_866e9f35-9035-4581-a4b1-75a621ab55cf.json,"These highlights do not include all the information needed to use OLUMIANT safely and effectively. See full prescribing information for OLUMIANT.
OLUMIANT (baricitinib) tablets, for oral useInitial U.S. Approval: 2018"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,zafirlukast,114970,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,Zafirlukast Tablets Rx only
8c9607a2-5b57-4a59-b159-cf196deebdd9,5,bremelanotide,2176312,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231205_8c9607a2-5b57-4a59-b159-cf196deebdd9.json,"These highlights do not include all the information needed to use VYLEESI® safely and effectively. See full prescribing information for VYLEESI
VYLEESI (bremelanotide injection), for subcutaneous useInitial U.S. Approval: 2019"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
9583405d-53a0-49dc-88eb-5e6384ebabcb,6,ropeginterferon alfa-2b,2587059,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240116_9583405d-53a0-49dc-88eb-5e6384ebabcb.json,"These highlights do not include all the information needed to use BESREMi safely and effectively. See full prescribing information for BESREMi. BESREMI (ropeginterferon alfa-2b-njft) injection, for subcutaneous use Initial U.S. Approval: 2021"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
9e79b42c-38a3-4b2c-a196-a5a1948250e2,57,lacosamide,623400,ALI,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20231011_9e79b42c-38a3-4b2c-a196-a5a1948250e2.json,"These highlights do not include all the information needed to use VIMPAT® safely and effectively.  See full prescribing information for VIMPAT. 
VIMPAT® (lacosamide) film coated tablet, for oral use, CV VIMPAT® (lacosamide) injection, for intravenous use, CV VIMPAT® (lacosamide) oral solution, CV Initial U.S. Approval: 2008"
a0478684-e477-4b52-97a9-04a76e794c87,5,romidepsin,877510,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230627_a0478684-e477-4b52-97a9-04a76e794c87.json,"These highlights do not include all the information needed to use ROMIDEPSIN INJECTION safely and effectively. See full prescribing information for ROMIDEPSIN INJECTION.




ROMIDEPSIN injection, for intravenous use

Initial U.S. Approval: 2009"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,ritonavir,85762,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
a74239bf-4684-424c-ba4e-6087e363265b,14,amlodipine,17767,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b0d6341b-d880-4f0b-8844-bc788c03004a,2,quinidine,9068,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231221_b0d6341b-d880-4f0b-8844-bc788c03004a.json,"Quinidine Sulfate Tablets, USP"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b31ff20a-c363-4be0-9bc0-3081c163b63c,7,atovaquone,60212,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,moexipril,30131,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,AKI,10038491,renal papillary necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,ferumoxytol,473387,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d4500795-3b07-4a7d-b432-73cafbb3dbc6,2,aztreonam,1272,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_d4500795-3b07-4a7d-b432-73cafbb3dbc6.json,"Aztreonam for Injection, USP"
d6364be4-056b-4ebe-83bc-3fc85e8f488c,7,lorazepam,6470,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_d6364be4-056b-4ebe-83bc-3fc85e8f488c.json,"Lorazepam Tablets, USP CIV
 
Rx only"
e23dcfd0-071a-4458-a595-3562fabccbd4,3,dantrolene,3105,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240203_e23dcfd0-071a-4458-a595-3562fabccbd4.json,Dantrolene Sodium capsules
e49e1a61-1b7c-4be5-ac84-af6240b511e7,22,baloxavir marboxil,2099995,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230824_e49e1a61-1b7c-4be5-ac84-af6240b511e7.json,"These highlights do not include all the information needed to use XOFLUZA safely and effectively. See full prescribing information for XOFLUZA. 
XOFLUZA® (baloxavir marboxil) tablets, for oral use XOFLUZA® (baloxavir marboxil) for oral suspension Initial U.S. Approval: 2018"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,cefotaxime,2186,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,"CEFOTAXIME FOR INJECTION, USP"
efbdafa9-d18c-4e85-b4a2-1e620fc74e50,11,idelalisib,1544460,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20220308_efbdafa9-d18c-4e85-b4a2-1e620fc74e50.json,"These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. 
 ZYDELIG® (idelalisib) tablets, for oral use Initial U.S. Approval: 2014"
f0ba651e-3d8a-11df-8fbe-119855d89593,14,pentosan polysulfate,155046,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221111_f0ba651e-3d8a-11df-8fbe-119855d89593.json,"ELMIRON 
 ®-100 MG
 

(PENTOSAN POLYSULFATE SODIUM)
 

CAPSULES"
f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,10,pretomanid,2198359,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20221230_f1906fc9-cb3c-4e13-8a4a-da76100c1bf3.json,"These highlights do not include all the information needed to use PRETOMANID TABLETS safely and effectively.  See full prescribing information for PRETOMANID TABLETS. 
PRETOMANID tablets, for oral use
Initial U.S. Approval: 2019LIMITED POPULATION"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f567d5c7-ea5d-49a7-a035-b47208135f73,9,quinine,9071,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005"
f96cfd69-da34-41ee-90a9-610a4655cd1c,35,aflibercept,1232150,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20231223_f96cfd69-da34-41ee-90a9-610a4655cd1c.json,"These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA.
 EYLEA® (aflibercept) injection, for intravitreal use Initial U.S. Approval:  2011"
f9ab6b1c-98d0-4373-0e9b-b10cb4a67543,22,deferoxamine,3131,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231202_f9ab6b1c-98d0-4373-0e9b-b10cb4a67543.json,"These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE safely and effectively. See full prescribing information for DEFEROXAMINE MESYLATE.

DEFEROXAMINE MESYLATE for injection, for intramuscular, intravenous, or subcutaneous use
Initial U.S. Approval: 1968"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fd427d2d-b78b-412a-9c80-606bc88ad112,10,eletriptan,231049,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10018836,haematochezia,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
038f2461-834b-4488-9ebd-863c83eef5a7,10,ixazomib,1723735,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231230_038f2461-834b-4488-9ebd-863c83eef5a7.json,"These highlights do not include all the information needed to use NINLARO safely and effectively. See full prescribing information for NINLARO.
 NINLARO® (ixazomib) capsules, for oral use Initial U.S. Approval: 2015"
04a413fe-95f4-47a7-42ac-283a9e78297d,20,ethionamide,4127,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231010_04a413fe-95f4-47a7-42ac-283a9e78297d.json,"Trecator®


 (ethionamide tablets, USP) 

Tablets"
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
08982e49-d2eb-4b25-b01a-1be52fd669ef,16,tipranavir,190548,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005"
0b8bf078-34c2-4f45-9012-38a8ac082b01,6,adagrasib,2625882,ALI,10066758,mixed liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022"
0c76d25b-abac-41a3-a547-4fa4796bf7a4,2,phenylbutyrate,81647,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240103_0c76d25b-abac-41a3-a547-4fa4796bf7a4.json,"Sodium Phenylbutyrate Tablets, USP"
106d9730-5938-8f27-e063-6294a90adc68,2,cyclobenzaprine,21949,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,"Cyclobenzaprine hydrochloride Tablets, USP"
106d9730-5938-8f27-e063-6294a90adc68,2,cyclobenzaprine,21949,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,"Cyclobenzaprine hydrochloride Tablets, USP"
10e39d3b-8621-16f8-e063-6294a90a254e,1,alvimopan,480639,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_10e39d3b-8621-16f8-e063-6294a90a254e.json,"ALVIMOPAN CAPSULES. These highlights do not include all the information needed to use ALVIMOPAN CAPSULES safely and effectively. See full prescribing information for ALVIMOPAN CAPSULES.
 

ALVIMOPAN capsules, for oral use
 
Initial U.S. Approval: 2008"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
17e597bc-d663-4d8e-a5d3-39816b628996,8,stavudine,59763,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994"
17e597bc-d663-4d8e-a5d3-39816b628996,8,stavudine,59763,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
1fd148fb-0fbc-4b6f-b790-23546fb46a71,20,doxorubicin,3639,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240124_1fd148fb-0fbc-4b6f-b790-23546fb46a71.json,"These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE. 
DOXORUBICIN HYDROCHLORIDE injection, for intravenous use DOXORUBICIN HYDROCHLORIDE for injection, for intravenous use Initial U.S. Approval: 1974"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
246a3c6c-a7fb-45c7-9509-49a48a5bdcc6,8,tranexamic acid,10691,AKI,10038422,renal cortical necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240220_246a3c6c-a7fb-45c7-9509-49a48a5bdcc6.json,"These highlights do not include all the information needed to use TRANEXAMIC ACID INJECTION safely and effectively. See full prescribing information for TRANEXAMIC ACID INJECTION.
 TRANEXAMIC ACID injection, for intravenous use Initial U.S. Approval: 1986"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
27f15fac-7d98-4114-a2ec-92494a91da98,8,semaglutide,1991302,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240208_27f15fac-7d98-4114-a2ec-92494a91da98.json,"These highlights do not include all the information needed to use RYBELSUS®
 safely and effectively.  See full prescribing information for RYBELSUS.
RYBELSUS (semaglutide) tablets, for oral use
Initial U.S. Approval: 2017"
2966aec7-2ef0-923c-d8ff-fe1a957bf095,84,upadacitinib,2196092,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231121_2966aec7-2ef0-923c-d8ff-fe1a957bf095.json,"These highlights do not include all the information needed to use RINVOQ safely and effectively. See full prescribing information for RINVOQ.

 

RINVOQ

®

 (upadacitinib) extended-release tablets, for oral use

Initial U.S. Approval: 2019"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,ALI,10019663,hepatic failure,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,AMI,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,7,lorlatinib,2103164,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230908_2b34d62d-e02a-4af3-bc0d-1571dd4ee76d.json,"These highlights do not include all the information needed to use LORBRENA safely and effectively. See full prescribing information for LORBRENA.
 LORBRENA® (lorlatinib) tablets, for oral use Initial U.S. Approval: 2018"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,andexanet alfa,2045114,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10054889,transaminases increased,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
326ef804-8d3a-425e-8513-8c9811856aa0,100,trimipramine,10834,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230616_326ef804-8d3a-425e-8513-8c9811856aa0.json,"TRIMIPRAMINE MALEATE CAPSULES, 25 MG, 50 MG and 100 MG Rx Only"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
369e89a4-9898-4a9f-a316-17d0fce8a08b,100,methazolamide,6826,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240206_369e89a4-9898-4a9f-a316-17d0fce8a08b.json,Methazolamide Tablets USP Rx only
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,levetiracetam,114477,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
44b0c461-47fb-4106-ba11-6ed85530235c,2,thioguanine,10485,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20230517_44b0c461-47fb-4106-ba11-6ed85530235c.json,"TABLOID®


brand 
Thioguanine

40-mg Scored Tablets"
4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,olutasidenib,2623641,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,AKI,10002847,anuria,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
58c4261e-e98f-4280-9562-2800956dff14,16,glimepiride,25789,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_58c4261e-e98f-4280-9562-2800956dff14.json,"These highlights do not include all the information needed to use GLIMEPIRIDE TABLETS safely and effectively. See full prescribing information for GLIMEPIRIDE TABLETS.
 

GLIMEPIRIDE tablets for oral use
 

Initial U.S. Approval: 1995"
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
632bb50c-3bcb-4c85-9056-fc33410550ae,5,lurbinectedin,2374729,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230811_632bb50c-3bcb-4c85-9056-fc33410550ae.json,"These highlights do not include all the information needed to use ZEPZELCA safely and effectively.  See full prescribing information for ZEPZELCA.

ZEPZELCA® (lurbinectedin) for injection, for intravenous use
Initial U.S. Approval: 2020"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
645af8f4-0843-4afb-9ddc-f587f38adb68,8,demeclocycline,3154,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,GIB,10030202,oesophageal ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5,100,probenecid,8698,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240127_6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5.json,"Probenecid Tablets, USP500 mg
Rx Only"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
7974d4ad-c419-4c7f-bbd6-f631d53e30de,3,tranylcypromine,10734,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230527_7974d4ad-c419-4c7f-bbd6-f631d53e30de.json,"These highlights do not include all the information needed to use TRANYLCYPROMINE SULFATE TABLETS safely and effectively. See full prescribing information for TRANYLCYPROMINE SULFATE TABLETS.TRANYLCYPROMINE SULFATE USP tablets, for oral useInitial U.S. Approval: 1961"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7df922bc-5750-4259-906f-64f960c38d5f,9,eszopiclone,461016,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
860c799c-5199-4f0c-b21b-9910273474d9,6,pentamidine,7994,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,Pentamidine isethionate for injection
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,arsenic trioxide,18330,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000"
8993651b-fff6-4e3f-9b60-78587bc9bcee,2,sulfadiazine,10171,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231221_8993651b-fff6-4e3f-9b60-78587bc9bcee.json,"sulfADIAZINE Tablets, USP"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,oseltamivir,260101,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999"
8edd78a9-d762-4578-a610-28d6595f4bf3,1,melphalan,6718,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,Melphalan Hydrochloride for Injection(For Intravenous Infusion)
90073508-6dca-4d27-aa5a-ed837737c35b,1,rezafungin,2639155,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023"
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
94d8cfb1-ff2a-4956-8954-17635ac505d9,8,sevelamer,214824,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_94d8cfb1-ff2a-4956-8954-17635ac505d9.json,"These highlights do not include all the information needed to use SEVELAMER CARBONATE TABLETS safely and effectively. See full prescribing information for SEVELAMER CARBONATE TABLETS.


SEVELAMER CARBONATE tablets, for oral use 

Initial U.S. Approval: 2000"
983ce15f-cd37-4f3a-9e51-205860e80976,3,sodium phosphate,36709,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,DESCRIPTION
98ad5af1-bde6-4137-a599-b6354d664da4,1,methylergonovine,6883,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_98ad5af1-bde6-4137-a599-b6354d664da4.json,"Methylergonovine Maleate Tablets, USP

Rx Only
  
8481394/0124F"
9914e793-a49c-eb00-1ab7-f606c786fe25,7,dactinomycin,3100,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964"
9929c166-8ba3-4159-a5f9-4618d5d227b0,102,flecainide,4441,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,Flecainide Acetate Tablets USPRx only
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
a0478684-e477-4b52-97a9-04a76e794c87,5,romidepsin,877510,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230627_a0478684-e477-4b52-97a9-04a76e794c87.json,"These highlights do not include all the information needed to use ROMIDEPSIN INJECTION safely and effectively. See full prescribing information for ROMIDEPSIN INJECTION.




ROMIDEPSIN injection, for intravenous use

Initial U.S. Approval: 2009"
a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,34,daratumumab,1721947,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.json,"These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX.
 



DARZALEX 
 ®(daratumumab) injection, for intravenous use
 

Initial U.S. Approval: 2015"
a74239bf-4684-424c-ba4e-6087e363265b,14,amlodipine,17767,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987"
a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,1,lisdexamfetamine,700810,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811.json,"These highlights do not include all the information needed to use LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS safely and effectively. See full prescribing information for LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS. LISDEXAMFETAMINE DIMESYLATE chewable tablets, for oral use, CII Initial U.S. Approval: 2007"
a9a590d9-0217-43c7-908d-e62a71279791,15,ravulizumab,2107301,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240223_a9a590d9-0217-43c7-908d-e62a71279791.json,"These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. 
ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous or subcutaneous use 
Initial U.S. Approval: 2018"
ad750031-08ec-4d92-af2d-97a80c454e14,1,tiopronin,6765,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20240207_ad750031-08ec-4d92-af2d-97a80c454e14.json,"These highlights do not include all the information needed to use TIOPRONIN DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for TIOPRONIN DELAYED-RELEASE TABLETS.
TIOPRONIN delayed-release tablets, for oral use Initial U.S. Approval: 1988"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b20b4e18-7a4b-4500-a08f-06c6dab0ee5b,10,alpelisib,2169285,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_b20b4e18-7a4b-4500-a08f-06c6dab0ee5b.json,"These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY.


PIQRAY® (alpelisib) tablets, for oral use

Initial U.S. Approval: 2019"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10038491,renal papillary necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b856bfaf-ec6b-4171-81c4-b9b07f780084,2,valganciclovir,275891,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
bf514e99-4958-44a0-a87a-02a950f87e60,7,acetazolamide,167,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,"Acetazolamide Extended-release Capsules, USP
Rx only"
bf514e99-4958-44a0-a87a-02a950f87e60,7,acetazolamide,167,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,"Acetazolamide Extended-release Capsules, USP
Rx only"
c0781dae-3ef6-4cab-b084-01d2e45f3764,1,eptifibatide,75635,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240131_c0781dae-3ef6-4cab-b084-01d2e45f3764.json,"These highlights do not include all the information needed to use EPTIFIBATIDE INJECTION safely and effectively. See full prescribing information for EPTIFIBATIDE INJECTION.
EPTIFIBATIDE injection, for intravenous useInitial U.S. Approval: 1998"
c23d89e9-b00b-4520-e053-2995a90a95af,9,pegcetacoplan,2557372,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_c23d89e9-b00b-4520-e053-2995a90a95af.json,"These highlights do not include all the information needed to use EMPAVELI safely and effectively. See full prescribing information for EMPAVELI. 
EMPAVELI® (pegcetacoplan) injection, for subcutaneous use Initial U.S. Approval: 2021"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,neratinib,1940643,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017"
d9d74915-6606-4570-9c52-c4001d3177de,20,anakinra,72435,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20201230_d9d74915-6606-4570-9c52-c4001d3177de.json,"These highlights do not include all the information needed to use KINERET safely and effectively.  See full prescribing information for KINERET.  
KINERET® (anakinra) injection, for subcutaneous useInitial U.S. Approval: 2001"
d9fd11d0-4269-12fb-95cf-b3c11d75e479,6,tolvaptan,358257,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_d9fd11d0-4269-12fb-95cf-b3c11d75e479.json,"These highlights do not include all the information needed to use TOLVAPTAN TABLETS safely and effectively. See full prescribing information for TOLVAPTAN TABLETS.

TOLVAPTAN tablets, for oral use

Initial U.S. Approval: 2009"
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
de61685e-2b8c-4e22-84bb-869e13600440,38,peginterferon alfa-2a,120608,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20221214_de61685e-2b8c-4e22-84bb-869e13600440.json,"These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. 
 PEGASYS® (peginterferon alfa-2a) injection, for subcutaneous use  Initial U.S. Approval: 2002"
e49e1a61-1b7c-4be5-ac84-af6240b511e7,22,baloxavir marboxil,2099995,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230824_e49e1a61-1b7c-4be5-ac84-af6240b511e7.json,"These highlights do not include all the information needed to use XOFLUZA safely and effectively. See full prescribing information for XOFLUZA. 
XOFLUZA® (baloxavir marboxil) tablets, for oral use XOFLUZA® (baloxavir marboxil) for oral suspension Initial U.S. Approval: 2018"
ed3039d8-3d27-4b71-a4b0-812943c9457f,10,trazodone,10737,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_ed3039d8-3d27-4b71-a4b0-812943c9457f.json,"These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.





TRAZODONE HYDROCHLORIDE tablets, for oral use




Initial U.S. Approval: 1981"
eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7,13,pazopanib,714438,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20240207_eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7.json,"These highlights do not include all the information needed to use VOTRIENT safely and effectively. See full prescribing information for VOTRIENT.
VOTRIENT® (pazopanib) tablets, for oral useInitial U.S. Approval: 2009"
f6dd2682-75a6-4863-90a8-a3197f6f78a8,12,selinexor,2178390,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220728_f6dd2682-75a6-4863-90a8-a3197f6f78a8.json,"These highlights do not include all the information needed to use XPOVIO safely and effectively. See full prescribing information for XPOVIO. 
XPOVIO® (selinexor) tablets, for oral useInitial U.S. Approval: 2019"
f87dc257-c131-47ca-acc3-55ab79f9107b,9,benazepril,18867,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_f87dc257-c131-47ca-acc3-55ab79f9107b.json,"These highlights do not include all the information needed to use BENAZEPRIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for use BENAZEPRIL HYDROCHLORIDE TABLETS.
 



BENAZEPRIL HYDROCHLORIDE tablets, film coated for oral use
 

Initial U.S. Approval: 1991"
faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,26,empagliflozin,1545653,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231122_faf3dd6a-9cd0-39c2-0d2e-232cb3f67565.json,"These highlights do not include all the information needed to use JARDIANCE safely and effectively.  See full prescribing information for JARDIANCE. 
JARDIANCE® (empagliflozin tablets), for oral useInitial U.S. Approval: 2014"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00fd1905-27e4-420e-8dc5-a69e4ddc1526,11,nitisinone,61805,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240124_00fd1905-27e4-420e-8dc5-a69e4ddc1526.json,"These highlights do not include all the information needed to use NITYR safely and effectively. See full prescribing information for NITYR.
NITYR® (nitisinone) tablets, for oral useInitial U.S. Approval: 2002"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
038f2461-834b-4488-9ebd-863c83eef5a7,10,ixazomib,1723735,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231230_038f2461-834b-4488-9ebd-863c83eef5a7.json,"These highlights do not include all the information needed to use NINLARO safely and effectively. See full prescribing information for NINLARO.
 NINLARO® (ixazomib) capsules, for oral use Initial U.S. Approval: 2015"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,cefixime,25033,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,ALI,10023136,jaundice hepatocellular,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,terbinafine,37801,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992"
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
144067b2-0532-476a-996e-e4a0a9d09b05,1,tenofovir disoproxil,300195,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
18bbd246-5709-4477-b10a-f811f3801962,6,imipramine,5691,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_18bbd246-5709-4477-b10a-f811f3801962.json,"Imipramine Hydrochloride Tablets, USP
 
Rx Only"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
1fd148fb-0fbc-4b6f-b790-23546fb46a71,20,doxorubicin,3639,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_1fd148fb-0fbc-4b6f-b790-23546fb46a71.json,"These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE. 
DOXORUBICIN HYDROCHLORIDE injection, for intravenous use DOXORUBICIN HYDROCHLORIDE for injection, for intravenous use Initial U.S. Approval: 1974"
20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,fludarabine,24698,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991"
222f77ff-d3f7-40f9-989c-e5902f44ef1e,10,rizatriptan,88014,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_222f77ff-d3f7-40f9-989c-e5902f44ef1e.json,"These highlights do not include all the information needed to use RIZATRIPTAN BENZOATE TABLETS safely and effectively. See full prescribing information for RIZATRIPTAN BENZOATE TABLETS.
 RIZATRIPTAN BENZOATE tablets, for oral use Initial U.S. Approval: 1998"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019768,hepatitis e,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
2966aec7-2ef0-923c-d8ff-fe1a957bf095,84,upadacitinib,2196092,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20231121_2966aec7-2ef0-923c-d8ff-fe1a957bf095.json,"These highlights do not include all the information needed to use RINVOQ safely and effectively. See full prescribing information for RINVOQ.

 

RINVOQ

®

 (upadacitinib) extended-release tablets, for oral use

Initial U.S. Approval: 2019"
2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee,11,erdafitinib,2123125,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240202_2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee.json,"These highlights do not include all the information needed to use BALVERSA safely and effectively. See full prescribing information for BALVERSA.
 

BALVERSA 
 ®(erdafitinib) tablets, for oral use
 
Initial U.S. Approval: 2019"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2,7,loxapine,6475,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2.json,"Loxapine Capsules, USP"
2d599ccf-8e63-4ff1-aa52-4809744ea97a,9,temozolomide,37776,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240216_2d599ccf-8e63-4ff1-aa52-4809744ea97a.json,"These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for TEMOZOLOMIDE CAPSULES.
 



TEMOZOLOMIDE capsules, for oral use
 



Initial U.S. Approval: 1999"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,desvenlafaxine,734064,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008"
33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,ertapenem,325642,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
4031017d-d768-46de-8081-476bcb883f5e,5,gemcitabine,12574,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
43ba3de1-ab2e-06f6-e054-00144ff8d46c,3,auranofin,1227,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20181215_43ba3de1-ab2e-06f6-e054-00144ff8d46c.json,"PRESCRIBING INFORMATION
 



RIDAURA 
 ®




Auranofin
 



Capsules"
44492772-5aed-4627-bd85-e8e89f308bb3,12,siponimod,2121085,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
454f092e-dcd0-47bd-a521-b07400403dad,5,mannitol,6628,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
487cd7e7-434c-4925-99fa-aa80b1cc776b,3,tirzepatide,2601723,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231116_487cd7e7-434c-4925-99fa-aa80b1cc776b.json,"These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND™ (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4a22e559-2dac-42d7-af8d-eb0ebbc2f76d,8,6-aminocaproic acid,99,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231229_4a22e559-2dac-42d7-af8d-eb0ebbc2f76d.json,"Aminocaproic Acid Tablets, USP

(500 mg)

Rx only"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5d31d815-50fa-4e78-8ebd-affc2514ce78,10,metoclopramide,6915,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240216_5d31d815-50fa-4e78-8ebd-affc2514ce78.json,"These highlights do not include all the information needed to use METOCLOPRAMIDE TABLETS safely and effectively. See full prescribing information for METOCLOPRAMIDE TABLETS.
 



METOCLOPRAMIDE tablets, for oral use
 

Initial U.S. Approval: 1979"
6240792b-9224-2d10-e053-2a91aa0a2c3e,8,orlistat,37925,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999"
67e3ba3c-77e1-43b5-a93c-5bf5e3855780,2,griseofulvin,5021,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_67e3ba3c-77e1-43b5-a93c-5bf5e3855780.json,"GRISEOFULVIN ORAL SUSPENSION, USP


Microsize


125 mg/5 mL




Rx only"
69301126-c901-4d0d-9acb-91ba1a87cd21,26,valacyclovir,73645,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995"
6a335659-03b0-4a2d-9cd4-7dcf7da96fe6,14,colistin,2709,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20231026_6a335659-03b0-4a2d-9cd4-7dcf7da96fe6.json,"Colistimethate for Injection, USP"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
740a0f37-aa95-4558-b415-be516b8c40a3,2,tolmetin,10636,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230713_740a0f37-aa95-4558-b415-be516b8c40a3.json,"Tolmetin Sodium Capsules, USP 400 mg
 Rx only"
74f84173-a43f-7788-e053-2991aa0a8fb2,6,hydrocortisone,5492,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_74f84173-a43f-7788-e053-2991aa0a8fb2.json,SOLU-CORTEF® 100mg 2mL ACT-O-VIAL®
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,ALI,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,tenofovir disoproxil,300195,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10013560,diverticulum intestinal haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
80eb1080-fe20-4af0-b2a5-a67999923fa8,10,tagraxofusp,2109055,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230804_80eb1080-fe20-4af0-b2a5-a67999923fa8.json,"These highlights do not include all the information needed to use ELZONRIS®safely and effectively.  See full prescribing information for ELZONRIS.
			
ELZONRIS (tagraxofusp-erzs) injection, for intravenous use
			Initial U.S. Approval: 2018"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
852f013f-6759-4438-83c1-8ff48133dc85,4,albendazole,430,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,zafirlukast,114970,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,Zafirlukast Tablets Rx only
8edd78a9-d762-4578-a610-28d6595f4bf3,1,melphalan,6718,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,Melphalan Hydrochloride for Injection(For Intravenous Infusion)
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a26cfa07-14a7-4468-8eed-3529f3d613f4,6,efavirenz,195085,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998"
a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,ritonavir,85762,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996"
a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,10,enasidenib,1940332,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240105_a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.json,"These highlights do not include all the information needed to use IDHIFA safely and effectively. See full prescribing information for IDHIFA. 
IDHIFA® (enasidenib) tablets, for oral use Initial U.S. Approval: 2017"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
adfc2b23-00a5-4f05-a08b-83087e1e4843,1,enoxaparin,67108,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_adfc2b23-00a5-4f05-a08b-83087e1e4843.json,"These highlights do not include all the information needed to use ENOXAPARIN SODIUM INJECTION safely and effectively. See full prescribing information for ENOXAPARIN SODIUM INJECTION.ENOXAPARIN SODIUM injection, for subcutaneous and intravenous useInitial U.S. Approval: 1993"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c01906fa-2c73-4c13-9765-2fd06628d263,26,lincomycin,6398,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231108_c01906fa-2c73-4c13-9765-2fd06628d263.json,"Lincocin®


 lincomycin injection, USP"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c522c860-84ce-4c61-ab72-077de73195df,1,tetracycline,10395,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240120_c522c860-84ce-4c61-ab72-077de73195df.json,"Tetracycline Hydrochloride Tablets, USP For Oral Use"
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c9a1d0a8-581f-4f91-a2b8-f419192d0ebf,12,roflumilast,1091836,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20220916_c9a1d0a8-581f-4f91-a2b8-f419192d0ebf.json,"These highlights do not include all the information needed to use DALIRESP safely and effectively. See full prescribing information for DALIRESP.
DALIRESP® (roflumilast) tabletsInitial U.S. Approval: 2011"
c9fe3f32-4219-466e-acb9-3f609b4f4df1,5,tisotumab,2571095,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230805_c9fe3f32-4219-466e-acb9-3f609b4f4df1.json,"These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.
TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 2021"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10061880,occult blood positive,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cc4da2c3-f939-444d-9b5b-a57b6051c190,11,levocarnitine,42955,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240123_cc4da2c3-f939-444d-9b5b-a57b6051c190.json,"LEVOCARNITINE INJECTION, USP1 g per 5 mL vial and 4 g per 20 mL vialFOR INTRAVENOUS USE ONLYRx Only"
cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c,13,etelcalcetide,1876119,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220626_cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c.json,"These highlights do not include all the information needed to use PARSABIV safely and effectively. See full prescribing information for PARSABIV. 
PARSABIV® (etelcalcetide) injection, for intravenous use Initial U.S. Approval: 2017"
ce9f0ea6-69f9-6b68-2811-3b51e34acea6,5,carboprost,2051,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240112_ce9f0ea6-69f9-6b68-2811-3b51e34acea6.json,""
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,ferumoxytol,473387,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
d72e0e10-4557-41b0-b65d-d395468cad19,11,aprepitant,358255,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_d72e0e10-4557-41b0-b65d-d395468cad19.json,"These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. 
APREPITANT capsules, for oral use Initial U.S. Approval: 2003"
d7836711-b677-412d-bf2d-0f7c8444103a,3,epcoritamab,2637392,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023"
d7c6bc5e-1916-43bf-b943-98f00f41b8de,4,cholestyramine resin,2447,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240126_d7c6bc5e-1916-43bf-b943-98f00f41b8de.json,"Cholestyramine for Oral Suspension USP, Light"
dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,bexarotene,233272,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
e4c45bb5-15f4-437e-ab98-a649b3676d14,22,lomitapide,1364479,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20220430_e4c45bb5-15f4-437e-ab98-a649b3676d14.json,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012"
e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,carbidopa,2019,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,CARBIDOPA tablets
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f941fc61-f7a3-4e4a-ab7c-87c1667fa05b,5,rituximab,121191,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_f941fc61-f7a3-4e4a-ab7c-87c1667fa05b.json,"These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. 
RUXIENCE® (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 
RUXIENCE (rituximab-pvvr) is biosimilar
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RUXIENCE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.
 to RITUXAN (rituximab)"
f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,8,hydromorphone,3423,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240130_f9ca2ef5-46d8-475a-a26e-f7c8becd6db7.json,"These highlights do not include all the information needed to use HYDROMORPHONE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for HYDROMORPHONE HYDROCHLORIDE INJECTION.
HYDROMORPHONE HYDROCHLORIDE injection, for intravenous, intramuscular, or subcutaneous use, CII
Initial U.S. Approval: 1984"
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/train_xml/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fee3bd4a-ade3-41fa-839a-48e9af69bcf4,5,propofol,8782,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231201_fee3bd4a-ade3-41fa-839a-48e9af69bcf4.json,"Diprivan® (Propofol) Injectable Emulsion, USP"
ff9baf45-830f-4a8a-8986-5caeaa1b38cf,4,lithium citrate,52105,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20230826_ff9baf45-830f-4a8a-8986-5caeaa1b38cf.json,"These highlights do not include all the information needed to use LITHIUM ORAL SOLUTION safely and effectively. See full prescribing information for LITHIUM ORAL SOLUTION.
 

LITHIUM oral solution, for oral use
 

Initial U.S. Approval: 1970"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10018836,haematochezia,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
040a97e5-efd1-4a2f-b737-2f13e5366d70,7,selegiline,9639,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_040a97e5-efd1-4a2f-b737-2f13e5366d70.json,Selegiline Hydrochloride Tablets USP 5 mg
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,cefixime,25033,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0a273a2d-a1ff-412a-925e-696648730dae,5,clofarabine,44151,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004"
0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,terbinafine,37801,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992"
0daf09f8-d884-439d-aa5e-00d445edc38f,8,lithium carbonate,42351,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240224_0daf09f8-d884-439d-aa5e-00d445edc38f.json,"These highlights do not include all the information needed to use LITHIUM CARBONATE CAPSULES safely and effectively. See full prescribing information for LITHIUM CARBONATE CAPSULES.
 



LITHIUM CARBONATE capsules, for oral use
 



Initial U.S. Approval: 1970"
0dfd0279-ff17-4ea9-89be-9803c71bab44,53,ibrutinib,1442981,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20240301_0dfd0279-ff17-4ea9-89be-9803c71bab44.json,"These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA.

 

IMBRUVICA

®

 (ibrutinib) capsules, for oral use

IMBRUVICA

®

 (ibrutinib) tablets, for oral use

IMBRUVICA

®

 (ibrutinib) oral suspension

Initial U.S. Approval: 2013"
0dfd0279-ff17-4ea9-89be-9803c71bab44,53,ibrutinib,1442981,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20240301_0dfd0279-ff17-4ea9-89be-9803c71bab44.json,"These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA.

 

IMBRUVICA

®

 (ibrutinib) capsules, for oral use

IMBRUVICA

®

 (ibrutinib) tablets, for oral use

IMBRUVICA

®

 (ibrutinib) oral suspension

Initial U.S. Approval: 2013"
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
0fd36cb9-c4f6-4167-93c9-8530865db3f9,155,darbepoetin alfa,283838,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_0fd36cb9-c4f6-4167-93c9-8530865db3f9.json,"These highlights do not include all the information needed to use 
ARANESP 
safely and effectively.  
See full prescribing information for 
ARANESP
.

   

ARANESP

®

 (darbepoetin alfa
)
 
i
njection, for intravenous or subcutaneous use

Initial U.S. Approval: 2001"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,AKI,10038491,renal papillary necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,bedaquiline,1364504,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1b97bd3a-1040-4511-b0e6-4758e8083ae5,3,panobinostat,1603350,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20210729_1b97bd3a-1040-4511-b0e6-4758e8083ae5.json,"These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK.


FARYDAK® (panobinostat) capsules, for oral use

Initial U.S. Approval: 2015"
1c90aa68-cc12-41ef-aebc-2616ae45683a,11,candesartan,214354,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
1fd148fb-0fbc-4b6f-b790-23546fb46a71,20,doxorubicin,3639,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240124_1fd148fb-0fbc-4b6f-b790-23546fb46a71.json,"These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE. 
DOXORUBICIN HYDROCHLORIDE injection, for intravenous use DOXORUBICIN HYDROCHLORIDE for injection, for intravenous use Initial U.S. Approval: 1974"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
22477d77-3369-43cf-a444-dfc7ea69cacf,2,baclofen,1292,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240209_22477d77-3369-43cf-a444-dfc7ea69cacf.json,"BACLOFEN TABLETS USP

Rx only"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
22d67228-6c24-47ca-afc7-52ef279520a0,5,nalmefene,31479,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_22d67228-6c24-47ca-afc7-52ef279520a0.json,""
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10017826,gastric ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,7,lorlatinib,2103164,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230908_2b34d62d-e02a-4af3-bc0d-1571dd4ee76d.json,"These highlights do not include all the information needed to use LORBRENA safely and effectively. See full prescribing information for LORBRENA.
 LORBRENA® (lorlatinib) tablets, for oral use Initial U.S. Approval: 2018"
32167dd7-5d37-457b-9b00-cd735de6b060,5,tinidazole,10612,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004"
34de1806-d921-4d2f-8c7f-03625b717a70,25,methylphenidate,6901,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
374013c9-18c9-4419-b9fb-9bc5c765688e,1,budesonide,19831,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240203_374013c9-18c9-4419-b9fb-9bc5c765688e.json,"Budesonide Inhalation Suspension
 

These highlights do not include all the information needed to use BUDESONIDE INHALATION SUSPENSION safely and effectively. See full prescribing information for BUDESONIDE INHALATION SUSPENSION.
 

BUDESONIDE Inhalation Suspension, for inhalation suspension
 
Initial U.S. Approval: 2000"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
4031017d-d768-46de-8081-476bcb883f5e,5,gemcitabine,12574,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42e99112-c402-4662-877f-9e3a84dff9f2,9,cinacalcet,407990,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_42e99112-c402-4662-877f-9e3a84dff9f2.json,"These highlights do not include all the information needed to use CINACALCET TABLETS safely and effectively. See full prescribing information for CINACALCET TABLETS. 
 CINACALCET tablets, for oral use  Initial U.S. Approval: 2004"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
4338428e-43d4-4e02-ac9d-bd98e738a7da,5,cabotegravir,2475077,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231222_4338428e-43d4-4e02-ac9d-bd98e738a7da.json,"These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE.
APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular useInitial U.S. Approval: 2021"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
454f092e-dcd0-47bd-a521-b07400403dad,5,mannitol,6628,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
472bd78e-be17-4b9d-90f4-9482c3aec9ff,12,trabectedin,1716278,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20200923_472bd78e-be17-4b9d-90f4-9482c3aec9ff.json,"These highlights do not include all the information needed to use YONDELIS® safely and effectively. See full prescribing information for YONDELIS.
YONDELIS (trabectedin) for injection, for intravenous useInitial U.S. Approval: 2015"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,GIB,10018836,haematochezia,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4dd14728-02b4-4e75-b9c6-227be7816d5b,9,abacavir,190521,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
5526617c-c7b9-4556-886d-729bbabbc566,21,tolvaptan,358257,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20221119_5526617c-c7b9-4556-886d-729bbabbc566.json,"These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.
 SAMSCA® (tolvaptan) tablets, for oral use Initial U.S. Approval: 2009"
55ae23ff-60f5-4de6-bd1b-472243b8636b,8,pioglitazone,33738,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999"
5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,cladribine,44157,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,CLADRIBINE INJECTION
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
59984249-e3ff-4f97-8d7a-c1a905d604a8,14,pralsetinib,2394936,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230818_59984249-e3ff-4f97-8d7a-c1a905d604a8.json,"These highlights do not include all the information needed to use GAVRETO safely and effectively.  See full prescribing information for GAVRETO.
 GAVRETO® (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020"
5c40e41f-6401-4bda-975c-e1fac69867e9,12,isoniazid,6038,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_5c40e41f-6401-4bda-975c-e1fac69867e9.json,"Isoniazid Tablets, USP"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
6a8a3f53-2062-48ff-9dbe-b939df133ca3,7,ofatumumab,712566,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240125_6a8a3f53-2062-48ff-9dbe-b939df133ca3.json,"These highlights do not include all the information needed to use KESIMPTA safely and effectively. See full prescribing information for KESIMPTA.


KESIMPTA® (ofatumumab) injection, for subcutaneous useInitial U.S. Approval: 2009"
6f4998ac-0714-4f5d-8944-9e6902b9f0a6,12,levothyroxine,10582,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_6f4998ac-0714-4f5d-8944-9e6902b9f0a6.json,"These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.
 

LEVOTHYROXINE SODIUM tablets, for oral use
 

Initial U.S. Approval: 2002"
722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,acarbose,16681,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,"Acarbose Tablets, USP"
726daf35-4c03-464f-a814-cc0a715d6031,1,fluconazole,4450,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,"Fluconazole Tablets USP
 
Rx only"
75c0c785-38e0-4049-a6fb-b77581f5b35c,6,cefiderocol,2265702,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019"
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
7db07b5f-4e22-467c-9c0a-f830b08dbb1d,7,tazemetostat,2274378,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231227_7db07b5f-4e22-467c-9c0a-f830b08dbb1d.json,"These highlights do not include all the information needed to use TAZVERIK® safely and effectively. See full prescribing information for TAZVERIK.
TAZVERIK (tazemetostat) tablets, for oral useInitial U.S. Approval:  2020"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,AKI,10083346,anticoagulant-related nephropathy,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10061880,occult blood positive,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
8192d79d-da2b-2532-e053-2991aa0ae8ad,6,procainamide,8700,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240220_8192d79d-da2b-2532-e053-2991aa0ae8ad.json,"PROCAINAMIDE HCI INJECTION, USP 1gram/10mL TOTAL (100mg/mL) 10mL VIAL"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
852f013f-6759-4438-83c1-8ff48133dc85,4,albendazole,430,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996"
88f28338-9a64-42aa-a4e9-b1ad3fd073fe,9,betamethasone,1514,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_88f28338-9a64-42aa-a4e9-b1ad3fd073fe.json,"BETAMETHASONE VALERATE CREAM USP, 0.1%

BETAMETHASONE VALERATE OINTMENT USP, 0.1%

BETAMETHASONE VALERATE LOTION USP, 0.1%

(Potency expressed as betamethasone)"
8c065559-bd35-4dda-ac8f-624eea0641ae,9,zidovudine,11413,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_8c065559-bd35-4dda-ac8f-624eea0641ae.json,"These highlights do not include all the information needed to use ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ZIDOVUDINE TABLETS.
 



ZIDOVUDINE tablets, for oral use
 



Initial U.S. Approval: 1987"
8edd78a9-d762-4578-a610-28d6595f4bf3,1,melphalan,6718,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,Melphalan Hydrochloride for Injection(For Intravenous Infusion)
8f7f73b8-586a-4df0-935f-fecd4696c16c,17,isavuconazonium,1608322,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015"
904899f2-9c54-44d2-901e-47e894571500,2,norethindrone,7514,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_904899f2-9c54-44d2-901e-47e894571500.json,"ERRIN® (NORETHINDRONE TABLETS USP, 0.35 MG)"
90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,nafcillin,7233,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,"Nafcillin for Injection, USP Rx only"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
983ce15f-cd37-4f3a-9e51-205860e80976,3,sodium phosphate,36709,AKI,10069688,acute phosphate nephropathy,../data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,DESCRIPTION
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9f416ce0-012f-4194-9382-74ac71e4b2a9,6,ranitidine,9143,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
accf9569-4b57-4e83-a7db-4e890a75d1ba,23,mitoxantrone,7005,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,"MitoXANTRONE Injection, USP (concentrate)"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1ac4c92-e1fd-4015-b172-0932790ae019,2,prednisone,8640,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240227_b1ac4c92-e1fd-4015-b172-0932790ae019.json,"Prednisone Tablets, USP   Rx only"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c0946de1-2a2d-47ff-8071-50c1d3ad7982,8,phenytoin,8183,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c0946de1-2a2d-47ff-8071-50c1d3ad7982.json,"These highlights do not include all the information needed to use EXTENDED PHENYTOIN SODIUM CAPSULES safely and effectively. See full prescribing information for EXTENDED PHENYTOIN SODIUM CAPSULES.
 

EXTENDED PHENYTOIN SODIUM capsules, for oral use
 
Initial U.S. Approval: 1953"
c09c4cde-9f6c-4c4f-9d96-18beb5377564,1,methyltestosterone,6904,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220223_c09c4cde-9f6c-4c4f-9d96-18beb5377564.json,"Methyltestosterone Capsules, USP, CIII (10 mg) Rx only"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,famciclovir,68099,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c,6,misoprostol,42331,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c.json,"Misoprostol
 

Tablets"
c6c48eee-240b-4425-8691-35462523652e,1,propoxyphene,8785,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,"DARVON-N  - propoxyphene napsylate tablet, film coated"
c79d3668-5243-4627-ad2b-cc7c045df120,100,levocetirizine,356887,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_c79d3668-5243-4627-ad2b-cc7c045df120.json,"These highlights do not include all the information needed to use LEVOCETIRIZINE DIHYDROCHLORIDE tablets safely and effectively. See full prescribing information for LEVOCETIRIZINE DIHYDROCHLORIDE tablets.
LEVOCETIRIZINE DIHYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1995"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cac4f544-536c-4886-a379-99eed2d35240,8,sildenafil,136411,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cf41a02d-c881-4b40-b99c-d5b79dbd645b,9,perphenazine,8076,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_cf41a02d-c881-4b40-b99c-d5b79dbd645b.json,"Perphenazine Tablets, USP"
cf41a02d-c881-4b40-b99c-d5b79dbd645b,9,perphenazine,8076,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20240215_cf41a02d-c881-4b40-b99c-d5b79dbd645b.json,"Perphenazine Tablets, USP"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d7836711-b677-412d-bf2d-0f7c8444103a,3,epcoritamab,2637392,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023"
dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,infliximab,191831,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab)."
dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,infliximab,191831,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab)."
dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,bexarotene,233272,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999"
df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,obinutuzumab,974779,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013"
e65d5108-22a2-4d87-a78d-15606f3cc9e2,3,nimodipine,7426,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_e65d5108-22a2-4d87-a78d-15606f3cc9e2.json,"Nimodipine Capsules


For Oral Use


Rx only"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f2abe3ed-ed3d-4215-a489-b18341ce85bc,2,vorapaxar,1537034,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20221019_f2abe3ed-ed3d-4215-a489-b18341ce85bc.json,"These highlights do not include all the information needed to use ZONTIVITY safely and effectively. See full prescribing information for ZONTIVITY.
 



ZONTIVITY 
 ® (vorapaxar) Tablets 2.08 mg*, for oral use
 

*Equivalent to 2.5 mg vorapaxar sulfate
 

Initial U.S. Approval: 2014"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f73feeae-62ad-401e-b9f7-5cb269127750,4,trientine,10798,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_f73feeae-62ad-401e-b9f7-5cb269127750.json,"These highlights do not include all the information needed to use CUVRIOR safely and effectively. See full prescribing information for CUVRIOR.
 CUVRIOR™ (trientine tetrahydrochloride) tablets, for oral use Initial U.S. Approval: 1985"
f8b01c77-620d-4734-a771-b8524b65bcca,3,ketamine,6130,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_f8b01c77-620d-4734-a771-b8524b65bcca.json,"These highlights do not include all the information needed to use KETAMINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for KETAMINE HYDROCHLORIDE INJECTION. KETAMINE HYDROCHLORIDE injection, for intravenous or intramuscular use, CIII Initial U.S. Approval: 1970"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00fb869a-40e7-4c85-8380-c5e0cdee8018,4,bupivacaine,1815,AKI,10059895,urine output decreased,../data/2024_latest_labels/latest_labels_ingredients/20240224_00fb869a-40e7-4c85-8380-c5e0cdee8018.json,"HiGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MARCAINE™ and MARCAINE™ WITH EPINEPHRINE safely and effectively. See full prescribing information for MARCAINE™ and MARCAINE™ WITH EPINEPHRINE.
  MARCAINE™ (bupivacaine hydrochloride) injection, for infiltration, perineural, caudal, epidural, or retrobulbar useMARCAINE™ WITH EPINEPHRINE (bupivacaine hydrochloride and epinephrine) injection, for infiltration, perineural, caudal, or epidural useInitial U.S. Approval: 1972"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
03af7d09-314a-fe85-e063-6294a90afa25,1,valsartan,69749,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996"
03cdbf5b-b572-448f-80e9-b3e812959901,2,estropipate,33747,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20120328_03cdbf5b-b572-448f-80e9-b3e812959901.json,DESCRIPTION
08f0ea03-4e6d-195d-aef4-886e32befa95,27,peginterferon beta-1a,1546168,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20230808_08f0ea03-4e6d-195d-aef4-886e32befa95.json,"These highlights do not include all the information needed to use PLEGRIDY® safely and effectively.  See full prescribing information for PLEGRIDY.
PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous or intramuscular useInitial U.S. Approval:  2014"
0a273a2d-a1ff-412a-925e-696648730dae,5,clofarabine,44151,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004"
0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,alogliptin,1368001,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1fd148fb-0fbc-4b6f-b790-23546fb46a71,20,doxorubicin,3639,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240124_1fd148fb-0fbc-4b6f-b790-23546fb46a71.json,"These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE. 
DOXORUBICIN HYDROCHLORIDE injection, for intravenous use DOXORUBICIN HYDROCHLORIDE for injection, for intravenous use Initial U.S. Approval: 1974"
20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,fludarabine,24698,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019768,hepatitis e,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,GIB,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
2f349a44-6d04-01d1-c8b7-12254aead77d,1,estazolam,4077,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240215_2f349a44-6d04-01d1-c8b7-12254aead77d.json,ESTAZOLAM TABLETS
2f349a44-6d04-01d1-c8b7-12254aead77d,1,estazolam,4077,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240215_2f349a44-6d04-01d1-c8b7-12254aead77d.json,ESTAZOLAM TABLETS
3516e753-f064-4d30-9bd5-e3f2e143f75d,2,glofitamab,2639782,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230622_3516e753-f064-4d30-9bd5-e3f2e143f75d.json,"These highlights do not include all the information needed to use COLUMVI™ safely and effectively. See full prescribing information for COLUMVI. 
 COLUMVI (glofitamab-gxbm) injection, for intravenous use  Initial U.S. Approval: 2023"
36377351-d208-4363-8826-0acfea3f0cc1,5,sodium ferric gluconate complex,261435,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230609_36377351-d208-4363-8826-0acfea3f0cc1.json,"These highlights do not include all the information needed to use sodium ferric gluconate complex in sucrose injection safely and effectively. See full prescribing information for sodium ferric gluconate complex in sucrose injection.
Sodium ferric gluconate complex in sucrose injection, for intravenous use 
Initial U.S. Approval: 1999"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/gold_xml/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,brentuximab vedotin,1147320,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011"
3fc03452-cbfb-48a2-a747-45b03399741c,8,canagliflozin,1373458,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231216_3fc03452-cbfb-48a2-a747-45b03399741c.json,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42e99112-c402-4662-877f-9e3a84dff9f2,9,cinacalcet,407990,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_42e99112-c402-4662-877f-9e3a84dff9f2.json,"These highlights do not include all the information needed to use CINACALCET TABLETS safely and effectively. See full prescribing information for CINACALCET TABLETS. 
 CINACALCET tablets, for oral use  Initial U.S. Approval: 2004"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,olutasidenib,2623641,ALI,10019727,hepatitis acute,../data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10018836,haematochezia,../data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
551e43d5-f700-4d6e-8029-026f8a8932ff,14,secnidazole,36314,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017
55ad6325-16f6-4f0c-a1dc-734847052d0b,2,danazol,3102,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,"Danazol Capsules, USP
 

Rx only"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
6370e342-16a5-4339-a13f-ba275fd5de09,103,clomiphene,2596,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240111_6370e342-16a5-4339-a13f-ba275fd5de09.json,Clomiphene Citrate Tablets
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
6690679c-be2f-4588-a2e4-89fff74dd6be,9,tremelimumab,2619313,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022"
6a44eefe-fbe8-431c-a418-2571b26aa42e,4,tegaserod,139778,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20200605_6a44eefe-fbe8-431c-a418-2571b26aa42e.json,"These highlights do not include all the information needed to use ZELNORM

™

 safely and effectively. See full prescribing information for ZELNORM

™

.  

ZELNORM

™

 (tegaserod) tablets, for oral use

Initial U.S. Approval: 2002"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10061577,ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6fa380c4-c885-4743-85bf-88819ae68645,8,almotriptan,279645,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001"
6fa380c4-c885-4743-85bf-88819ae68645,8,almotriptan,279645,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
726daf35-4c03-464f-a814-cc0a715d6031,1,fluconazole,4450,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,"Fluconazole Tablets USP
 
Rx only"
7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,etoposide,4179,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983"
749e42fb-2fe0-45dd-9268-b43bb3f4081c,32,bosentan,75207,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_749e42fb-2fe0-45dd-9268-b43bb3f4081c.json,"These highlights do not include all the information needed to use TRACLEER safely and effectively. See full prescribing information for TRACLEER.
 



TRACLEER 
 ®(bosentan) tablets, for oral use
 

TRACLEER 
 ®(bosentan) tablets for oral suspension
 

Initial U.S. Approval: 2001"
755476e5-62a2-4f01-92a3-307e192ad42c,5,paricalcitol,73710,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_755476e5-62a2-4f01-92a3-307e192ad42c.json,"These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively.
 
See full prescribing information for PARICALCITOL CAPSULES.
 

PARICALCITOL capsules, for oral use
 
Initial U.S. Approval: 1998"
755476e5-62a2-4f01-92a3-307e192ad42c,5,paricalcitol,73710,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_755476e5-62a2-4f01-92a3-307e192ad42c.json,"These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively.
 
See full prescribing information for PARICALCITOL CAPSULES.
 

PARICALCITOL capsules, for oral use
 
Initial U.S. Approval: 1998"
75672079-589f-451a-bdbf-eaebcfcc80a9,28,tedizolid,1540825,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230325_75672079-589f-451a-bdbf-eaebcfcc80a9.json,"These highlights do not include all the information needed to use SIVEXTRO® safely and effectively. See full prescribing information for SIVEXTRO. 
SIVEXTRO (tedizolid phosphate) for injection, for intravenous use  SIVEXTRO (tedizolid phosphate) tablet, for oral use Initial U.S. Approval:  2014"
75c0c785-38e0-4049-a6fb-b77581f5b35c,6,cefiderocol,2265702,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019"
7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,epinephrine,3992,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
83e3ba94-d882-4b5c-87cb-af1eb0997efc,7,alendronate,46041,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240123_83e3ba94-d882-4b5c-87cb-af1eb0997efc.json,"These highlights do not include all the information needed to use ALENDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for ALENDRONATE SODIUM TABLETS.
ALENDRONATE SODIUM tablets, for oral useInitial U.S. Approval:1995"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
8b6261f6-4bdc-462e-8af1-4064664c62f3,2,empagliflozin,1545653,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221214_8b6261f6-4bdc-462e-8af1-4064664c62f3.json,"These highlights do not include all the information
needed to use JARDIANCE safely and effectively.  See full prescribing
information for JARDIANCE.
 JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014"
8bc2ddf8-d695-46b3-bf76-9f85ce6027e3,4,gallium,1310124,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120323_8bc2ddf8-d695-46b3-bf76-9f85ce6027e3.json,Ganite® (gallium nitrate injection)
9001c081-f455-4fb0-aef0-175d41810c12,8,mercaptopurine,103,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240104_9001c081-f455-4fb0-aef0-175d41810c12.json,"Mercaptopurine Tablets 50 mg
 

HIGHLIGHTS OF PRESCRIBING INFORMATION
 
These highlights do not include all the information needed to use Mercaptopurine Tablets safely and effectively. See full prescribing information for Mercaptopurine Tablets.
 
Mercaptopurine tablets, for oral use
 
Initial U.S. Approval: 1953"
90073508-6dca-4d27-aa5a-ed837737c35b,1,rezafungin,2639155,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9914e793-a49c-eb00-1ab7-f606c786fe25,7,dactinomycin,3100,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964"
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,galantamine,4637,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a23063c0-099a-4256-b95f-3a857bbf704b,18,alprazolam,596,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240209_a23063c0-099a-4256-b95f-3a857bbf704b.json,"These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS.


ALPRAZOLAM tablets, for oral use, CIV 


Initial U.S. Approval: 1981"
a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,hydroxocobalamin,5514,AKI,10061481,renal injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,"HYDROXOCOBALAMIN INJECTION USP
Rx Only"
a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,alogliptin,1368001,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a64a50ba-e3da-4227-9bce-87101d60409e,2,sapropterin,753340,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231205_a64a50ba-e3da-4227-9bce-87101d60409e.json,"These highlights do not include all the information needed to use SAPROPTERIN DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SAPROPTERIN DIHYDROCHLORIDE TABLETS.
 
SAPROPTERIN DIHYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2007"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,AKI,10059895,urine output decreased,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
a9b01bc6-95ac-46f9-befa-d845a74d53c1,16,estramustine,4089,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_a9b01bc6-95ac-46f9-befa-d845a74d53c1.json,"Emcyt®


 estramustine phosphate sodium

capsules"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
ae8d2354-7ddb-41b8-9d55-77c84782b18f,3,temsirolimus,657797,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240216_ae8d2354-7ddb-41b8-9d55-77c84782b18f.json,"These highlights do not include all the information needed to use TEMSIROLIMUS INJECTION safely and effectively.
 

See full prescribing information for TEMSIROLIMUS INJECTION.
 





TEMSIROLIMUS injection, for intravenous use
 

Initial U.S. Approval: 2007"
b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,5,ziconotide,68503,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231201_b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1.json,"These highlights do not include all the information needed to use PRIALT safely and effectively.  See full prescribing information for PRIALT.PRIALT (ziconotide) solution, intrathecal infusion Initial U.S. Approval: 2004"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
bb9a3820-f31a-4dd9-bef4-97094c01a398,7,sargramostim,69634,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991"
bb9a3820-f31a-4dd9-bef4-97094c01a398,7,sargramostim,69634,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c94e51d9-beef-4b06-e053-2a95a90a754a,3,talc,10323,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230115_c94e51d9-beef-4b06-e053-2a95a90a754a.json,Steritalc
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cfeab9e3-58b9-4890-9185-11b62904e2af,13,metronidazole,6922,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,Metronidazole Tablets USP
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,ALI,10067389,herpes simplex hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
d5050d0e-81d1-4707-a38a-e80de2aebf09,2,cefditoren,83682,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20130606_d5050d0e-81d1-4707-a38a-e80de2aebf09.json,Cefditoren Pivoxil Tablets 200 mg and 400 mg
d79a4b28-ef2b-4f0f-baec-002df7d06dd4,10,cefaclor,2176,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240201_d79a4b28-ef2b-4f0f-baec-002df7d06dd4.json,Cefaclor Capsules USP
d82aa06e-5a33-4844-99b7-4701313455a4,4,daprodustat,2628210,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230907_d82aa06e-5a33-4844-99b7-4701313455a4.json,"These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ.JESDUVROQ (daprodustat) tablets, for oral useInitial U.S. Approval: 2023"
d953457e-0aff-6c38-e053-2995a90a7d32,3,eplerenone,298869,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e23dcfd0-071a-4458-a595-3562fabccbd4,3,dantrolene,3105,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240203_e23dcfd0-071a-4458-a595-3562fabccbd4.json,Dantrolene Sodium capsules
e2e576e6-6181-4178-b989-61d0e795e559,13,sitagliptin,593411,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240202_e2e576e6-6181-4178-b989-61d0e795e559.json,"These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. 
JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006"
e5247ed5-6170-c13f-e053-2a95a90a4101,2,sodium chloride,9863,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240129_e5247ed5-6170-c13f-e053-2a95a90a4101.json,"0.9% SODIUM CHLORIDE INJECTION, USP 500 mL BAG"
f073b58e-56d6-4c8d-a2ce-b37719402d77,3,vinblastine,11198,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,Vinblastine Sulfate Injection
f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,10,pretomanid,2198359,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20221230_f1906fc9-cb3c-4e13-8a4a-da76100c1bf3.json,"These highlights do not include all the information needed to use PRETOMANID TABLETS safely and effectively.  See full prescribing information for PRETOMANID TABLETS. 
PRETOMANID tablets, for oral use
Initial U.S. Approval: 2019LIMITED POPULATION"
f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,10,pretomanid,2198359,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20221230_f1906fc9-cb3c-4e13-8a4a-da76100c1bf3.json,"These highlights do not include all the information needed to use PRETOMANID TABLETS safely and effectively.  See full prescribing information for PRETOMANID TABLETS. 
PRETOMANID tablets, for oral use
Initial U.S. Approval: 2019LIMITED POPULATION"
f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,tucatinib,2361285,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,ALI,10019727,hepatitis acute,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
03b39d40-90fe-11df-9de6-0002a5d5c51b,21,romidepsin,877510,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230603_03b39d40-90fe-11df-9de6-0002a5d5c51b.json,"These highlights do not include all the information needed to use ISTODAX safely and effectively.  See full prescribing information for ISTODAX.
ISTODAX® (romidepsin) for injection, for intravenous useInitial U.S. Approval:  2009"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
09c6c750-ae05-459f-83e8-4a9e4fd85212,28,atorvastatin,83367,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996"
0ae10bc4-6b65-402f-9db5-2d7753054922,21,rasburicase,283821,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230819_0ae10bc4-6b65-402f-9db5-2d7753054922.json,"These highlights do not include all the information needed to use Elitek safely and effectively. See full prescribing information for Elitek®. ELITEK (rasburicase) for injection, for intravenous useInitial U.S. Approval: 2002"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0edeb103-5e94-4f42-828f-c7336486c784,3,cephalexin,2231,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_0edeb103-5e94-4f42-828f-c7336486c784.json,These highlights do not include all the information needed to use CEPHALEXIN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEPHALEXIN FOR ORAL SUSPENSION CEPHALEXIN for oral suspension Initial U.S. Approval: 1971
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
1276283e-21b0-4932-864f-547c62bd49e5,5,ursodeoxycholate,62427,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240217_1276283e-21b0-4932-864f-547c62bd49e5.json,"Ursodiol Capsules, USP
 

Rx Only
 

Prescribing Information"
1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,bedaquiline,1364504,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012"
1738a682-5903-b675-3a7a-61d299a6f248,19,zoledronic acid,77655,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,ALI,10019636,hepatic artery thrombosis,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,ALI,10019663,hepatic failure,../data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
20293943-46ff-4345-1aa4-929b4e017a25,28,sufentanil,56795,AKI,10059895,urine output decreased,../data/2024_latest_labels/latest_labels_ingredients/20240227_20293943-46ff-4345-1aa4-929b4e017a25.json,"These highlights do not include all the information needed to use SUFENTANIL CITRATE INJECTION, safely and effectively. See full prescribing information for SUFENTANIL CITRATE INJECTION.
Sufentanil Citrate Injection, for intravenous and epidural use, CIIInitial U.S. Approval: 1984"
20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,fludarabine,24698,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991"
2102da5f-a1a0-4ac7-a1f6-38698cf7273a,9,tenapanor,2199674,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220421_2102da5f-a1a0-4ac7-a1f6-38698cf7273a.json,"These highlights do not include all the information needed to use IBSRELA® safely and effectively. See full prescribing information for IBSRELA.
IBSRELA (tenapanor) tablets, for oral useInitial U.S. Approval: 2019"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,ALI,10019636,hepatic artery thrombosis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22477d77-3369-43cf-a444-dfc7ea69cacf,2,baclofen,1292,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240209_22477d77-3369-43cf-a444-dfc7ea69cacf.json,"BACLOFEN TABLETS USP

Rx only"
23527b8b-9b28-4e6d-9751-33b143975ac7,24,dalteparin,67109,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230922_23527b8b-9b28-4e6d-9751-33b143975ac7.json,"These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. 
FRAGMIN® (dalteparin sodium) injection, USP, for subcutaneous use Initial U.S. Approval: 1994"
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,metoprolol,6918,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992"
2d18cfc4-e0de-4814-a712-c1b7c504bff5,31,exenatide,60548,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231014_2d18cfc4-e0de-4814-a712-c1b7c504bff5.json,"These highlights do not include all the information needed to use BYDUREON BCISE safely and effectively. See full prescribing information for BYDUREON BCISE.
BYDUREON BCISE® (exenatide) extended-release injectable suspension, for subcutaneous useInitial U.S. Approval: 2005"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
3a404db2-7a7d-476f-81cf-979a67d37f66,7,tadalafil,358263,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
453a5759-2f0d-421d-be78-81ab97c8ce77,1,desvenlafaxine,734064,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,AKI,10046337,urate nephropathy,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
471baba2-7154-4488-9891-0db2f46791e7,9,romosozumab,2123126,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220623_471baba2-7154-4488-9891-0db2f46791e7.json,"These highlights do not include all the information needed to use EVENITY safely and effectively. See full prescribing information for EVENITY.  

   

EVENITY

®

 
(
romosozumab-aqqg
) 
injection, 
for
 
subcutaneous
 use

Initial U.S. Approval: 2019"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4dd14728-02b4-4e75-b9c6-227be7816d5b,9,abacavir,190521,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53103d2f-4453-49a8-9e36-888d919879f6,1,zaleplon,74667,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_53103d2f-4453-49a8-9e36-888d919879f6.json,"Zaleplon Capsules, USP

CIV"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
55ad6325-16f6-4f0c-a1dc-734847052d0b,2,danazol,3102,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,"Danazol Capsules, USP
 

Rx only"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,flucytosine,4451,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,FLUCYTOSINE Capsules USPRx only
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
596c923d-db8d-4b96-bf31-52186a38c30d,11,prasugrel,613391,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240202_596c923d-db8d-4b96-bf31-52186a38c30d.json,"These highlights do not include all the information needed to use PRASUGREL TABLETS safely and effectively. See full prescribing information for PRASUGREL TABLETS.
 PRASUGREL tablets, for oral use Initial U.S. Approval: 2009"
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a,43,iron sucrose,24909,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230107_626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a.json,"These highlights do not include all the information needed to use VENOFER ® safely and effectively. See full prescribing information for VENOFER.Venofer (iron sucrose) injection, for intravenous useInitial U.S. Approval:  2000"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,GIB,10061577,ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
666f89b4-fd81-420a-a390-eb1cd4014f61,10,diflunisal,3393,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,Rx only
674e0e6d-46ed-4868-9196-04019d667716,24,pentostatin,8011,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,""
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,ALI,10019727,hepatitis acute,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
74e5060c-8426-1b77-e053-2a91aa0a1f13,8,methylprednisolone,6902,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
77785ce3-e8df-4ca1-8f8e-6c418c6a17de,9,ofatumumab,712566,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230803_77785ce3-e8df-4ca1-8f8e-6c418c6a17de.json,"These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA.
ARZERRA® (ofatumumab) injection, for intravenous useInitial U.S. Approval: 2009"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
83e3ba94-d882-4b5c-87cb-af1eb0997efc,7,alendronate,46041,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240123_83e3ba94-d882-4b5c-87cb-af1eb0997efc.json,"These highlights do not include all the information needed to use ALENDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for ALENDRONATE SODIUM TABLETS.
ALENDRONATE SODIUM tablets, for oral useInitial U.S. Approval:1995"
86c0b4ae-5e38-4efe-88af-50ac560e294f,8,ibandronate,115264,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240202_86c0b4ae-5e38-4efe-88af-50ac560e294f.json,"These highlights do not include all the information needed to use IBANDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for IBANDRONATE SODIUM TABLETS.
 IBANDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 2003"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8d5f892b-e4f3-4a9e-9a91-95e2fca34144,9,canagliflozin,1373458,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231216_8d5f892b-e4f3-4a9e-9a91-95e2fca34144.json,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013"
8d731e7e-3b04-49a2-a0f6-3779422174cc,11,tamoxifen,10324,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_8d731e7e-3b04-49a2-a0f6-3779422174cc.json,"Tamoxifen Citrate Tablets, USP


Rx 
O
nly"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a23063c0-099a-4256-b95f-3a857bbf704b,18,alprazolam,596,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_a23063c0-099a-4256-b95f-3a857bbf704b.json,"These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS.


ALPRAZOLAM tablets, for oral use, CIV 


Initial U.S. Approval: 1981"
a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,alogliptin,1368001,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013"
a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,torsemide,38413,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993"
a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,torsemide,38413,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993"
a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,ambrisentan,358274,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007"
a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe,6,human vaccinia immune globulin,597392,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20190522_a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe.json,"These highlights do not include all the information needed to use CNJ-016 (vaccinia immune globulin intravenous, human), VIGIV safely and effectively. See full prescribing information for VIGIV. VIGIV (vaccinia immune globulin, human), 5% sterile solution for intravenous use.Initial U.S. Approval: 2005"
a64a50ba-e3da-4227-9bce-87101d60409e,2,sapropterin,753340,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231205_a64a50ba-e3da-4227-9bce-87101d60409e.json,"These highlights do not include all the information needed to use SAPROPTERIN DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SAPROPTERIN DIHYDROCHLORIDE TABLETS.
 
SAPROPTERIN DIHYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2007"
a65803a2-0f7a-461e-b0ab-81ebb9e4f789,8,silver sulfadiazine,9793,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_a65803a2-0f7a-461e-b0ab-81ebb9e4f789.json,DESCRIPTION
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,valproate,40254,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
ae8d2354-7ddb-41b8-9d55-77c84782b18f,3,temsirolimus,657797,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240216_ae8d2354-7ddb-41b8-9d55-77c84782b18f.json,"These highlights do not include all the information needed to use TEMSIROLIMUS INJECTION safely and effectively.
 

See full prescribing information for TEMSIROLIMUS INJECTION.
 





TEMSIROLIMUS injection, for intravenous use
 

Initial U.S. Approval: 2007"
af9d68b3-c43e-44e5-bf7d-80dbc2edc53a,11,hydroxyurea,5552,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_af9d68b3-c43e-44e5-bf7d-80dbc2edc53a.json,"These highlights do not include all the information needed to use HYDROXYUREA Capsules safely and effectively. See full prescribing information for HYDROXYUREA Capsules. HYDROXYUREA capsules, USP, for oral use
 

Initial U.S. Approval: 1967
 



---------------------RECENT MAJOR CHANGES--------------


Warnings and Precautions, Pulmonary Toxicity (5.9) 7/2019"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
b7f675e2-159c-490c-b6f4-3f16d9492b7d,3,niraparib,1918231,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240109_b7f675e2-159c-490c-b6f4-3f16d9492b7d.json,"These highlights do not include all the information needed to use ZEJULA safely and effectively.  See full prescribing information for ZEJULA.
ZEJULA (niraparib) tablets, for oral useInitial U.S. Approval: 2017"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c0d1c22b-566b-4776-bdbf-00f96dad0cae,9,filgrastim,68442,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240202_c0d1c22b-566b-4776-bdbf-00f96dad0cae.json,"These highlights do not include all the information needed to use ZARXIO safely and effectively. See full prescribing information for ZARXIO.
ZARXIO® (filgrastim-sndz) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2015ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim)."
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c391fe11-fd47-4a35-af6d-c823ab7b8838,11,letrozole,72965,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0,8,maribavir,2586068,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230509_c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0.json,"These highlights do not include all the information needed to use LIVTENCITY safely and effectively. See full prescribing information for LIVTENCITY.
 LIVTENCITY™  (maribavir) tablets, for oral use Initial U.S. Approval: 2021"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cfeab9e3-58b9-4890-9185-11b62904e2af,13,metronidazole,6922,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,Metronidazole Tablets USP
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,AMI,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
da3c2935-817d-4331-83c3-ed68ba5d35fd,2,chlorpromazine,2403,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_da3c2935-817d-4331-83c3-ed68ba5d35fd.json,"ChlorproMAZINE Hydrochloride Tablets, USP 
Rx only"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,obinutuzumab,974779,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,darunavir,460132,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006"
ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1,rosiglitazone,84108,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20100225_ef14122b-7fff-45fa-b13b-0ea9e48bd57d.json,1  INDICATIONS AND USAGE
f073b58e-56d6-4c8d-a2ce-b37719402d77,3,vinblastine,11198,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,Vinblastine Sulfate Injection
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,vipivotide tetraxetan,2597054,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fc2a08dd-4fb6-4ac4-9082-f99552fae25c,11,bromocriptine,1760,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231215_fc2a08dd-4fb6-4ac4-9082-f99552fae25c.json,Parlodel Capsules and Tablets
fc2a08dd-4fb6-4ac4-9082-f99552fae25c,11,bromocriptine,1760,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231215_fc2a08dd-4fb6-4ac4-9082-f99552fae25c.json,Parlodel Capsules and Tablets
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
01f90c94-71cb-4a1f-81ff-8004b850529b,15,dapagliflozin,1488564,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231213_01f90c94-71cb-4a1f-81ff-8004b850529b.json,"These highlights do not include all the information needed to use FARXIGA safely and effectively.  See full prescribing information for FARXIGA.
FARXIGA® (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014"
03af7d09-314a-fe85-e063-6294a90afa25,1,valsartan,69749,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996"
040a97e5-efd1-4a2f-b737-2f13e5366d70,7,selegiline,9639,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_040a97e5-efd1-4a2f-b737-2f13e5366d70.json,Selegiline Hydrochloride Tablets USP 5 mg
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
09beda19-56d6-4a56-afdc-9a77b70b2ef3,33,linaclotide,1307404,GIB,10018836,haematochezia,../data/2024_latest_labels/gold_xml/20230921_09beda19-56d6-4a56-afdc-9a77b70b2ef3.json,"These highlights do not include all the information needed to use 
LINZESS
 
safely and effectively. 
See full prescribing information for 
LINZESS
.

  

LINZESS

®

 (
linaclotide
) 
capsules, for oral use

Initial U.S. Approval: 
 
2012"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,losartan,52175,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1af01887-b69d-444b-91ed-ebfe12784440,13,basiliximab,196102,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information"
1af01887-b69d-444b-91ed-ebfe12784440,13,basiliximab,196102,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10061577,ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,7,defibrotide,1311089,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221217_2c3db989-d7ad-41ed-9ebf-698dcf6c24ec.json,"These highlights do not include all the information needed to use DEFITELIO safely and effectively.  See full prescribing information for DEFITELIO.
DEFITELIO (defibrotide sodium) injection, for intravenous useInitial U.S. Approval: 2016"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,ertapenem,325642,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
35b2db65-4c6c-4173-ab56-b2bca69193bd,6,etranacogene dezaparvovec,2626727,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230517_35b2db65-4c6c-4173-ab56-b2bca69193bd.json,"These highlights do not include all the information needed to use HEMGENIX safely and effectively. See full prescribing information for HEMGENIX.
 HEMGENIX (etranacogene dezaparvovec-drlb) suspension, for intravenous infusion Initial U.S. Approval: 2022"
3631ee95-692a-4426-8edf-62c27f7c32cb,100,ribavirin,9344,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240210_3631ee95-692a-4426-8edf-62c27f7c32cb.json,"Ribavirin for Inhalation Solution, USP"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
38f5341f-5ae3-46bf-8bfc-30dff2068477,102,alosetron,85248,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20240112_38f5341f-5ae3-46bf-8bfc-30dff2068477.json,"These highlights do not include all the information needed to use ALOSETRON TABLETS safely and effectively. See full prescribing information for ALOSETRON TABLETS. 
ALOSETRON tablets, for oral use   Initial U.S. Approval: 2000"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,ceftaroline fosamil,1040004,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,olmesartan,321064,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002"
454f092e-dcd0-47bd-a521-b07400403dad,5,mannitol,6628,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
4681f23e-6b5e-433b-b245-3d0b4e64ebb2,4,floxuridine,4488,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240117_4681f23e-6b5e-433b-b245-3d0b4e64ebb2.json,FLOXURIDINE FOR INJECTION USP
4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,20,cariprazine,1667655,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_4b5f7c65-aa2d-452a-b3db-bc85c06ff12f.json,"These highlights do not include all the information needed to use 
VRAYLAR
 safely and effectively.  
See full prescribing information for 
VRAYLAR
.  

   

VRAYLAR

®

 (
cariprazine
)
 
c
apsules
,
 
for 
o
ral 
u
se

Initial U.S. Approval: 
2015"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,GIB,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10013839,duodenal ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10061577,ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,pralatrexate,662019,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009"
5fccc31d-32c9-49e7-91a9-664cc726872b,102,triazolam,10767,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231129_5fccc31d-32c9-49e7-91a9-664cc726872b.json,"These highlights do not include all the information needed to use TRIAZOLAM TABLETS safely and effectively. See full prescribing information for TRIAZOLAM TABLETS. 

TRIAZOLAM tablets, for oral use, CIV

Initial U.S. Approval: 1982"
6236b0bc-82e9-4447-9a78-f57d94770269,24,alemtuzumab,117055,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_6236b0bc-82e9-4447-9a78-f57d94770269.json,"These highlights do not include all the information needed to use LEMTRADA safely and effectively. See full prescribing information for LEMTRADA. 
LEMTRADA® (alemtuzumab) injection, for intravenous use Initial U.S. Approval: 2001"
69301126-c901-4d0d-9acb-91ba1a87cd21,26,valacyclovir,73645,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995"
69ea2d58-5353-4222-b61f-cab976fa7e5e,2,prasugrel,613391,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20220909_69ea2d58-5353-4222-b61f-cab976fa7e5e.json,"These highlights do not include all the information needed to use EFFIENT safely and effectively. See full prescribing information for EFFIENT.
 



EFFIENT 
 ® (prasugrel) tablets, for oral use
 

Initial U.S. Approval: 2009"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10017826,gastric ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,acarbose,16681,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,"Acarbose Tablets, USP"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
77a67dc6-35d3-48ff-9d18-292d4d442f70,15,alvimopan,480639,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231214_77a67dc6-35d3-48ff-9d18-292d4d442f70.json,"These highlights do not include all the information needed to use ENTEREG safely and effectively. See full prescribing information for ENTEREG.
 ENTEREG® (alvimopan) capsules, for oral use Initial U.S. Approval: 2008"
7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,tenofovir disoproxil,300195,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
80686b7e-f6f4-4154-b5c0-c846425e2d91,12,elotuzumab,1726104,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8993651b-fff6-4e3f-9b60-78587bc9bcee,2,sulfadiazine,10171,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_8993651b-fff6-4e3f-9b60-78587bc9bcee.json,"sulfADIAZINE Tablets, USP"
8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,nisoldipine,7435,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,Nisoldipine
8f7f73b8-586a-4df0-935f-fecd4696c16c,17,isavuconazonium,1608322,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
973ed458-f46b-4f61-a329-816c4db79a2c,5,amifostine,4126,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_973ed458-f46b-4f61-a329-816c4db79a2c.json,"These highlights do not include all the information needed to use ETHYOL safely and effectively. See full prescribing information for ETHYOL.
ETHYOL® (amifostine) for injection, for intravenous useInitial U.S. Approval: 1995"
983ce15f-cd37-4f3a-9e51-205860e80976,3,sodium phosphate,36709,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,DESCRIPTION
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
99fb821a-fe33-4468-9026-9729a8deff08,5,cyproheptadine,3013,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240118_99fb821a-fe33-4468-9026-9729a8deff08.json,CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,GIB,10051585,gastric antral vascular ectasia,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe,6,human vaccinia immune globulin,597392,AKI,10061481,renal injury,../data/2024_latest_labels/latest_labels_ingredients/20190522_a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe.json,"These highlights do not include all the information needed to use CNJ-016 (vaccinia immune globulin intravenous, human), VIGIV safely and effectively. See full prescribing information for VIGIV. VIGIV (vaccinia immune globulin, human), 5% sterile solution for intravenous use.Initial U.S. Approval: 2005"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0,13,adenosine,296,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0.json,"ADENOSINE INJECTION, USP"
af9d68b3-c43e-44e5-bf7d-80dbc2edc53a,11,hydroxyurea,5552,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240215_af9d68b3-c43e-44e5-bf7d-80dbc2edc53a.json,"These highlights do not include all the information needed to use HYDROXYUREA Capsules safely and effectively. See full prescribing information for HYDROXYUREA Capsules. HYDROXYUREA capsules, USP, for oral use
 

Initial U.S. Approval: 1967
 



---------------------RECENT MAJOR CHANGES--------------


Warnings and Precautions, Pulmonary Toxicity (5.9) 7/2019"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b1b84d62-a369-a4b7-5c41-dd1f553a18f3,15,triptorelin,38782,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231203_b1b84d62-a369-a4b7-5c41-dd1f553a18f3.json,"These highlights do not include all the information needed to use TRELSTAR safely and effectively. See full prescribing information for TRELSTAR.
TRELSTAR®  (triptorelin pamoate for injectable suspension), for intramuscular use  Initial U.S. Approval: 2000"
b31ff20a-c363-4be0-9bc0-3081c163b63c,7,atovaquone,60212,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992"
b6b1d427-e19a-4fc1-b518-f58bacc46736,8,guanfacine,40114,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,"Guanfacine Tablets, USP 


Rx only"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
ba02a95d-d82e-4a13-90b4-a219abc0249a,18,desipramine,3247,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,"Desipramine Hydrochloride Tablets, USP"
bc9c338c-1fc7-4bc2-a357-a78e433cbe9d,6,cefpodoxime,20489,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240106_bc9c338c-1fc7-4bc2-a357-a78e433cbe9d.json,"Cefpodoxime Proxetil Tablets, USP
 Rx only"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bf93022c-a965-49c5-a852-c59e580d7d91,14,indomethacin,5781,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965"
c0946de1-2a2d-47ff-8071-50c1d3ad7982,8,phenytoin,8183,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_c0946de1-2a2d-47ff-8071-50c1d3ad7982.json,"These highlights do not include all the information needed to use EXTENDED PHENYTOIN SODIUM CAPSULES safely and effectively. See full prescribing information for EXTENDED PHENYTOIN SODIUM CAPSULES.
 

EXTENDED PHENYTOIN SODIUM capsules, for oral use
 
Initial U.S. Approval: 1953"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c391fe11-fd47-4a35-af6d-c823ab7b8838,11,letrozole,72965,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997"
c669f77c-fa48-478b-a14b-80b20a0139c2,12,alteplase,8410,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220916_c669f77c-fa48-478b-a14b-80b20a0139c2.json,"These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. 
Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987"
c669f77c-fa48-478b-a14b-80b20a0139c2,12,alteplase,8410,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220916_c669f77c-fa48-478b-a14b-80b20a0139c2.json,"These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. 
Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987"
c82eb602-12e1-692b-d660-f8d5b5736b54,11,salmon calcitonin,36118,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
d953457e-0aff-6c38-e053-2995a90a7d32,3,eplerenone,298869,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002"
d9d74915-6606-4570-9c52-c4001d3177de,20,anakinra,72435,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20201230_d9d74915-6606-4570-9c52-c4001d3177de.json,"These highlights do not include all the information needed to use KINERET safely and effectively.  See full prescribing information for KINERET.  
KINERET® (anakinra) injection, for subcutaneous useInitial U.S. Approval: 2001"
dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,bexarotene,233272,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e07862df-f324-4575-a1ef-f7e1cbab4c7a,11,granisetron,26237,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240105_e07862df-f324-4575-a1ef-f7e1cbab4c7a.json,"These highlights do not include all the information needed to use Granisetron Hydrochloride Injection, USP safely and effectively. See full prescribing information for Granisetron Hydrochloride Injection, USP.  

GRANISETRON hydrochloride injection, USP for intravenous use

Initial U.S. Approval: 1993"
e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,carbidopa,2019,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,CARBIDOPA tablets
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,darunavir,460132,AKI,10071503,crystal nephropathy,../data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006"
f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,paclitaxel,56946,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005"
f16ecb50-e54e-43e1-8789-eaf5bc94f332,2,miglitol,30009,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220426_f16ecb50-e54e-43e1-8789-eaf5bc94f332.json,Miglitol Tablets
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,tucatinib,2361285,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020"
f2abe3ed-ed3d-4215-a489-b18341ce85bc,2,vorapaxar,1537034,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20221019_f2abe3ed-ed3d-4215-a489-b18341ce85bc.json,"These highlights do not include all the information needed to use ZONTIVITY safely and effectively. See full prescribing information for ZONTIVITY.
 



ZONTIVITY 
 ® (vorapaxar) Tablets 2.08 mg*, for oral use
 

*Equivalent to 2.5 mg vorapaxar sulfate
 

Initial U.S. Approval: 2014"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
f6dd2682-75a6-4863-90a8-a3197f6f78a8,12,selinexor,2178390,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220728_f6dd2682-75a6-4863-90a8-a3197f6f78a8.json,"These highlights do not include all the information needed to use XPOVIO safely and effectively. See full prescribing information for XPOVIO. 
XPOVIO® (selinexor) tablets, for oral useInitial U.S. Approval: 2019"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
fb77637a-88d9-4aea-958f-e270030ce30d,18,delafloxacin,1927663,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20231115_fb77637a-88d9-4aea-958f-e270030ce30d.json,"These highlights do not include all the information needed to use BAXDELA® safely and effectively. See full prescribing information for BAXDELA. 
BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00fb869a-40e7-4c85-8380-c5e0cdee8018,4,bupivacaine,1815,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_00fb869a-40e7-4c85-8380-c5e0cdee8018.json,"HiGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MARCAINE™ and MARCAINE™ WITH EPINEPHRINE safely and effectively. See full prescribing information for MARCAINE™ and MARCAINE™ WITH EPINEPHRINE.
  MARCAINE™ (bupivacaine hydrochloride) injection, for infiltration, perineural, caudal, epidural, or retrobulbar useMARCAINE™ WITH EPINEPHRINE (bupivacaine hydrochloride and epinephrine) injection, for infiltration, perineural, caudal, or epidural useInitial U.S. Approval: 1972"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,relugolix,2472778,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020"
0836c6ac-ee37-5640-2fed-a3185a0b16eb,32,abatacept,614391,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240201_0836c6ac-ee37-5640-2fed-a3185a0b16eb.json,"These highlights do not include all the information needed to use ORENCIA safely and effectively. See full prescribing information for ORENCIA.
ORENCIA (abatacept) for injection, for intravenous useORENCIA (abatacept) injection, for subcutaneous useInitial U.S. Approval: 2005"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
09beda19-56d6-4a56-afdc-9a77b70b2ef3,33,linaclotide,1307404,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230921_09beda19-56d6-4a56-afdc-9a77b70b2ef3.json,"These highlights do not include all the information needed to use 
LINZESS
 
safely and effectively. 
See full prescribing information for 
LINZESS
.

  

LINZESS

®

 (
linaclotide
) 
capsules, for oral use

Initial U.S. Approval: 
 
2012"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
10c7b62d-6c39-453c-8d9a-2f441725bc3b,6,lubiprostone,623033,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231024_10c7b62d-6c39-453c-8d9a-2f441725bc3b.json,"These highlights do not include all the information needed to use LUBIPROSTONE CAPSULES safely and effectively. See full prescribing information for LUBIPROSTONE CAPSULES.  LUBIPROSTONE capsules, for oral use Initial U.S. Approval: 2006"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
116f4f0d-66c5-49dd-e063-6394a90ab2b5,1,acyclovir,281,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f4f0d-66c5-49dd-e063-6394a90ab2b5.json,"Acyclovir Tablets, USP"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,ALI,10047216,venoocclusive liver disease,../data/2024_latest_labels/latest_labels_ingredients/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1b97bd3a-1040-4511-b0e6-4758e8083ae5,3,panobinostat,1603350,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20210729_1b97bd3a-1040-4511-b0e6-4758e8083ae5.json,"These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK.


FARYDAK® (panobinostat) capsules, for oral use

Initial U.S. Approval: 2015"
1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,sulindac,10237,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,SULINDAC TABLETS USP
20293943-46ff-4345-1aa4-929b4e017a25,28,sufentanil,56795,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240227_20293943-46ff-4345-1aa4-929b4e017a25.json,"These highlights do not include all the information needed to use SUFENTANIL CITRATE INJECTION, safely and effectively. See full prescribing information for SUFENTANIL CITRATE INJECTION.
Sufentanil Citrate Injection, for intravenous and epidural use, CIIInitial U.S. Approval: 1984"
21002702-422b-1402-73b8-670314d8e579,3,liothyronine,10814,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_21002702-422b-1402-73b8-670314d8e579.json,"These highlights do not include all the information needed to use LIOTHYRONINE SODIUM TABLETS safely and effectively. See full prescribing information for LIOTHYRONINE SODIUM TABLETS.
LIOTHYRONINE SODIUM tablets, for oral useInitial U.S. Approval: 1956"
21149cc3-049b-43e2-b141-c9499160556c,9,fostamatinib,2044896,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240103_21149cc3-049b-43e2-b141-c9499160556c.json,"These highlights do not include all the information needed to use TAVALISSE® safely and effectively.  See full prescribing information for TAVALISSE. 
TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for oral useInitial U.S. Approval: 2018"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,GIB,10056091,varices oesophageal,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
2ef0cf38-101c-4681-98fe-c05dc9ead443,3,mosunetuzumab,2625122,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20221230_2ef0cf38-101c-4681-98fe-c05dc9ead443.json,"These highlights do not include all the information needed to use LUNSUMIO safely and effectively. See full prescribing information for LUNSUMIO. LUNSUMIO™ (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022"
3495a71a-cc04-4776-851f-f185956f32af,22,azacitidine,1251,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004"
3495a71a-cc04-4776-851f-f185956f32af,22,azacitidine,1251,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
3631ee95-692a-4426-8edf-62c27f7c32cb,100,ribavirin,9344,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240210_3631ee95-692a-4426-8edf-62c27f7c32cb.json,"Ribavirin for Inhalation Solution, USP"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3d4ec829-7835-4d59-bc5b-6ce38811fba7,7,entacapone,60307,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_3d4ec829-7835-4d59-bc5b-6ce38811fba7.json,"Entacapone Tablets, USP

8418821/0821

Rx only

Prescribing Information"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
44dcbf97-99ec-427c-ba50-207e0069d6d2,9,pitavastatin,861634,ALI,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20240203_44dcbf97-99ec-427c-ba50-207e0069d6d2.json,"These highlights do not include all the information needed to use LIVALO® safely and effectively.  See full prescribing information for LIVALO.
 LIVALO (pitavastatin) tablets, for oral use Initial U.S. Approval: 2009"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4afb20ee-eb3f-1937-ffa4-5d3228e82688,3,penicillamine,7975,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231205_4afb20ee-eb3f-1937-ffa4-5d3228e82688.json,Penicillamine Capsules
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
53103d2f-4453-49a8-9e36-888d919879f6,1,zaleplon,74667,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_53103d2f-4453-49a8-9e36-888d919879f6.json,"Zaleplon Capsules, USP

CIV"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,pralatrexate,662019,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009"
60f0aa03-ad25-4d48-80ce-7fcfa76f325f,10,tezepelumab,2587789,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_60f0aa03-ad25-4d48-80ce-7fcfa76f325f.json,"These highlights do not include all the information needed to use TEZSPIRE safely and effectively.  See full prescribing information for TEZSPIRE.
TEZSPIRE® (tezepelumab-ekko) injection, for subcutaneous useInitial U.S. Approval: 2021"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
6690679c-be2f-4588-a2e4-89fff74dd6be,9,tremelimumab,2619313,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022"
6935e846-d5a1-49e5-89a2-f8ebe4d5590d,22,enfuvirtide,139896,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20221122_6935e846-d5a1-49e5-89a2-f8ebe4d5590d.json,"These highlights do not include all the information needed to use FUZEON safely and effectively. See full prescribing information for FUZEON. 
 FUZEON® (enfuvirtide) for Injection  Initial U.S. Approval: 2003"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6ee2265b-1da5-4215-848b-12aa5eb25eff,10,hydralazine,5470,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,Rx only
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
740a0f37-aa95-4558-b415-be516b8c40a3,2,tolmetin,10636,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230713_740a0f37-aa95-4558-b415-be516b8c40a3.json,"Tolmetin Sodium Capsules, USP 400 mg
 Rx only"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,liraglutide,475968,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,ALI,10019676,hepatic haematoma,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,ALI,10019677,hepatic haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,GIB,10027141,melaena,../data/2024_latest_labels/gold_xml/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
860c799c-5199-4f0c-b21b-9910273474d9,6,pentamidine,7994,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,Pentamidine isethionate for injection
8e4b636e-ee9c-4111-779d-28c8369d283b,22,epoprostenol,8814,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231103_8e4b636e-ee9c-4111-779d-28c8369d283b.json,"These highlights do not include all the information needed to use FLOLAN safely and effectively. See full prescribing information for FLOLAN.
FLOLAN (epoprostenol sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
99fb821a-fe33-4468-9026-9729a8deff08,5,cyproheptadine,3013,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240118_99fb821a-fe33-4468-9026-9729a8deff08.json,CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
9f489295-1156-52c7-5fd0-5c4c52f9b813,8,voclosporin,2475166,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a26cfa07-14a7-4468-8eed-3529f3d613f4,6,efavirenz,195085,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998"
a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,hydroxocobalamin,5514,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,"HYDROXOCOBALAMIN INJECTION USP
Rx Only"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a865e0ef-8685-4f69-8838-648c4f3bab47,6,emapalumab,2104604,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230921_a865e0ef-8685-4f69-8838-648c4f3bab47.json,"These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT.
GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
abe317a5-6c63-469c-89c8-9fedfe859c3d,5,diazoxide,3327,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20231003_abe317a5-6c63-469c-89c8-9fedfe859c3d.json,"DIAZOXIDE ORAL SUSPENSION, USP FOR ORAL ADMINISTRATION Rx Only"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
ae77f00f-d43b-4b75-afd5-a2a9cb7138da,9,pemetrexed,68446,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20240112_ae77f00f-d43b-4b75-afd5-a2a9cb7138da.json,"These highlights do not include all the information needed to use PEMETREXED FOR INJECTION safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
PEMETREXED FOR INJECTION, for Intravenous Use Initial U.S. Approval: 2004"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10061298,mucosal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae,16,"lymphocyte immune globulin, anti-thymocyte globulin",1011,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230407_bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae.json,"These highlights do not include all the information needed to use THYMOGLOBULIN® safely and effectively.  See full prescribing information for THYMOGLOBULIN. 
THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) for injection, for intravenous use Initial U.S. Approval: 1998"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c82eb602-12e1-692b-d660-f8d5b5736b54,11,salmon calcitonin,36118,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c9fe3f32-4219-466e-acb9-3f609b4f4df1,5,tisotumab,2571095,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230805_c9fe3f32-4219-466e-acb9-3f609b4f4df1.json,"These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.
TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 2021"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10050953,lower gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d7354af1-f304-f4d9-e053-2995a90ab219,2,sparsentan,2630535,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230225_d7354af1-f304-f4d9-e053-2995a90ab219.json,"These highlights do not include all the information needed to use FILSPARITM safely and effectively. See full prescribing information for FILSPARITM.
FILSPARITM (sparsentan) tablets, for oral useInitial U.S. Approval: 2023"
d7c6bc5e-1916-43bf-b943-98f00f41b8de,4,cholestyramine resin,2447,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240126_d7c6bc5e-1916-43bf-b943-98f00f41b8de.json,"Cholestyramine for Oral Suspension USP, Light"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
dd3dcc9a-e40c-4677-9ee6-f318e7c7d835,31,vinorelbine,39541,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230613_dd3dcc9a-e40c-4677-9ee6-f318e7c7d835.json,"These highlights do not include all the information needed to use VINORELBINE INJECTION safely and effectively. See full prescribing information for VINORELBINE INJECTION. 


VINORELBINE injection, for intravenous use 

Initial U.S. Approval: 1994"
e1114a58-9ab5-486e-85ed-360365b06396,1,methyldopa,6876,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230105_e1114a58-9ab5-486e-85ed-360365b06396.json,"Methyldopa Tablets, USP"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
e4f2a84f-5117-4738-b769-aba8debbddb0,11,saxagliptin,857974,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230219_e4f2a84f-5117-4738-b769-aba8debbddb0.json,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009"
e53960ab-42a1-40d1-9c7d-eb013fe7f18f,14,mogamulizumab,2054068,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230428_e53960ab-42a1-40d1-9c7d-eb013fe7f18f.json,"These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO.
POTELIGEO® (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
eeb0fcfd-e4e8-4fb1-9635-901dc9446235,8,iloperidone,73178,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20221224_eeb0fcfd-e4e8-4fb1-9635-901dc9446235.json,"These highlights do not include all the information needed to use ILOPERIDONE TABLETS safely and effectively. See full prescribing information for ILOPERIDONE TABLETS.
ILOPERIDONE tablets, for oral use
Initial U.S. Approval: 2009"
eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,amoxapine,722,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,"Amoxapine Tablets, USP
 
Rx only"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10061880,occult blood positive,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f2feda53-54b9-4e40-8a01-9e7b45cb3d8c,9,arformoterol,304962,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240110_f2feda53-54b9-4e40-8a01-9e7b45cb3d8c.json,"These highlights do not include all the information needed to use ARFORMOTEROL TARTRATE INHALATION SOLUTION safely and effectively. See full prescribing information for ARFORMOTEROL TARTRATE INHALATION SOLUTION.
 ARFORMOTEROL TARTRATE inhalation solution Initial U.S. Approval: 2006"
f3bc9031-0620-4a50-b440-f661cadfeb1d,10,dinoprostone,3478,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230607_f3bc9031-0620-4a50-b440-f661cadfeb1d.json,"These highlights do not include all the information needed to use CERVIDIL safely and effectively. See full prescribing information for CERVIDIL. 
CERVIDIL® (dinoprostone) vaginal insert Initial U.S. Approval: 1977"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,AKI,10059895,urine output decreased,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f567d5c7-ea5d-49a7-a035-b47208135f73,9,quinine,9071,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005"
f9feb925-e1b8-41bc-b9c5-89198f07c0e9,11,caffeine,1886,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240208_f9feb925-e1b8-41bc-b9c5-89198f07c0e9.json,"Caffeine Citrate Injection, USP"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
03819118-86f6-4329-adaf-4599e7b71f46,29,buprenorphine,1819,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
09c6c750-ae05-459f-83e8-4a9e4fd85212,28,atorvastatin,83367,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996"
0a273a2d-a1ff-412a-925e-696648730dae,5,clofarabine,44151,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004"
0b8bf078-34c2-4f45-9012-38a8ac082b01,6,adagrasib,2625882,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022"
0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,alogliptin,1368001,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
11d5a86e-7861-43f1-ae04-84daa0de7888,13,exemestane,258494,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
1502544d-1b3a-46bd-84f5-af92cab72ce8,9,rifapentine,35617,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_1502544d-1b3a-46bd-84f5-af92cab72ce8.json,"These highlights do not include all the information needed to use PRIFTIN® safely and effectively. See full prescribing information for PRIFTIN.
 PRIFTIN (rifapentine) tablets, for oral use Initial U.S. Approval: 1998"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1af01887-b69d-444b-91ed-ebfe12784440,13,basiliximab,196102,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,fludarabine,24698,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,AKI,10046337,urate nephropathy,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
2a7300d3-95e3-427e-bf37-55fa654cc90a,9,olanzapine,61381,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996"
2a7300d3-95e3-427e-bf37-55fa654cc90a,9,olanzapine,61381,ALI,10066758,mixed liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,metoprolol,6918,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992"
2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,andexanet alfa,2045114,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018"
2dd58c88-142f-41ad-bc31-0a4fff074970,1,ceftibuten,20492,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20100115_2dd58c88-142f-41ad-bc31-0a4fff074970.json,"CEDAX® 
(ceftibuten capsules) and (ceftibuten for oral suspension)"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
36d50a08-60bd-40eb-807c-778d69bf2d2e,1,velmanase alfa,2630725,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230301_36d50a08-60bd-40eb-807c-778d69bf2d2e.json,"These highlights do not include all the information needed to use 
LAMZEDE

®

 
safely and effectively. 
See full prescribing information for 
LAMZEDE
.

  

LAMZEDE
 (
velmanase alfa
-
tycv
) 
for 
injection
, 
for intravenous use

Initial U.S. Approval: 
2023"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
4031017d-d768-46de-8081-476bcb883f5e,5,gemcitabine,12574,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,olmesartan,321064,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
43ba3de1-ab2e-06f6-e054-00144ff8d46c,3,auranofin,1227,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20181215_43ba3de1-ab2e-06f6-e054-00144ff8d46c.json,"PRESCRIBING INFORMATION
 



RIDAURA 
 ®




Auranofin
 



Capsules"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
53103d2f-4453-49a8-9e36-888d919879f6,1,zaleplon,74667,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240217_53103d2f-4453-49a8-9e36-888d919879f6.json,"Zaleplon Capsules, USP

CIV"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5be69660-738c-4db7-b0d4-517aa873dc41,9,ponesimod,2532300,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230817_5be69660-738c-4db7-b0d4-517aa873dc41.json,"These highlights do not include all the information needed to use PONVORY safely and effectively. See full prescribing information for PONVORY.
 

PONVORY 
 ®(ponesimod) tablets, for oral use
 
Initial U.S. Approval: 2021"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
6402435f-9f6a-4f02-91a2-6267d783fa78,3,gefitinib,328134,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231229_6402435f-9f6a-4f02-91a2-6267d783fa78.json,"These highlights do not include all the information needed to use GEFITINIB TABLETS safely and effectively. See full prescribing information for GEFITINIB TABLETS.GEFITINIB tablets, for oral useInitial U.S. Approval: 2015"
651bf4d2-75b0-4a60-8014-7006ffe61084,5,nelarabine,274771,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240105_651bf4d2-75b0-4a60-8014-7006ffe61084.json,"These highlights do not include all the information needed to use NELARABINE INJECTION safely and effectively. See full prescribing information for NELARABINE INJECTION. NELARABINE injection, for intravenous use Initial U.S. Approval: 2005"
651bf4d2-75b0-4a60-8014-7006ffe61084,5,nelarabine,274771,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240105_651bf4d2-75b0-4a60-8014-7006ffe61084.json,"These highlights do not include all the information needed to use NELARABINE INJECTION safely and effectively. See full prescribing information for NELARABINE INJECTION. NELARABINE injection, for intravenous use Initial U.S. Approval: 2005"
6690679c-be2f-4588-a2e4-89fff74dd6be,9,tremelimumab,2619313,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022"
6935e846-d5a1-49e5-89a2-f8ebe4d5590d,22,enfuvirtide,139896,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221122_6935e846-d5a1-49e5-89a2-f8ebe4d5590d.json,"These highlights do not include all the information needed to use FUZEON safely and effectively. See full prescribing information for FUZEON. 
 FUZEON® (enfuvirtide) for Injection  Initial U.S. Approval: 2003"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
6ee2265b-1da5-4215-848b-12aa5eb25eff,10,hydralazine,5470,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,Rx only
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
726daf35-4c03-464f-a814-cc0a715d6031,1,fluconazole,4450,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,"Fluconazole Tablets USP
 
Rx only"
74a611bc-9977-46bb-b626-0370b3031628,8,fexinidazole,2564146,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021"
75d68f19-4208-109e-e053-2991aa0ac857,19,riluzole,35623,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_75d68f19-4208-109e-e053-2991aa0ac857.json,"These highlights do not include all the information needed to use TIGLUTIK® safely and effectively. See full prescribing information for TIGLUTIK.
 



TIGLUTIK (riluzole) oral suspension
 

Initial U.S. Approval: 1995"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7b97c681-4514-c544-e053-2991aa0a3d78,6,hetastarch,5531,AKI,10076664,delayed graft function,../data/2024_latest_labels/latest_labels_ingredients/20240131_7b97c681-4514-c544-e053-2991aa0a3d78.json,6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION 500mL BAG
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,tenofovir disoproxil,300195,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
979205ee-b0b8-4483-ae61-f283f750bb7f,100,dapagliflozin,1488564,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_979205ee-b0b8-4483-ae61-f283f750bb7f.json,"These highlights do not include all the information needed to use DAPAGLIFLOZIN TABLETS  safely and effectively.  See full prescribing information for DAPAGLIFLOZIN TABLETS.
DAPAGLIFLOZIN tablets, for oral useInitial U.S. Approval: 2014"
988513ab-b06f-4dd0-93f7-d2d4531dcce4,33,agalsidase beta,338817,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_988513ab-b06f-4dd0-93f7-d2d4531dcce4.json,"These highlights do not include all the information needed to use FABRAZYME® safely and effectively. See full prescribing information for FABRAZYME®. 
 FABRAZYME® (agalsidase beta) for injection, for intravenous use  Initial U.S. Approval: 2003"
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
9e1f2222-1d89-4e63-989c-ccebe2ab1eb4,11,pemigatinib,2359268,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230615_9e1f2222-1d89-4e63-989c-ccebe2ab1eb4.json,"These highlights do not include all the information needed to use PEMAZYRE safely and effectively. See full prescribing information for PEMAZYRE.


PEMAZYRE® (pemigatinib) tablets, for oral use

Initial U.S. Approval: 
2020"
9f489295-1156-52c7-5fd0-5c4c52f9b813,8,voclosporin,2475166,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021"
a0891a32-105b-48bc-a246-5e179d2e7fa1,3,meprobamate,6760,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20230111_a0891a32-105b-48bc-a246-5e179d2e7fa1.json,"Meprobamate Tablets USP


  Rx Only"
a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,torsemide,38413,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993"
a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,ambrisentan,358274,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007"
a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,ambrisentan,358274,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a8c46363-f739-4f6e-bca8-1ce5e8d3f78d,9,mebendazole,6672,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231217_a8c46363-f739-4f6e-bca8-1ce5e8d3f78d.json,"These highlights do not include all the information needed to use EMVERM® safely and effectively. See full prescribing information for EMVERM®.
EMVERM® (mebendazole) chewable tablets, for oral use Initial U.S. Approval: 1974"
ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,valproate,40254,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10059175,intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b5ff59aa-9c0d-49a8-9053-1f179b482383,9,gilteritinib,2105806,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230429_b5ff59aa-9c0d-49a8-9053-1f179b482383.json,"These highlights do not include all the information needed to use XOSPATA safely and effectively.  See full prescribing information for XOSPATA.
XOSPATA® (gilteritinib) tablets, for oral useInitial U.S. Approval: 2018"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,ALI,10019677,hepatic haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bf514e99-4958-44a0-a87a-02a950f87e60,7,acetazolamide,167,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,"Acetazolamide Extended-release Capsules, USP
Rx only"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/train_xml/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c5e8e2fd-7087-4b78-9181-cc259c0be2f1,46,rifaximin,35619,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231116_c5e8e2fd-7087-4b78-9181-cc259c0be2f1.json,"These highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN.
 
XIFAXAN 
 ®(rifaximin) tablets, for oral use
 
Initial U.S. Approval: 2004
 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c6c7c39e-e510-4f4a-bf7a-926f0e075d3a,10,protriptyline,8886,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231221_c6c7c39e-e510-4f4a-bf7a-926f0e075d3a.json,"Protriptyline Hydrochloride Tablets, USPRx Only"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AKI,10038380,renal artery thrombosis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10061878,occult blood,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cf74ba2f-afc5-4baa-8594-979c889a5831,44,tofacitinib,1357536,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20231128_cf74ba2f-afc5-4baa-8594-979c889a5831.json,"These highlights do not include all the information needed to use XELJANZ/XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution. 
XELJANZ® (tofacitinib) tablets, for oral use XELJANZ® XR (tofacitinib) extended-release tablets, for oral use XELJANZ® (tofacitinib) Oral Solution Initial U.S. Approval: 2012"
cfeab9e3-58b9-4890-9185-11b62904e2af,13,metronidazole,6922,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,Metronidazole Tablets USP
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d288e484-32fc-4b46-b504-d75a0fac8663,11,azathioprine,1256,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240209_d288e484-32fc-4b46-b504-d75a0fac8663.json,"Azathioprine Tablets, USP
  
(50 mg)
 

Rx only"
d3e8dd09-d7d2-43da-8f63-bdf0ea0fcdf5,3,pazopanib,714438,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240221_d3e8dd09-d7d2-43da-8f63-bdf0ea0fcdf5.json,"These highlights do not include all the information needed to use PAZOPANIB TABLETS safely and effectively.  See full prescribing information for PAZOPANIB TABLETS.PAZOPANIB tablets, for oral useInitial U.S. Approval: 2009"
d6510282-1a57-4614-9859-299a227a089c,12,moxetumomab pasudotox,2099295,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230623_d6510282-1a57-4614-9859-299a227a089c.json,"These highlights do not include all the information needed to use LUMOXITI safely and effectively.  See full prescribing information for LUMOXITI.LUMOXITI® (moxetumomab pasudotox-tdfk) for injection, for intravenous useInitial U.S. Approval: 2018"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
dc42ab17-cd30-4d1a-e053-2995a90a86ea,3,acetaminophen,161,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240123_dc42ab17-cd30-4d1a-e053-2995a90a86ea.json,"ACETAMINOPHEN INJECTION 1,000mg PER 100mL (10mg/mL)"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,darunavir,460132,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f2feda53-54b9-4e40-8a01-9e7b45cb3d8c,9,arformoterol,304962,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240110_f2feda53-54b9-4e40-8a01-9e7b45cb3d8c.json,"These highlights do not include all the information needed to use ARFORMOTEROL TARTRATE INHALATION SOLUTION safely and effectively. See full prescribing information for ARFORMOTEROL TARTRATE INHALATION SOLUTION.
 ARFORMOTEROL TARTRATE inhalation solution Initial U.S. Approval: 2006"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,vipivotide tetraxetan,2597054,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022"
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fea50328-b3d5-4300-8c67-82cda0a975b7,6,triamterene,10763,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,"Triamterene Capsule, USP Potassium-Sparing Diuretic"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10013839,duodenal ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10027141,melaena,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10052534,large intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,relugolix,2472778,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0c721ba4-ae19-417f-aae1-221ed1a0866a,29,epoetin alfa,105694,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231102_0c721ba4-ae19-417f-aae1-221ed1a0866a.json,"These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT.
 

PROCRIT 
 ®(epoetin alfa) injection, for intravenous or subcutaneous use
 
Initial U.S. Approval: 1989"
0d6111be-aabe-88e2-e063-6394a90a3963,2,mycophenolic acid,7145,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004"
0fe9ff20-d402-41f3-bc1e-7002ea7007db,14,brigatinib,1921217,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230901_0fe9ff20-d402-41f3-bc1e-7002ea7007db.json,"These highlights do not include all the information needed to use ALUNBRIG safely and effectively. See full prescribing information for ALUNBRIG.
 ALUNBRIG® (brigatinib) tablets, for oral use Initial U.S. Approval: 2017"
106b33e3-b199-e555-e063-6294a90a5af5,1,diltiazem,3443,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,"Diltiazem Hydrochloride Tablets, USP


Tablets"
106b33e3-b199-e555-e063-6294a90a5af5,1,diltiazem,3443,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,"Diltiazem Hydrochloride Tablets, USP


Tablets"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
1522921b-d6c2-420d-ba0d-39ac16ba8b37,13,phenazopyridine,8120,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_1522921b-d6c2-420d-ba0d-39ac16ba8b37.json,"PHENAZOPYRIDINE HYDROCHLORIDE TABLETS, USP



Rx Only"
1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,bedaquiline,1364504,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012"
1aa75a3a-18c9-49e1-91a6-293d0b7da756,8,procarbazine,8702,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231121_1aa75a3a-18c9-49e1-91a6-293d0b7da756.json,"MATULANE 
  ®(procarbazine hydrochloride) Capsules"
1af01887-b69d-444b-91ed-ebfe12784440,13,basiliximab,196102,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information"
1c275825-0275-4c73-b650-e4c1519f13b8,2,carboplatin,40048,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240108_1c275825-0275-4c73-b650-e4c1519f13b8.json,"CARBOplatin Injection
 

Rx Only"
1dea37fd-ec17-416e-b28e-980a87d49e1a,2,fomepizole,15226,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231229_1dea37fd-ec17-416e-b28e-980a87d49e1a.json,"Fomepizole Injection, 1.5 grams per 1.5 mL (1 gram per mL)(For Intravenous Infusion Only)Sterile"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,GIB,10052535,small intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,crizotinib,1148495,AKI,10061481,renal injury,../data/2024_latest_labels/latest_labels_ingredients/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011"
2b70cf0c-45be-428f-b396-5001ed4e30fc,6,amiloride,644,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231130_2b70cf0c-45be-428f-b396-5001ed4e30fc.json,"Amiloride HCl Tablets, USP"
3495a71a-cc04-4776-851f-f185956f32af,22,azacitidine,1251,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004"
3516e753-f064-4d30-9bd5-e3f2e143f75d,2,glofitamab,2639782,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230622_3516e753-f064-4d30-9bd5-e3f2e143f75d.json,"These highlights do not include all the information needed to use COLUMVI™ safely and effectively. See full prescribing information for COLUMVI. 
 COLUMVI (glofitamab-gxbm) injection, for intravenous use  Initial U.S. Approval: 2023"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,brentuximab vedotin,1147320,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011"
39e62997-8781-449a-e054-00144ff88e88,7,nizatidine,42319,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only"
3a404db2-7a7d-476f-81cf-979a67d37f66,7,tadalafil,358263,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
4338428e-43d4-4e02-ac9d-bd98e738a7da,5,cabotegravir,2475077,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231222_4338428e-43d4-4e02-ac9d-bd98e738a7da.json,"These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE.
APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular useInitial U.S. Approval: 2021"
47547f93-489c-4298-aeea-d6a37ca6cb1d,5,duvelisib,2058509,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,GIB,10027141,melaena,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6,1,isotretinoin,6064,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240207_4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6.json,"These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES.
 ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
5359b759-db7c-4672-9e8a-59c93869bd91,5,telavancin,473837,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,flucytosine,4451,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,FLUCYTOSINE Capsules USPRx only
5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,flucytosine,4451,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,FLUCYTOSINE Capsules USPRx only
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,liraglutide,475968,ALI,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,GIB,10052535,small intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
726b1e63-437a-4b3b-b773-3ac47a5c0f38,8,ezetimibe,341248,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240218_726b1e63-437a-4b3b-b773-3ac47a5c0f38.json,"These highlights do not include all the information needed to use EZETIMIBE TABLETS safely and effectively. See full prescribing information for EZETIMIBE TABLETS.
 EZETIMIBE tablets, for oral use Initial U.S. Approval: 2002"
7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,etoposide,4179,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983"
74a611bc-9977-46bb-b626-0370b3031628,8,fexinidazole,2564146,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7c6c02a1-1774-4332-babd-dff86f9638a0,102,chlorzoxazone,2410,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_7c6c02a1-1774-4332-babd-dff86f9638a0.json,"Chlorzoxazone Tablets, USP 500 mg"
7e659505-c902-4906-9461-1cc83e2236d2,25,raltegravir,719872,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231210_7e659505-c902-4906-9461-1cc83e2236d2.json,"These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. 
ISENTRESS® (raltegravir) film-coated tablets, for oral useISENTRESS® HD (raltegravir) film-coated tablets, for oral useISENTRESS® (raltegravir) chewable tablets, for oral useISENTRESS® (raltegravir) for oral suspensionInitial U.S. Approval: 2007"
7e659505-c902-4906-9461-1cc83e2236d2,25,raltegravir,719872,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231210_7e659505-c902-4906-9461-1cc83e2236d2.json,"These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. 
ISENTRESS® (raltegravir) film-coated tablets, for oral useISENTRESS® HD (raltegravir) film-coated tablets, for oral useISENTRESS® (raltegravir) chewable tablets, for oral useISENTRESS® (raltegravir) for oral suspensionInitial U.S. Approval: 2007"
7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,daptomycin,22299,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
852f013f-6759-4438-83c1-8ff48133dc85,4,albendazole,430,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
8b4c8696-e23e-4c51-a4d2-babab5bd945a,3,remifentanil,73032,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231223_8b4c8696-e23e-4c51-a4d2-babab5bd945a.json,"These highlights do not include all the information needed to use ULTIVA safely and effectively.  See full prescribing information for ULTIVA. 
ULTIVA® (remifentanil hydrochloride), for injection, for intravenous use, CII
Initial U.S. Approval: 1996"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,zafirlukast,114970,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,Zafirlukast Tablets Rx only
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,decitabine,15657,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006"
9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23,21,pamidronate,11473,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231220_9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23.json,Pamidronate Disodium Injection
9c2e1055-2fa1-462c-90f3-6d77e89ea38a,100,mexiletine,6926,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240208_9c2e1055-2fa1-462c-90f3-6d77e89ea38a.json,MEXILETINE HYDROCHLORIDE CAPSULES USP
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,galantamine,4637,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,hydroxocobalamin,5514,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,"HYDROXOCOBALAMIN INJECTION USP
Rx Only"
a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,ritonavir,85762,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996"
a586be28-96af-4fed-a13f-9b94fd4c7405,24,medroxyprogesterone,6691,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240227_a586be28-96af-4fed-a13f-9b94fd4c7405.json,"PROVERA®

 (medroxyprogesterone acetate tablets, USP)"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a88ac1b4-e2c9-45c0-b321-4785902172e3,41,vigabatrin,14851,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20240203_a88ac1b4-e2c9-45c0-b321-4785902172e3.json,"These highlights do not include all the information needed to use 
SABRIL
 
safely and effectively. See full prescribing information for 
SABRIL
.


SABRIL

®

 
(
vigabatrin
)
  
t
ablet
s
, for oral use

SABRIL

®

 
(
vigabatrin
) 
for 
o
ral 
s
olution       
Initial U.S. Approval:
 
2009"
ad965f38-dd22-4607-a673-2fb92f3b527a,8,rilonacept,763450,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230510_ad965f38-dd22-4607-a673-2fb92f3b527a.json,"These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. 
ARCALYST® (rilonacept) for injection, for subcutaneous use Initial U.S. Approval: 2008"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10019795,hepatitis toxic,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
ae77f00f-d43b-4b75-afd5-a2a9cb7138da,9,pemetrexed,68446,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_ae77f00f-d43b-4b75-afd5-a2a9cb7138da.json,"These highlights do not include all the information needed to use PEMETREXED FOR INJECTION safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
PEMETREXED FOR INJECTION, for Intravenous Use Initial U.S. Approval: 2004"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b856bfaf-ec6b-4171-81c4-b9b07f780084,2,valganciclovir,275891,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,moexipril,30131,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg"
bc737938-ae36-460b-a2a8-609f3fe59156,2,vancomycin,11124,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_bc737938-ae36-460b-a2a8-609f3fe59156.json,"These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE CAPSULES.  VANCOMYCIN HYDROCHLORIDE capsules, for oral use Initial U.S. Approval: 1986 To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules and other antibacterial drugs, vancomycin hydrochloride capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria."
bc9c338c-1fc7-4bc2-a357-a78e433cbe9d,6,cefpodoxime,20489,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240106_bc9c338c-1fc7-4bc2-a357-a78e433cbe9d.json,"Cefpodoxime Proxetil Tablets, USP
 Rx only"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c488fb7c-0a5b-487c-b452-996809d1cb99,65,methylnaltrexone,29899,AMI,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008"
c488fb7c-0a5b-487c-b452-996809d1cb99,65,methylnaltrexone,29899,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008"
c5116390-e0fe-4969-94cb-e9de5165fbab,23,saxagliptin,857974,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_c5116390-e0fe-4969-94cb-e9de5165fbab.json,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009"
c522c860-84ce-4c61-ab72-077de73195df,1,tetracycline,10395,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240120_c522c860-84ce-4c61-ab72-077de73195df.json,"Tetracycline Hydrochloride Tablets, USP For Oral Use"
c732b415-e1f9-478f-896d-1dc8b6362da4,9,ethambutol,4110,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_c732b415-e1f9-478f-896d-1dc8b6362da4.json,ETHAMBUTOL HYDROCHLORIDE TABLETS USP
c76f4b3b-9f93-349f-e053-2995a90a2d57,2,sodium tetradecyl sulfate,9913,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_c76f4b3b-9f93-349f-e053-2995a90a2d57.json,SOTRADECOL® 1% (SODIUM TETRADECYL SULFATE INJECTION) 20mg/2mL (10mg/mL)
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10018836,haematochezia,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,GIB,10060717,mesenteric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,21,nafarelin,28656,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230301_d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6.json,"Synarel®


(nafarelin acetate)

nasal solution"
d138ab10-1ed9-44be-8d81-49dda1e434ac,2,anidulafungin,341018,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240221_d138ab10-1ed9-44be-8d81-49dda1e434ac.json,"These highlights do not include all the information needed to use ERAXIS safely and effectively. See full prescribing information for ERAXIS. 
ERAXIS® (anidulafungin) for injection, for intravenous use Initial U.S. Approval: 2006"
d30a87b9-90fb-35b2-e053-2995a90aea2c,3,dichlorphenamide,3353,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240207_d30a87b9-90fb-35b2-e053-2995a90aea2c.json,"These highlights do not include all the information needed to use KEVEYIS 
 ® safely and effectively. See full prescribing information for KEVEYIS 
 ®.
 

KEVEYIS 
 ® (dichlorphenamide) tablets, for oral use
 

Initial U.S. Approval: 1958"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,GIB,10046274,upper gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
d7354af1-f304-f4d9-e053-2995a90ab219,2,sparsentan,2630535,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230225_d7354af1-f304-f4d9-e053-2995a90ab219.json,"These highlights do not include all the information needed to use FILSPARITM safely and effectively. See full prescribing information for FILSPARITM.
FILSPARITM (sparsentan) tablets, for oral useInitial U.S. Approval: 2023"
d7c6bc5e-1916-43bf-b943-98f00f41b8de,4,cholestyramine resin,2447,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240126_d7c6bc5e-1916-43bf-b943-98f00f41b8de.json,"Cholestyramine for Oral Suspension USP, Light"
da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b,10,ropivacaine,35780,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240125_da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b.json,"These highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE INJECTION.



ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use 

Initial U.S. Approval: 1996"
da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b,10,ropivacaine,35780,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240125_da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b.json,"These highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE INJECTION.



ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use 

Initial U.S. Approval: 1996"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
dd966338-c820-4270-b704-09ef75fa3ceb,19,fidaxomicin,1111103,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011"
df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,obinutuzumab,974779,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013"
df4cd207-c3b8-4008-5290-02f296c2b4a6,21,fenoldopam,24853,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997"
df918ec2-0907-443f-a52a-b72866959644,22,filgrastim,68442,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231208_df918ec2-0907-443f-a52a-b72866959644.json,"These highlights do not include all the information needed to use GRANIX safely and effectively.  See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012"
e55f3dc2-c754-4550-a2c0-c304471a8791,2,nitrofurantoin,7454,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only"
ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1,rosiglitazone,84108,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20100225_ef14122b-7fff-45fa-b13b-0ea9e48bd57d.json,1  INDICATIONS AND USAGE
f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,paclitaxel,56946,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005"
f16ecb50-e54e-43e1-8789-eaf5bc94f332,2,miglitol,30009,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220426_f16ecb50-e54e-43e1-8789-eaf5bc94f332.json,Miglitol Tablets
f1a91500-a944-4cb8-b4a8-ae278bcf728d,4,mobocertinib,2570736,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230930_f1a91500-a944-4cb8-b4a8-ae278bcf728d.json,"These highlights do not include all the information needed to use EXKIVITY safely and effectively. See full prescribing information for EXKIVITY.
 EXKIVITY® (mobocertinib) capsules, for oral use Initial U.S. Approval: 2021"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f5f56c59-04d5-4c5d-9441-5a93d3bdec82,6,felodipine,4316,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_f5f56c59-04d5-4c5d-9441-5a93d3bdec82.json,"Felodipine Extended-Release Tablets, USP
 Rx only"
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fc25635d-7449-4853-8a6e-b5b4b53fbd03,101,fosfomycin,4550,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240113_fc25635d-7449-4853-8a6e-b5b4b53fbd03.json,Fosfomycin Tromethamine Granules for Oral Solution Rx only
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fea50328-b3d5-4300-8c67-82cda0a975b7,6,triamterene,10763,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,"Triamterene Capsule, USP Potassium-Sparing Diuretic"
fedbffa7-087d-4448-85c9-0350a3947080,10,linezolid,190376,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_fedbffa7-087d-4448-85c9-0350a3947080.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LINEZOLID INJECTION safely and effectively. See full prescribing information for LINEZOLID INJECTION.




LINEZOLID injection, for intravenous use

Initial U.S. Approval: 2000"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
ff3b5265-f533-4332-a861-d8c9c1664ffd,15,lamivudine,68244,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,ALI,10019676,hepatic haematoma,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
03819118-86f6-4329-adaf-4599e7b71f46,29,buprenorphine,1819,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981"
03880372-2c68-45c6-a53a-f420c49541d6,21,rilpivirine,1102270,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20221103_03880372-2c68-45c6-a53a-f420c49541d6.json,"These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. 
EDURANT® (rilpivirine) tablets for oral useInitial U.S. Approval: 2011"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,GIB,10056091,varices oesophageal,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
0c8ca614-58b2-4aa4-83d3-0387a8f782fd,9,larotrectinib,2105628,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231117_0c8ca614-58b2-4aa4-83d3-0387a8f782fd.json,"These highlights do not include all the information needed to use VITRAKVI safely and effectively.  See full prescribing information for VITRAKVI.
VITRAKVI® (larotrectinib) capsules, for oral use VITRAKVI® (larotrectinib) oral solutionInitial U.S. Approval: 2018"
0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,alogliptin,1368001,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,sulindac,10237,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,SULINDAC TABLETS USP
201b0eb8-4a1e-4e22-ab4b-addb642710d6,6,dolasetron,68091,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_201b0eb8-4a1e-4e22-ab4b-addb642710d6.json,Anzemet
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,ALI,10054889,transaminases increased,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
2421dc8f-a60d-4249-b093-c9e8e1d4bb82,10,glyburide,4815,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2421dc8f-a60d-4249-b093-c9e8e1d4bb82.json,"Glyburide Tablets, USP
 

1.25, 2.5, and 5 mg"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
29ba0172-7ca3-4122-af1b-f0da522318cb,6,hydroxychloroquine,5521,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_29ba0172-7ca3-4122-af1b-f0da522318cb.json,"These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.
HYDROXYCHLOROQUINE SULFATE Tablets, for oral use
Initial U.S. Approval: 1955"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2d599ccf-8e63-4ff1-aa52-4809744ea97a,9,temozolomide,37776,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_2d599ccf-8e63-4ff1-aa52-4809744ea97a.json,"These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for TEMOZOLOMIDE CAPSULES.
 



TEMOZOLOMIDE capsules, for oral use
 



Initial U.S. Approval: 1999"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
31ce4750-ded5-4a0b-95e9-f229fa6bc822,66,eribulin,1045453,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231118_31ce4750-ded5-4a0b-95e9-f229fa6bc822.json,"These highlights do not include all the information needed to use HALAVEN safely and effectively.  See full prescribing information for HALAVEN.

 

HALAVEN

®

 (eribulin mesylate) injection, for intravenous use

Initial U.S. Approval: 2010"
32fd2bb2-1cfa-4250-feb8-d7956c794e05,16,gemtuzumab ozogamicin,1294580,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20210905_32fd2bb2-1cfa-4250-feb8-d7956c794e05.json,"These highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG.
 MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000"
33f60b40-3fca-11de-8f56-0002a5d5c51b,24,iloperidone,73178,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/train_xml/20210916_33f60b40-3fca-11de-8f56-0002a5d5c51b.json,"These highlights do not include all the information needed to use FANAPT safely and effectively. See full prescribing information for FANAPT.


FANAPT® (iloperidone) tablets, for oral use

Initial U.S. Approval: 2009"
3495a71a-cc04-4776-851f-f185956f32af,22,azacitidine,1251,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004"
34de1806-d921-4d2f-8c7f-03625b717a70,25,methylphenidate,6901,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
36377351-d208-4363-8826-0acfea3f0cc1,5,sodium ferric gluconate complex,261435,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230609_36377351-d208-4363-8826-0acfea3f0cc1.json,"These highlights do not include all the information needed to use sodium ferric gluconate complex in sucrose injection safely and effectively. See full prescribing information for sodium ferric gluconate complex in sucrose injection.
Sodium ferric gluconate complex in sucrose injection, for intravenous use 
Initial U.S. Approval: 1999"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38eea320-7e0c-485a-bc30-98c3c45e2763,24,vemurafenib,1147220,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/gold_xml/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011"
3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,brentuximab vedotin,1147320,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/train_xml/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
44492772-5aed-4627-bd85-e8e89f308bb3,12,siponimod,2121085,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019"
453a5759-2f0d-421d-be78-81ab97c8ce77,1,desvenlafaxine,734064,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,AMI,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
499ab990-2b21-474f-aaba-d86388965f40,9,amikacin,641,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231005_499ab990-2b21-474f-aaba-d86388965f40.json,"These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. 
ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION"
4afb20ee-eb3f-1937-ffa4-5d3228e82688,3,penicillamine,7975,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231205_4afb20ee-eb3f-1937-ffa4-5d3228e82688.json,Penicillamine Capsules
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
4f9bd52a-99a7-4606-92b4-456a917aabef,13,ticagrelor,1116632,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_4f9bd52a-99a7-4606-92b4-456a917aabef.json,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
55ae23ff-60f5-4de6-bd1b-472243b8636b,8,pioglitazone,33738,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5cf989d5-36f5-4561-a30b-9fcb9deb6b6a,10,tafenoquine,2054023,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20230811_5cf989d5-36f5-4561-a30b-9fcb9deb6b6a.json,"These highlights do not include all the information needed to use KRINTAFEL safely and effectively. See full prescribing information for KRINTAFEL.
KRINTAFEL (tafenoquine) tablets, for oral useInitial U.S. Approval: 2018"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6e22050f-95ee-410a-b770-0c32fb8b321b,100,doxepin,3638,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240127_6e22050f-95ee-410a-b770-0c32fb8b321b.json,"Doxepin Hydrochloride Capsules, USP 10 mg, 25 mg, 50 mg, 75 mg and 100 mg"
6e22050f-95ee-410a-b770-0c32fb8b321b,100,doxepin,3638,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240127_6e22050f-95ee-410a-b770-0c32fb8b321b.json,"Doxepin Hydrochloride Capsules, USP 10 mg, 25 mg, 50 mg, 75 mg and 100 mg"
6f4998ac-0714-4f5d-8944-9e6902b9f0a6,12,levothyroxine,10582,ALI,10019719,hepatitis a,../data/2024_latest_labels/latest_labels_ingredients/20240220_6f4998ac-0714-4f5d-8944-9e6902b9f0a6.json,"These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.
 

LEVOTHYROXINE SODIUM tablets, for oral use
 

Initial U.S. Approval: 2002"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,haloperidol,5093,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,"Haloperidol Tablets, USP"
74e5060c-8426-1b77-e053-2a91aa0a1f13,8,methylprednisolone,6902,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®
74f84173-a43f-7788-e053-2991aa0a8fb2,6,hydrocortisone,5492,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74f84173-a43f-7788-e053-2991aa0a8fb2.json,SOLU-CORTEF® 100mg 2mL ACT-O-VIAL®
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,liraglutide,475968,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,GIB,10017826,gastric ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
80686b7e-f6f4-4154-b5c0-c846425e2d91,12,elotuzumab,1726104,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,arsenic trioxide,18330,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000"
8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,arsenic trioxide,18330,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000"
88698921-cd8f-4d41-96e6-ff671913c5c3,7,nateglinide,274332,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20231110_88698921-cd8f-4d41-96e6-ff671913c5c3.json,"These highlights do not include all the information needed to use NATEGLINIDE TABELTS safely and effectively. See full prescribing information for NATEGLINIDE TABELTS.
NATEGLINIDE tablets, for oral useInitial U.S. Approval: 2000"
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10019795,hepatitis toxic,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
a9b01bc6-95ac-46f9-befa-d845a74d53c1,16,estramustine,4089,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_a9b01bc6-95ac-46f9-befa-d845a74d53c1.json,"Emcyt®


 estramustine phosphate sodium

capsules"
af9d68b3-c43e-44e5-bf7d-80dbc2edc53a,11,hydroxyurea,5552,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240215_af9d68b3-c43e-44e5-bf7d-80dbc2edc53a.json,"These highlights do not include all the information needed to use HYDROXYUREA Capsules safely and effectively. See full prescribing information for HYDROXYUREA Capsules. HYDROXYUREA capsules, USP, for oral use
 

Initial U.S. Approval: 1967
 



---------------------RECENT MAJOR CHANGES--------------


Warnings and Precautions, Pulmonary Toxicity (5.9) 7/2019"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
ba02a95d-d82e-4a13-90b4-a219abc0249a,18,desipramine,3247,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,"Desipramine Hydrochloride Tablets, USP"
bf93022c-a965-49c5-a852-c59e580d7d91,14,indomethacin,5781,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c8c50e03-5cb8-43f4-bdef-8edd12f1945f,10,pitavastatin,861634,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_c8c50e03-5cb8-43f4-bdef-8edd12f1945f.json,"These highlights do not include all the information needed to use ZYPITAMAG® safely and effectively. See full prescribing information for ZYPITAMAG. 
ZYPITAMAG (pitavastatin) tablets, for oral use 
 Initial U.S. Approval: 2009"
ca1d3449-ea29-49a4-8863-365ec95f1553,6,potassium iodide,8597,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_ca1d3449-ea29-49a4-8863-365ec95f1553.json,"SSKI® 
Potassium Iodide Oral Solution, USP (Saturated) 1 g/mL"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,GIB,10067786,haemorrhagic erosive gastritis,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cd86ee78-2781-468b-930c-3c4677bcc092,25,vorinostat,194337,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006"
cee4cdd0-58c5-4704-9fb6-d4bffb1764a8,2,midazolam,6960,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_cee4cdd0-58c5-4704-9fb6-d4bffb1764a8.json,"Midazolam Injection, USP

 CIV

 (For Intravenous or Intramuscular Use Only)

 Rx only

 NOT FOR USE IN NEONATES

 CONTAINS BENZYL ALCOHOL"
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d3832a1a-a140-49c1-a7df-134fa81341e3,8,disulfiram,3554,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231227_d3832a1a-a140-49c1-a7df-134fa81341e3.json,"Disulfiram Tablets, USP
 
IN ALCOHOLISM
 

Rx only"
d4500795-3b07-4a7d-b432-73cafbb3dbc6,2,aztreonam,1272,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240110_d4500795-3b07-4a7d-b432-73cafbb3dbc6.json,"Aztreonam for Injection, USP"
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,AKI,10079840,atypical haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,allogeneic processed thymus tissue,2626460,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021"
e2e576e6-6181-4178-b989-61d0e795e559,13,sitagliptin,593411,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240202_e2e576e6-6181-4178-b989-61d0e795e559.json,"These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. 
JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006"
e65d5108-22a2-4d87-a78d-15606f3cc9e2,3,nimodipine,7426,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231228_e65d5108-22a2-4d87-a78d-15606f3cc9e2.json,"Nimodipine Capsules


For Oral Use


Rx only"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
eb368bb6-80e3-4df9-8a85-91df0a2ada6a,14,vismodegib,1242987,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/gold_xml/20230331_eb368bb6-80e3-4df9-8a85-91df0a2ada6a.json,"These highlights do not include all the information needed to use ERIVEDGE safely and effectively. See full prescribing information for ERIVEDGE. 
ERIVEDGE® (vismodegib) capsules, for oral useInitial U.S. Approval: 2012"
eb368bb6-80e3-4df9-8a85-91df0a2ada6a,14,vismodegib,1242987,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20230331_eb368bb6-80e3-4df9-8a85-91df0a2ada6a.json,"These highlights do not include all the information needed to use ERIVEDGE safely and effectively. See full prescribing information for ERIVEDGE. 
ERIVEDGE® (vismodegib) capsules, for oral useInitial U.S. Approval: 2012"
eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,amoxapine,722,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,"Amoxapine Tablets, USP
 
Rx only"
efbdafa9-d18c-4e85-b4a2-1e620fc74e50,11,idelalisib,1544460,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20220308_efbdafa9-d18c-4e85-b4a2-1e620fc74e50.json,"These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. 
 ZYDELIG® (idelalisib) tablets, for oral use Initial U.S. Approval: 2014"
f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,paclitaxel,56946,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005"
f2feda53-54b9-4e40-8a01-9e7b45cb3d8c,9,arformoterol,304962,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_f2feda53-54b9-4e40-8a01-9e7b45cb3d8c.json,"These highlights do not include all the information needed to use ARFORMOTEROL TARTRATE INHALATION SOLUTION safely and effectively. See full prescribing information for ARFORMOTEROL TARTRATE INHALATION SOLUTION.
 ARFORMOTEROL TARTRATE inhalation solution Initial U.S. Approval: 2006"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f6725df6-50ee-4b0a-b900-d02ba634395d,26,aflibercept,1232150,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/gold_xml/20231222_f6725df6-50ee-4b0a-b900-d02ba634395d.json,"These highlights do not include all the information needed to use ZALTRAP safely and effectively. See full prescribing information for ZALTRAP.
ZALTRAP® (ziv-aflibercept) injection, for intravenous useInitial U.S. Approval: 2012"
f96cfd69-da34-41ee-90a9-610a4655cd1c,35,aflibercept,1232150,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231223_f96cfd69-da34-41ee-90a9-610a4655cd1c.json,"These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA.
 EYLEA® (aflibercept) injection, for intravitreal use Initial U.S. Approval:  2011"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fb77637a-88d9-4aea-958f-e270030ce30d,18,delafloxacin,1927663,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231115_fb77637a-88d9-4aea-958f-e270030ce30d.json,"These highlights do not include all the information needed to use BAXDELA® safely and effectively. See full prescribing information for BAXDELA. 
BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
ff9baf45-830f-4a8a-8986-5caeaa1b38cf,4,lithium citrate,52105,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230826_ff9baf45-830f-4a8a-8986-5caeaa1b38cf.json,"These highlights do not include all the information needed to use LITHIUM ORAL SOLUTION safely and effectively. See full prescribing information for LITHIUM ORAL SOLUTION.
 

LITHIUM oral solution, for oral use
 

Initial U.S. Approval: 1970"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
03a58215-dba7-4f63-8b98-d74d054a574a,6,frovatriptan,228783,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_03a58215-dba7-4f63-8b98-d74d054a574a.json,"These highlights do not include all the information needed to use FROVATRIPTAN SUCCINATE TABLETS safely and effectively. See full prescribing information for FROVATRIPTAN SUCCINATE TABLETS.
FROVATRIPTAN SUCCINATE tablets, for oral useInitial U.S. Approval:  2001"
08982e49-d2eb-4b25-b01a-1be52fd669ef,16,tipranavir,190548,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005"
08f0ea03-4e6d-195d-aef4-886e32befa95,27,peginterferon beta-1a,1546168,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230808_08f0ea03-4e6d-195d-aef4-886e32befa95.json,"These highlights do not include all the information needed to use PLEGRIDY® safely and effectively.  See full prescribing information for PLEGRIDY.
PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous or intramuscular useInitial U.S. Approval:  2014"
0b1332a1-0581-4707-9bf6-1eccfa39bef4,2,futibatinib,2628190,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230203_0b1332a1-0581-4707-9bf6-1eccfa39bef4.json,"These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI.
LYTGOBI® (futibatinib) tablets, for oral use
Initial U.S. Approval: 2022"
0b8bf078-34c2-4f45-9012-38a8ac082b01,6,adagrasib,2625882,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,losartan,52175,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995"
102e4ef4-7f84-4e34-8df1-479c24d1575d,5,belumosudil,2564025,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231117_102e4ef4-7f84-4e34-8df1-479c24d1575d.json,"These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK.


REZUROCK® (belumosudil) tablets, for oral use
Initial U.S. Approval: 2021"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
116f655e-e32f-5030-e063-6394a90a64e5,1,amoxicillin,723,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f655e-e32f-5030-e063-6394a90a64e5.json,"These highlights do not include all the information needed to use AMOXICILLIN CAPSULES safely and effectively. See full prescribing information for AMOXICILLIN CAPSULES.
 

AMOXICILLIN capsules, for oral use
 
Initial U.S. Approval: 1974"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,GIB,10013839,duodenal ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
144067b2-0532-476a-996e-e4a0a9d09b05,1,tenofovir disoproxil,300195,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
144067b2-0532-476a-996e-e4a0a9d09b05,1,tenofovir disoproxil,300195,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
167e663c-11e1-497b-a3fc-951d65d58eaa,11,givosiran,2265712,AKI,10018358,glomerular filtration rate decreased,../data/2024_latest_labels/latest_labels_ingredients/20230224_167e663c-11e1-497b-a3fc-951d65d58eaa.json,"These highlights do not include all the information needed to use GIVLAARI® safely and effectively. See full prescribing information for GIVLAARI.
 GIVLAARI (givosiran) injection, for subcutaneous use Initial U.S. Approval: 2019"
16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,ponatinib,1364347,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012"
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1abc06c7-6a45-4a0b-b2da-c228aaa137ed,3,pirfenidone,1592254,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240204_1abc06c7-6a45-4a0b-b2da-c228aaa137ed.json,"These highlights do not include all the information needed to use PIRFENIDONE TABLETS safely and effectively. See full prescribing information for PIRFENIDONE TABLETS.
 

PIRFENIDONE tablets, for oral use
 
Initial U.S. Approval: 2014"
20a16ab2-f338-4abb-9dcd-254bd949a2bc,8,polatuzumab vedotin,2174090,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240123_20a16ab2-f338-4abb-9dcd-254bd949a2bc.json,"These highlights do not include all the information needed to use POLIVY safely and effectively. See full prescribing information for POLIVY.
 POLIVY® (polatuzumab vedotin-piiq) for injection, for intravenous use Initial U.S. Approval: 2019"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,AMI,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2,7,loxapine,6475,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2.json,"Loxapine Capsules, USP"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,belinostat,1543543,ALI,10019663,hepatic failure,../data/2024_latest_labels/train_xml/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
38f5341f-5ae3-46bf-8bfc-30dff2068477,102,alosetron,85248,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240112_38f5341f-5ae3-46bf-8bfc-30dff2068477.json,"These highlights do not include all the information needed to use ALOSETRON TABLETS safely and effectively. See full prescribing information for ALOSETRON TABLETS. 
ALOSETRON tablets, for oral use   Initial U.S. Approval: 2000"
39b58213-b9e2-4847-9010-99e187c1b778,19,fosphenytoin,72236,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231226_39b58213-b9e2-4847-9010-99e187c1b778.json,"These highlights do not include all the information needed to use FOSPHENYTOIN SODIUM INJECTION safely and effectively. See full prescribing information for FOSPHENYTOIN SODIUM  INJECTION.




FOSPHENYTOIN SODIUM injection, for intravenous or intramuscular use

Initial U.S. Approval: 1996"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,AKI,10059895,urine output decreased,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,ceftaroline fosamil,1040004,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
4681f23e-6b5e-433b-b245-3d0b4e64ebb2,4,floxuridine,4488,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240117_4681f23e-6b5e-433b-b245-3d0b4e64ebb2.json,FLOXURIDINE FOR INJECTION USP
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,dalbavancin,1539239,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014"
4c2a1403-3862-1efd-0a91-444989222b37,6,aspirin,1191,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20151015_4c2a1403-3862-1efd-0a91-444989222b37.json,"These highlights do not include all the information needed to use DURLAZA™ safely and effectively.  See full prescribing information for DURLAZA.
DURLAZA (aspirin) Extended Release Capsules, for oral useInitial U.S. Approval:2015"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
551e43d5-f700-4d6e-8029-026f8a8932ff,14,secnidazole,36314,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10017826,gastric ulcer haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
57a597d2-03f0-472e-b148-016d7169169d,12,sacituzumab,2360231,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020"
57a597d2-03f0-472e-b148-016d7169169d,12,sacituzumab,2360231,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020"
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
58c4261e-e98f-4280-9562-2800956dff14,16,glimepiride,25789,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_58c4261e-e98f-4280-9562-2800956dff14.json,"These highlights do not include all the information needed to use GLIMEPIRIDE TABLETS safely and effectively. See full prescribing information for GLIMEPIRIDE TABLETS.
 

GLIMEPIRIDE tablets for oral use
 

Initial U.S. Approval: 1995"
59984249-e3ff-4f97-8d7a-c1a905d604a8,14,pralsetinib,2394936,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230818_59984249-e3ff-4f97-8d7a-c1a905d604a8.json,"These highlights do not include all the information needed to use GAVRETO safely and effectively.  See full prescribing information for GAVRETO.
 GAVRETO® (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
61a0be9d-ee58-43e0-b5cb-141011835081,23,lomitapide,1364479,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240221_61a0be9d-ee58-43e0-b5cb-141011835081.json,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6585bd0d-bd78-4341-9e87-0f7664821f05,11,calaspargase pegol,2121416,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018"
666f89b4-fd81-420a-a390-eb1cd4014f61,10,diflunisal,3393,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,Rx only
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,GIB,10052535,small intestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,haloperidol,5093,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,"Haloperidol Tablets, USP"
74e5060c-8426-1b77-e053-2a91aa0a1f13,8,methylprednisolone,6902,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7731e46a-2121-441b-b090-12dcefe240f0,9,tirofiban,73137,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_7731e46a-2121-441b-b090-12dcefe240f0.json,"These highlights do not include all the information needed to use TIROFIBAN HYDROCHLORIDE injection safely and effectively. See full prescribing information for TIROFIBAN HYDROCHLORIDE injection.
TIROFIBAN HYDROCHLORIDE injection, for intravenous use Initial U.S. Approval: 1998"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7df922bc-5750-4259-906f-64f960c38d5f,9,eszopiclone,461016,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004"
7df922bc-5750-4259-906f-64f960c38d5f,9,eszopiclone,461016,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10017788,gastric haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
80a31286-a741-4440-b200-290c08925d06,9,atropine,1223,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_80a31286-a741-4440-b200-290c08925d06.json,"These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.
ATROPINE SULFATE injection, for intravenous use
Initial U.S. Approval: 1960"
819207a2-0c37-b275-e053-2a91aa0afb36,7,aminophylline,689,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240202_819207a2-0c37-b275-e053-2a91aa0afb36.json,"AMINOPHYLLINE INJ., USP 500mg (25mg/mL) 20mL VIAL"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
82f4d266-3f52-41eb-86ba-0abf3cf468e8,18,luspatercept,2262544,AKI,10011372,creatinine renal clearance decreased,../data/2024_latest_labels/latest_labels_ingredients/20230907_82f4d266-3f52-41eb-86ba-0abf3cf468e8.json,"These highlights do not include all the information needed to use REBLOZYL safely and effectively. See full prescribing information for REBLOZYL.
 REBLOZYL® (luspatercept-aamt) for injection, for subcutaneous use Initial U.S. Approval:  2019"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8c073f84-cdd0-40e4-b3a9-172687267f28,5,elapegademase,2059219,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20220902_8c073f84-cdd0-40e4-b3a9-172687267f28.json,"These highlights do not include all the information needed to use REVCOVI® safely and effectively.  See full prescribing information for REVCOVI.

REVCOVI (elapegademase-lvlr) injection, for intramuscular use
Initial U.S. Approval: 2018"
8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,decitabine,15657,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
90073508-6dca-4d27-aa5a-ed837737c35b,1,rezafungin,2639155,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023"
90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,nafcillin,7233,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,"Nafcillin for Injection, USP Rx only"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9e5e2ce4-7a57-4c61-a826-64c8d11d038e,8,papaverine,7895,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231118_9e5e2ce4-7a57-4c61-a826-64c8d11d038e.json,"PAPAVERINE HYDROCHLORIDE INJECTION, USP"
9f416ce0-012f-4194-9382-74ac71e4b2a9,6,ranitidine,9143,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only"
a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,galantamine,4637,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a6d46c03-bb1d-417b-b8e5-3bffe352fe29,14,rucaparib,1862579,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_a6d46c03-bb1d-417b-b8e5-3bffe352fe29.json,"These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.
 
RUBRACA 
 ®(rucaparib) tablets, for oral use
 
Initial U.S. Approval: 2016"
a88ac1b4-e2c9-45c0-b321-4785902172e3,41,vigabatrin,14851,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240203_a88ac1b4-e2c9-45c0-b321-4785902172e3.json,"These highlights do not include all the information needed to use 
SABRIL
 
safely and effectively. See full prescribing information for 
SABRIL
.


SABRIL

®

 
(
vigabatrin
)
  
t
ablet
s
, for oral use

SABRIL

®

 
(
vigabatrin
) 
for 
o
ral 
s
olution       
Initial U.S. Approval:
 
2009"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,valproate,40254,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
adfc2b23-00a5-4f05-a08b-83087e1e4843,1,enoxaparin,67108,ALI,10067969,cholestatic liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_adfc2b23-00a5-4f05-a08b-83087e1e4843.json,"These highlights do not include all the information needed to use ENOXAPARIN SODIUM INJECTION safely and effectively. See full prescribing information for ENOXAPARIN SODIUM INJECTION.ENOXAPARIN SODIUM injection, for subcutaneous and intravenous useInitial U.S. Approval: 1993"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,ALI,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c01906fa-2c73-4c13-9765-2fd06628d263,26,lincomycin,6398,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231108_c01906fa-2c73-4c13-9765-2fd06628d263.json,"Lincocin®


 lincomycin injection, USP"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,ALI,10068237,hypertransaminasaemia,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c,6,misoprostol,42331,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240110_c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c.json,"Misoprostol
 

Tablets"
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
d267f492-43f6-45ba-8421-82ae2771788b,6,montelukast,88249,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/latest_labels_ingredients/20240224_d267f492-43f6-45ba-8421-82ae2771788b.json,"These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS safely and effectively. See full prescribing information for MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS .


MONTELUKAST SODIUM tablets, for oral use
  
MONTELUKAST SODIUM chewable tablets, for oral use 
 

Initial U.S. Approval: 1998"
d7836711-b677-412d-bf2d-0f7c8444103a,3,epcoritamab,2637392,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023"
d9fd11d0-4269-12fb-95cf-b3c11d75e479,6,tolvaptan,358257,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231216_d9fd11d0-4269-12fb-95cf-b3c11d75e479.json,"These highlights do not include all the information needed to use TOLVAPTAN TABLETS safely and effectively. See full prescribing information for TOLVAPTAN TABLETS.

TOLVAPTAN tablets, for oral use

Initial U.S. Approval: 2009"
dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,infliximab,191831,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab)."
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,GIB,10067786,haemorrhagic erosive gastritis,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
dd966338-c820-4270-b704-09ef75fa3ceb,19,fidaxomicin,1111103,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/train_xml/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,obinutuzumab,974779,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013"
df4cd207-c3b8-4008-5290-02f296c2b4a6,21,fenoldopam,24853,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997"
e03d32dd-878f-43ee-b8c2-3adad98bf66c,100,methimazole,6835,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_e03d32dd-878f-43ee-b8c2-3adad98bf66c.json,"Methimazole Tablets, USP

 Rx only"
e53960ab-42a1-40d1-9c7d-eb013fe7f18f,14,mogamulizumab,2054068,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20230428_e53960ab-42a1-40d1-9c7d-eb013fe7f18f.json,"These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO.
POTELIGEO® (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018"
e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,nelfinavir,134527,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
f073b58e-56d6-4c8d-a2ce-b37719402d77,3,vinblastine,11198,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,Vinblastine Sulfate Injection
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f3b50bbb-df03-4ed7-9d8d-180edc2abd54,9,betaxolol,1520,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240215_f3b50bbb-df03-4ed7-9d8d-180edc2abd54.json,"Betaxolol Tablets, USP"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f7b3f443-e83d-4bf2-0e96-023448fed9a8,49,ticagrelor,1116632,AKI,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20231104_f7b3f443-e83d-4bf2-0e96-023448fed9a8.json,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fc937c08-7bc0-4f97-80c9-e091e97f2f9a,1,metolazone,6916,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_fc937c08-7bc0-4f97-80c9-e091e97f2f9a.json,"Metolazone Tablets, USP"
fd427d2d-b78b-412a-9c80-606bc88ad112,10,eletriptan,231049,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fee3bd4a-ade3-41fa-839a-48e9af69bcf4,5,propofol,8782,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231201_fee3bd4a-ade3-41fa-839a-48e9af69bcf4.json,"Diprivan® (Propofol) Injectable Emulsion, USP"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,GIB,10018830,haematemesis,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
03151cb5-d32b-4484-8f2a-8c5d24c7f6f1,10,glipizide,4821,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_03151cb5-d32b-4484-8f2a-8c5d24c7f6f1.json,"These highlights do not include all the information needed to use GLIPIZIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for GLIPIZIDE EXTENDED-RELEASE TABLETS.
 



GLIPIZIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1994"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
0935cd31-3251-4a0a-ac23-25ca4be12be9,2,odevixibat,2563966,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20240214_0935cd31-3251-4a0a-ac23-25ca4be12be9.json,"These highlights do not include all the information needed to use BYLVAY safely and effectively. See full prescribing information for BYLVAY. 
BYLVAY (odevixibat) capsules, for oral use BYLVAY (odevixibat) oral pellets Initial U.S. Approval: 2021"
09beda19-56d6-4a56-afdc-9a77b70b2ef3,33,linaclotide,1307404,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230921_09beda19-56d6-4a56-afdc-9a77b70b2ef3.json,"These highlights do not include all the information needed to use 
LINZESS
 
safely and effectively. 
See full prescribing information for 
LINZESS
.

  

LINZESS

®

 (
linaclotide
) 
capsules, for oral use

Initial U.S. Approval: 
 
2012"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,alogliptin,1368001,ALI,10000804,acute hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013"
0d447b48-3f4b-430e-9e68-d8b9401c002e,4,desmopressin,3251,AMI,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0d447b48-3f4b-430e-9e68-d8b9401c002e.json,"Desmopressin Acetate Tablets
  
8472121/1222
  
Rx only"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
11d5a86e-7861-43f1-ae04-84daa0de7888,13,exemestane,258494,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999"
1401d590-0967-4c6b-b52b-a83e9f6df097,34,doxycycline,3640,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240221_1401d590-0967-4c6b-b52b-a83e9f6df097.json,DOXYCYCLINE HYCLATE TABLETS USP 100 mg
1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,bedaquiline,1364504,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012"
17e597bc-d663-4d8e-a5d3-39816b628996,8,stavudine,59763,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,ALI,10019754,hepatitis cholestatic,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,dipyridamole,3521,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1d3e7aea-02a4-46b1-8a14-0324e4777cb4,5,ivermectin,6069,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_1d3e7aea-02a4-46b1-8a14-0324e4777cb4.json,"These highlights do not include all the information needed to use IVERMECTIN CREAM safely and effectively.  See full prescribing information for IVERMECTIN CREAM.IVERMECTIN cream, 1%, for topical useInitial U.S. Approval: 1996"
1dea37fd-ec17-416e-b28e-980a87d49e1a,2,fomepizole,15226,AKI,10002847,anuria,../data/2024_latest_labels/latest_labels_ingredients/20231229_1dea37fd-ec17-416e-b28e-980a87d49e1a.json,"Fomepizole Injection, 1.5 grams per 1.5 mL (1 gram per mL)(For Intravenous Infusion Only)Sterile"
202d5142-6180-4d48-9a9f-1bd6992fc49b,2,nebivolol,31555,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007"
20a16ab2-f338-4abb-9dcd-254bd949a2bc,8,polatuzumab vedotin,2174090,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240123_20a16ab2-f338-4abb-9dcd-254bd949a2bc.json,"These highlights do not include all the information needed to use POLIVY safely and effectively. See full prescribing information for POLIVY.
 POLIVY® (polatuzumab vedotin-piiq) for injection, for intravenous use Initial U.S. Approval: 2019"
220a9b3c-c583-49e3-8bf0-d0c97dc9b829,102,lovastatin,6472,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_220a9b3c-c583-49e3-8bf0-d0c97dc9b829.json,"Lovastatin Tablet USP
 


Revision M"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,ALI,10054889,transaminases increased,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2348f06e-8004-4040-832e-e9e86a39f905,11,caplacizumab,2110605,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230520_2348f06e-8004-4040-832e-e9e86a39f905.json,"These highlights do not include all the information needed to use CABLIVI® safely and effectively. See full prescribing information for CABLIVI.
 CABLIVI (caplacizumab-yhdp) for injection, for intravenous or subcutaneous use Initial U.S. Approval: 2019"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2a7300d3-95e3-427e-bf37-55fa654cc90a,9,olanzapine,61381,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996"
2a90b899-7746-43dc-ac8a-e754428eb30c,13,desloratadine,275635,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_2a90b899-7746-43dc-ac8a-e754428eb30c.json,"These highlights do not include all the information needed to use DESLORATADINE TABLETS safely and effectively. See full prescribing information for DESLORATADINE TABLETS.
DESLORATADINE tablets for oral use Initial U.S. Approval: 2001"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,AKI,10045170,tumour lysis syndrome,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
32167dd7-5d37-457b-9b00-cd735de6b060,5,tinidazole,10612,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004"
33f60b40-3fca-11de-8f56-0002a5d5c51b,24,iloperidone,73178,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20210916_33f60b40-3fca-11de-8f56-0002a5d5c51b.json,"These highlights do not include all the information needed to use FANAPT safely and effectively. See full prescribing information for FANAPT.


FANAPT® (iloperidone) tablets, for oral use

Initial U.S. Approval: 2009"
34de1806-d921-4d2f-8c7f-03625b717a70,25,methylphenidate,6901,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
38955939-8d1e-4db2-9aed-3bab72ca5f8f,8,bleomycin,1622,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231224_38955939-8d1e-4db2-9aed-3bab72ca5f8f.json,"​ 
BLEO 15K

Bleomycin sulfate.  

Bleomycin sulfate powder for injection contains bleomycin sulfate 15,000 IU per vial"
39b58213-b9e2-4847-9010-99e187c1b778,19,fosphenytoin,72236,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20231226_39b58213-b9e2-4847-9010-99e187c1b778.json,"These highlights do not include all the information needed to use FOSPHENYTOIN SODIUM INJECTION safely and effectively. See full prescribing information for FOSPHENYTOIN SODIUM  INJECTION.




FOSPHENYTOIN SODIUM injection, for intravenous or intramuscular use

Initial U.S. Approval: 1996"
39e62997-8781-449a-e054-00144ff88e88,7,nizatidine,42319,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only"
3a404db2-7a7d-476f-81cf-979a67d37f66,7,tadalafil,358263,GIB,10054787,haemorrhoidal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,levetiracetam,114477,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
406883ea-7f97-4eff-8d43-0bab004654f1,9,insulin glargine,274783,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_406883ea-7f97-4eff-8d43-0bab004654f1.json,"These highlights do not include all the information needed to use INSULIN GLARGINE safely and effectively. See full prescribing information for INSULIN GLARGINE. 
INSULIN GLARGINE injection, for subcutaneous use Initial U.S. Approval: 2000 
This product is LANTUS® (insulin glargine)."
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
453a5759-2f0d-421d-be78-81ab97c8ce77,1,desvenlafaxine,734064,AMI,10011086,coronary artery occlusion,../data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008"
47547f93-489c-4298-aeea-d6a37ca6cb1d,5,duvelisib,2058509,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018"
47547f93-489c-4298-aeea-d6a37ca6cb1d,5,duvelisib,2058509,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
5451bcaa-0aca-4581-bcea-2f9c2a33b260,20,oxycodone,7804,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5451bcaa-0aca-4581-bcea-2f9c2a33b260.json,"These highlights do not include all the information needed to use OXYCODONE HYDROCHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for OXYCODONE HYDROCHLORIDE ORAL SOLUTION.
OXYCODONE HYDROCHLORIDE oral solution, CIIInitial U.S. Approval: 1950"
551e43d5-f700-4d6e-8029-026f8a8932ff,14,secnidazole,36314,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,AKI,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
58a3c995-5ad6-465d-8437-5970c9088213,1,chlorambucil,2346,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230517_58a3c995-5ad6-465d-8437-5970c9088213.json,"LEUKERAN®
(chlorambucil) Tablets"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,GIB,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,GIB,10013836,duodenal ulcer,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
645af8f4-0843-4afb-9ddc-f587f38adb68,8,demeclocycline,3154,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
66311f74-0472-4fa3-848a-06002ca0def5,22,interferon beta-1b,72257,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230812_66311f74-0472-4fa3-848a-06002ca0def5.json,"These highlights do not include all the information needed to use BETASERON safely and effectively.  See full prescribing information for BETASERON.
BETASERON (interferon beta-1b) for injection, for subcutaneous useInitial U.S. Approval: 1993"
69301126-c901-4d0d-9acb-91ba1a87cd21,26,valacyclovir,73645,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,ALI,10019772,hepatitis fulminant,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fb99b0c-d937-f095-513b-b2c561047abf,4,lacosamide,623400,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fb99b0c-d937-f095-513b-b2c561047abf.json,"These highlights do not include all the information needed to use LACOSAMIDE ORAL SOLUTION safely and effectively. See full prescribing information for LACOSAMIDE ORAL SOLUTION.  LACOSAMIDE oral solution, CVInitial U.S. Approval: 2008"
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
71448ab0-e23e-4cf7-940e-7d67e7362fb4,1,cetirizine,20610,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240212_71448ab0-e23e-4cf7-940e-7d67e7362fb4.json,"CETIRIZINE HYDROCHLORIDE ORAL SOLUTION USP

1 mg/mL

Rx Only"
722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,acarbose,16681,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,"Acarbose Tablets, USP"
72e6b33c-0351-4070-9172-eeaa186c01d2,14,tenofovir alafenamide,1721603,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_72e6b33c-0351-4070-9172-eeaa186c01d2.json,"These highlights do not include all the information needed to use VEMLIDY safely and effectively. See full prescribing information for VEMLIDY. 
 VEMLIDY® (tenofovir alafenamide) tablets, for oral use  Initial U.S. Approval: 2015"
7602fb73-3ce3-5978-e053-2991aa0abea3,8,phenylephrine,8163,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7602fb73-3ce3-5978-e053-2991aa0abea3.json,"PHENYLEPHRINE HCI INJECTION, USP 10mg/mL 1mL VIAL"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7df922bc-5750-4259-906f-64f960c38d5f,9,eszopiclone,461016,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004"
7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,daptomycin,22299,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,GIB,10061878,occult blood,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,GIB,10014896,enterocolitis haemorrhagic,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
86766b51-4443-4cec-97a2-c483b07681de,8,tobramycin,10627,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20240214_86766b51-4443-4cec-97a2-c483b07681de.json,"Tobramycin

Ophthalmic Solution, USP

0.3%

(Sterile)
 
Rx only"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,GIB,10017866,gastritis haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8c065559-bd35-4dda-ac8f-624eea0641ae,9,zidovudine,11413,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_8c065559-bd35-4dda-ac8f-624eea0641ae.json,"These highlights do not include all the information needed to use ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ZIDOVUDINE TABLETS.
 



ZIDOVUDINE tablets, for oral use
 



Initial U.S. Approval: 1987"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,AKI,10019846,hepatorenal syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,GIB,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9929c166-8ba3-4159-a5f9-4618d5d227b0,102,flecainide,4441,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,Flecainide Acetate Tablets USPRx only
a0891a32-105b-48bc-a246-5e179d2e7fa1,3,meprobamate,6760,AKI,10030302,oliguria,../data/2024_latest_labels/latest_labels_ingredients/20230111_a0891a32-105b-48bc-a246-5e179d2e7fa1.json,"Meprobamate Tablets USP


  Rx Only"
a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,galantamine,4637,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001"
a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,hydroxocobalamin,5514,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,"HYDROXOCOBALAMIN INJECTION USP
Rx Only"
a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,torsemide,38413,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993"
a6f42739-5bfc-4b76-8795-e93fa58f3d29,12,oxandrolone,7779,ALI,10019692,hepatic necrosis,../data/2024_latest_labels/latest_labels_ingredients/20230707_a6f42739-5bfc-4b76-8795-e93fa58f3d29.json,"Oxandrolone Tablet, USP"
a865e0ef-8685-4f69-8838-648c4f3bab47,6,emapalumab,2104604,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230921_a865e0ef-8685-4f69-8838-648c4f3bab47.json,"These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT.
GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018"
ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,valproate,40254,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989"
accf9569-4b57-4e83-a7db-4e890a75d1ba,23,mitoxantrone,7005,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,"MitoXANTRONE Injection, USP (concentrate)"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,ALI,10072268,drug-induced liver injury,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b272ef9c-4d83-4ee2-b9cc-477440822cca,10,cefoxitin,2189,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_b272ef9c-4d83-4ee2-b9cc-477440822cca.json,"CEFOXITIN FOR INJECTION, USP(For Intravenous Use)"
b6b1d427-e19a-4fc1-b518-f58bacc46736,8,guanfacine,40114,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,"Guanfacine Tablets, USP 


Rx only"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
bf3425e0-428d-4bdb-ac9a-3b9d483df83a,9,isradipine,33910,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240105_bf3425e0-428d-4bdb-ac9a-3b9d483df83a.json,"Isradipine Capsules, USP

Rx only"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,AKI,10038540,renal tubular necrosis,../data/2024_latest_labels/latest_labels_ingredients/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,GIB,10012741,diarrhoea haemorrhagic,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/gold_xml/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,ALI,10019636,hepatic artery thrombosis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c9fe3f32-4219-466e-acb9-3f609b4f4df1,5,tisotumab,2571095,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230805_c9fe3f32-4219-466e-acb9-3f609b4f4df1.json,"These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.
TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 2021"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,GIB,10049555,anal haemorrhage,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cac4f544-536c-4886-a379-99eed2d35240,8,sildenafil,136411,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998"
cd86ee78-2781-468b-930c-3c4677bcc092,25,vorinostat,194337,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,ALI,10019795,hepatitis toxic,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,AKI,10038460,renal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,allogeneic processed thymus tissue,2626460,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021"
e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,nelfinavir,134527,GIB,10017955,gastrointestinal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,GIB,10038063,rectal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,tucatinib,2361285,ALI,10019837,hepatocellular injury,../data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,AKI,10018932,haemolytic uraemic syndrome,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f30421f7-63d1-4800-99f5-479f2ca336be,11,paliperidone,679314,ALI,10054889,transaminases increased,../data/2024_latest_labels/latest_labels_ingredients/20231229_f30421f7-63d1-4800-99f5-479f2ca336be.json,"These highlights do not include all the information needed to use PALIPERIDONE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for PALIPERIDONE EXTENDED-RELEASE TABLETS.
PALIPERIDONE extended-release tablets, for oral useInitial U.S. Approval: 2006"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f3b50bbb-df03-4ed7-9d8d-180edc2abd54,9,betaxolol,1520,AMI,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_f3b50bbb-df03-4ed7-9d8d-180edc2abd54.json,"Betaxolol Tablets, USP"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,ALI,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,GIB,10027141,melaena,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f567d5c7-ea5d-49a7-a035-b47208135f73,9,quinine,9071,AKI,10048302,tubulointerstitial nephritis,../data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005"
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,AKI,10046406,ureteric obstruction,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
f7573809-7741-04c9-e053-6294a90ab193,1,zileuton,40575,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20230321_f7573809-7741-04c9-e053-6294a90ab193.json,"ZILEUTON EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use ZILEUTON EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ZILEUTON EXTENDED-RELEASE TABLETS.
 

ZILEUTON extended-release tablets, for oral use
 

Initial U.S. Approval: 1996"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,ALI,10019663,hepatic failure,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,AKI,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,GIB,10018836,haematochezia,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,ALI,10019851,hepatotoxicity,../data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
